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ABSTRACT 
ADAMTS13 is a plasma metalloproteinase that regulates the multimeric size and 
function of von Willebrand factor (VWF), important for mediating platelet adhesion at 
sites of vessel injury. It is currently unclear how ADAMTS13 activity is regulated. I 
have investigated the effect of serine proteases generated at sites of vascular injury 
upon ADAMTS 13 activity. Using purified proteins, ADAMTS 13 was sensitive to 
proteolysis at several sites by thrombin, plasmin, and to a lesser extent by activated 
factor X. Proteolysis of ADAMTS13 by thrombin and plasmin ablated activity against 
purified multimeric VWF, but not against VWF 115, a short recombinant substrate. 
Using site directed mutagenesis and Edman degradation analysis of cleavage 
fragments, R257 and R1176 were determined to be the favoured thrombin cleavage 
sites in ADAMTS13. Preincubation of thrombin with fibrinogen or soluble 
thrombomodulin, but not heparin, inhibited ADAMTS13 proteolysis suggesting 
exosite I was involved in ADAMTS 13 recognition. This was confirmed using a library 
of thrombin variants that revealed exosite I residues R67, H71, R73, T74, R77, Y76 
and L81 were involved in ADAMTSI3 recognition. Proteolysis of ADAMTSI3 was 
also studied in plasma. Initiation of coagulation in plasma supplemented with 
ADAMTS 13 resulted in the disappearance of the full-length enzyme. This loss was 
completely inhibited by hirudin suggesting a thrombin dependent mechanism. 
However, endogenous plasma ADAMTSI3 remained intact after initiating thrombin 
generation in both normal and fibrinogen deficient plasma. This may due to the 
affinity of thrombin for ADAMTS 13 (KD -80nM) being much lower than its plasma 
concentration (-5nM). While thrombin has a defined molecular interaction with 
ADAMTS13 leading to cleavage, this may only occur under selective conditions in 
vivo. 
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Page 18: "a" removed from last sentence of top paragraph. 
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1 INTRODUCTION 
1.1 Haemostasis overview 
Haemostasis involves a series of complex interactions between vessel wall 
components, platelets and plasma proteins that interact to arrest bleeding at the site of 
vascular injury, whilst maintaining normal blood flow. Haemostasis involves four 
distinct interrelated functions. First, vasoconstriction of the vessel wall limits the 
blood flow to the site of endothelial damage. Second, initial platelet plug formation 
provides a surface for clotting factors to assemble and become activated. Third, the 
platelet plug is stabilised and converted into a haemostatic plug through the deposition 
of fibrin, which is generated by activation of the coagulation cascade. Finally, 
procoagulant responses are terminated and tissue repair mechanisms activated during 
fibrinolysis. 
1.2 Platelets 
1.2.1 Platelet function 
Platelets play a central role in the physiological process of haemostasis, but are also 
involved in the pathological process of thrombosis'. Platelets are derived from 
megakaryocytes in the bone marrow and circulate in a resting state. They express 
multiple glycoprotein (GP) receptors on their membrane surface, which bind various 
ligands that facilitate the adhesion, activation and aggregation of platelets. 
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1.2.2 Shear stress and platelet tethering at sites of vessel injury 
To perform their haemostatic function, platelets must bind to sites of vascular injury 
and oppose the haemodynamic forces exerted by the flowing blood in the luminal 
space. The velocity of blood flow through a vessel is maximal in the centre and is 
virtually zero next to the vessel wall. The flow of blood can be imagined as being 
divided in a series of adjacent layers (laminae) moving at different velocities. The 
rheological properties of blood flow are measured by shear rate and shear stress. The 
shear rate (expressed in s'') is the rate of change of velocity with respect to distance 
measured perpendicularly to the direction of flow. Inversely proportional to the 
velocity, shear rate is greater near the vessel wall and close to zero at the centre. Shear 
stress (expressed in Pa, dyn/cm2, or N/m2) is the tangential force per unit area of 
contact between the laminae. Shear stress is directly proportional to shear rate and 
fluid viscosity2. 
At low shear rates found in veins and arteries (-. 100s'ß), GPVI present on platelet 
membrane surfaces is primarily involved in binding directly to sub-endothelial 
3, SC 
collagen and activating platelets". GPVI is a member of the immunoglobulin 
superfamily that non-covalently associates with the FcRy-chain, which bears an 
immunoreceptor tyrosine-based activation motif. This serves as the signal transducing 
subunit that stimulates both platelet adhesion and activation upon its interaction with 
collagen. Integrin a2ß1 present on platelet membrane surfaces can also bind directly to 
collagen to assist platelet adhesion7'10, but can also contribute to platelet tethering in 
high shear stress conditions in conjunction with GPIb-Von Willebrand Factor (VWF) 
binding. 
In small arterioles and arterial capillaries where shear rates vary from 470s"1 to 4700s'' 
respectively 11, platelets cannot interact directly with collagen via GPVI since the 
15 
strength of this binding is not sufficient to resist the haemodynamic force of the 
flowing blood. Under these conditions, VWF immobilised onto exposed collagen 
assists in the tethering of platelets to sites of vascular injury by binding the GPIb-IX-V 
complex on platelet membrane surfaces 12"'3. The role of this receptor in platelet 
tethering will be discussed below in more detail (section 1.4.6). 
1.2.3 Platelet activation 
Once platelets are immobilised onto collagen at sites of vascular injury, either directly 
via GPVI and integrin a2131 or indirectly via the binding of GPIb-IX-V complex on 
VWF, platelets become activated through various intracellular signalling pathways 
elicited by a range of soluble agonists such as thrombin' 4-17, adenosine diphosphate18' 
22, thromboxane A223"27 and adrenaline28. Most of the agonists involved- activate 
platelets through different receptors that are coupled to heterotrimeric G-proteins. This 
leads to the activation of phospholipases, increases in intracellular calcium, 
suppression of cyclic adenosine monophosphate synthesis and reorganisation of the 
platelet cytoskeleton. Subsequently, platelet activation amplifies initial platelet 
responses and recruits circulating platelets from the flowing blood into a growing 
platelet plug through a number of mechanisms. Activated platelets express GPIIbIIIa 
on the membrane surface, which aggregates and firmly adheres platelet to sites of 
vessel injury. They also undergo morphological changes in which platelets alter their 
shape by flattening and extending pseudopodia. This results in the anchoring of 
platelets that provide a negatively charged surface for the binding of clotting factors 
(through the exposure of phosphatidylserine), which is critical for efficient thrombin 
generation 29'30. The activation process causes the secretion of a-granule and dense 
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granule contents, which contribute to platelet adhesion and aggregation. The a- 
granules contains P-selectin, VWF and fibrinogen31, fibronectin32.33, thrombospondin- 
1 (TSP-1)34-38, vitronectin39-a2, GPIb, GPIIbIIIa and factorX (prefixed 
by F) sueh as FV awl. The dense granules contain platelet agonists such as 
adenosine diphosphate, thron e-AZ and serotonin. 
1.2.4 Platelet aggregation 
Although the initial platelet plug acts to seal the vascular lesion, it is only temporary 
and unstable. Therefore, platelet aggregation is essential for the formation of a stable 
haemostatic plug at sites of vascular injury. This process is primarily mediated by 
GPIIbII1a on activated platelet membrane surfaces, which binds a number of different 
adhesive substrates such as VWF, fibrinogen and fibronectin that help recruit and 
locally aggregate plate Iets31'32'a3. This forms a structural scaffold that helps consolidate 
the developing platelet plug. At high shear stress, fibrinogen alone cannot support the 
formation of stable platelet aggregates. Thus, VWF is critical in stabilising the platelet 
plug due to its multimeric conformation and conferring resistance to rheological forces 
aa , as of the circulating blood 
1.3 Coagulation cascade 
1.3.1 Extrinsic pathway 
Upon vessel injury, circulating FVII/VIIa binds tissue factor (TF), a transmembrane- 
protein that is most abundant in the sub-endothelial layer46,47 The TF/FVIIa complex 
activates FX to FXa and catalyses the conversion of small amounts of prothrombin to 
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thrombin. The trace amounts of thrombin generated can then activate platelets to cause 
the exposure of negatively charged phospholipid surfaces30. The low thrombin 
concentrations can also activate FV and FVIII48. FVIIIa and FVa are important 
cofactors in the intrinsic tenase and prothrombinase complexes respectively, which are 
both critical for enhanced thrombin generation. The TF/FVIIa complex can also 
activate FIX, the enzymatic)( component of the tenase complex. 
1.3.2 Intrinsic pathway 
Generation of FXa can also be brought about through the intrinsic pathway by 
exposure of the blood to negatively charged collagen fibres underlying the 
endothelium in the blood vessels or on negatively charged platelet surfaces. An early 
reaction begins with conversion of prekallikrein to kallikrein by high molecular weight 
kininogen, which is able to activate FXII to FXIIa. This activates FXI to FXIa and 
leads to the release of bradykinin, a potent vasodilator, from high molecular weight 
kininogen. FXIa then catalyses the proteolytic activation of FIX to FIXa in the 
presence of calciumav, so FIXa forms a complex with FVIIIa in the presence of calcium 
on the surface of activated platelets. This is known as the intrinsic tenase complex and 
is required for the activation of FX to FXa. 
1.3.3 Common pathway 
FXa generated via the tenase complex arising from both the intrinsic and extrinsic 
pathways, converts prothrombin to thrombin by specific proteolytic cleavages. FXa 
alone is a poor activator of prothrombin, but its activity against prothrombin is 
enhanced 300,000-fold when part of the prothrombinase complex consisting of FVa, 
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calcium and phospholipid membrane51. As 20% of FV in the blood is stored in 
platelets and released only upon platelet activation, physiological prothrombin 
activation normally takes place at a significant rate only in the vicinity of vascular 
injury 52'53. Once thrombin is generated, fibrinogen is converted into fibrin to form a 
haemostatic "plug". This plug is stabilised by FXIIIa, a transglutaminase activated by 
thrombin which cross-links fibrin fibrils 54 (Figure 1.1). 
INTRINSIC Blood '''' 
PATHWAY Tissue factor (TF) 
(Vessel damage) FVIIa 
FIX FIXa Ca2+ 
FVIIa EXTRINSIC 
FIIa FVLLia Ca2+ PI Ca2+ PATHWAY 
FVIII 10 (Tenase) 
FX FXa FX 
C'o-'+ Pl FV'a Va FV 
(Protlu"outbjJtase) COMMON 
PATHWAY 
Prothrombin thrombin (FIIa) 
Fibrinogen Fibrin 
FXIII- 
FII 
FXIIIa I 
a 
Cross-linked fibrin 
Figure 1.1. Coagulation cascade. 
Blood coagulation is initiated by exposure of tissue factor (TF), present in sub-endothelial cell surfaces. 
Circulating FVIla/FVII in plasma then comes into contact with TF and forms a complex to activate both 
FIX and FX. This generates small amounts of thrombin, which activates FVIII to FVIIIa and FV to 
FVa. FVIIIa and FVa are important cofactors for the tenase and prothrombinase complexes 
respectively. These complexes are formed in the presence of Ca2+ and phospholipids (P1) on activated 
platelet surfaces (green). This process enhances thrombin generation to convert fibrinogen into fibrin. 
This generates a haemostatic plug, which is stabilised by the crosslinking of fibrin fibrils in the presence 
of FXIIIa. 
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1.3.4 Regulation of Coagulation 
In order to localise coagulation to the site of injury, several mechanisms exist that 
regulate the coagulation cascade. Tissue factor pathway inhibitor (TFPI) is a member 
of the Kunitz family of inhibitors, which is important in regulating the initial stimulus 
that triggers the extrinsic pathwayS5. TFPI achieves this by binding to TF-FVIIa and 
FXa, to form a quaternary complex that inhibits both FVIIa and FXa56. Antithrombin 
is a member of the serpin family that primarily inhibits thrombin and FXa, but also 
FXIa and FIXa to a lesser extent57. In the presence of heparan sulphate, a 
glycosaminoglycan (GAG) present on the surface of endothelial cells, antithrombin 
activity is increased up to 2000-fold58. This serves to inhibit any thrombin that has 
escaped from the site of injury and into the circulation. Consequently, thrombin has a 
half-life that has been estimated to be approximately 15 seconds in the circulation. The 
protein C (PC) pathway down-regulates the clotting cascade by inactivating FVIIIa 
and FVa, cofactors required for the tenase and prothrombinase complexes 
respectively59. In the PC pathway, thrombin binds thrombomodulin (TM) on the 
surface of intact endothelial cells adjacent to the site of injury. Thrombin then cleaves 
and converts PC into activated protein C (APC), which in turn inactivates FVa and 
FVIIIa60. APC activity against FVa and FVIIIa is further enhanced by its cofactor, 
protein S61. Recently, protein S has been shown to inhibit the extrinsic pathway by 
enhancing the interaction between TFPI and FXa62. Over the large vessel endothelium 
(i. e. arteries and veins), endothelial cells express the endothelial protein C receptor 
which localises PC to the cell surface and presents PC to the thrombin-TM complex, 
thereby enhancing APC generation63. 
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1.3.5 Fibrinolysis 
As the haemostatic plug is stabilised, wound repair mechanisms are initiated. These 
involve the fibrinolytic cascade whereby plasminogen is activated to plasmin, which 
converts fibrin into fibrin degradation products and can activate tissue-remodelling 
( toem nkr m, e , su, OLdcWo, and comigenJa) 
proteins and cell growth factors important in vessel repairO'Od. Tissue plasminogen 
activator (tPA) and urokinase plasminogen activator (uPA) activate plasminogen. tPA 
is expressed by endothelial cells and circulates in plasma. Its plasminogen cleaving 
activity is greatly enhanced by fibrin66. uPA is expressed by a variety of cells in tissues 
and binds to its receptor on cell surfaces, which enhances plasmin generation in these 
locations. Plasminogen activator inhibitor 1 and 2 inhibits tPA and uPA, while plasmin 
activity is controlled by a2-antiplasmin and a2-macroglobulin. Plasmin fibrinolytic 
activity is also indirectly modulated by thrombin activatable fibrinolysis inhibitor, 
which modifies fibrin to make it less susceptible to plasmin cleavage67. 
1.4 Von Willebrand factor 
Adherence and activation of platelets at sites of vascular injury is critical for efficient 
haemostasis. An important mediator for the adherence of platelets to the exposed sub- 
endothelium is VWF. 
1.4.1 VWF gene structure and domain structure 
The Vwf gene is located on chromosome 12p13.2 and spans approximately 180kb68. 
Vwf contains 52 exons in which exon 1 represents the 5'-untranslated sequence, exons 
2 to 18 encodes the signal peptide and the propeptide and the remaining exons encode v 
69 the mature VWF protein 
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PreproVWF consists of 2813 amino acids. The first 22 amino acids correspond to the 
signal peptide. The next 741 amino acids represent the propeptide and the remaining 
2050 amino acids embody the mature VWF protein. VWF is composed of 4 "D", 3 
"A", 3 "B" and 2 "C" domains. The multiple functions of VWF depend on the 
presence of D, A and C domains to establish complex interactions with other proteins 
involved in the haemostatic response (Figure 1.2). Thus far, the B domains have no 
known function. 
Von Willebrand Factor 
Multimerisation Dimerisation 
IS D1 D2 D' D3 D41 E 
TTT 
Signal peptide 22 Heparin 
Gplb Collagen GPllb/Illa 
amino acids FVIII Collagen 
Heparin 
Propeptide 741 Mature VWF 2050 amino acids 
amino acids 
Figure 1.2. Domain structure of preproVWF. 
Arrows indicate binding sites within the subunit for several macromolecules. Activated platelet integrin 
GPIIbIIIa binds VWF through a segment that includes the Arg-Gly-Asp-Ser (RGDS) integrin binding 
sequence in VWF domain Cl. 
-T)we c Ace 
VWF is remarkably rich in cysteine residues (234/2813 residues). las abundant in all 
of the domains except the A domains, which together contain only 6 cysteine residues. 
Two regions of the mature subunit are involved in intermolecular disulphide bonds 
Is 
formation: one in the N-terminal portion of the molecule (residues 1046-1242) and the 
n 
other in the C-terminal portion (residues 2671-2813) (amino acid numbering from the 
start of the signal peptide). In the secreted protein, there are no detectable free 
sulphydryl groups, suggesting that all cysteine residues are paired in intramolecular 
disulphide bonds7-73 
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The D1-D2-D'-D3 domains located in the N-terminal part of pro-VWF are comprised 
of approximately 360 residues, each containing 32 to 36 cysteine residues. They share 
significant sequence homology suggesting their tertiary structure may be similar. The 
D domains are involved in the multimerisation process: D1 and D2 form the VWF 
propeptide, and D3 contains cysteine residues involved in the formation of 
intermolecular disulphide bonds, important for VWF multimerisation2,72,74. Moreover, 
the D' and D3 domains bind to coagulation FVIII 75 and to heparin76 (section 1.4.4). 
The A domains are present in a wide variety of proteins including extracellular matrix 
components (non fibrillar collagen and cartilage matrix protein), cellular adhesion 
proteins (integrins, leukocyte adhesion receptors, collagen receptors) and complement 
components. The A domains play an important role in establishing specific 
interactions with macromolecular ligands77. The crystal structure of the Al domain has 
a central ß sheet flanked by a helices on each side with an intramolecular disulphide 
bond between residues Cys1272 and Cys1458 that forms a "loop" of 186 residues. The 
Al domain can bind GPIb on platelet surfaces, but also binds collagen and 
heparin 78"79. The A2 domain primary sequence is similar to Al and A3, but lacks the 
conserved cysteine residues. A crystal structure for the A2 domain has not been 
generated, but a structural model of the A2 domain has been predicted based on its 
homology to Al and A3 domains in VWF80. Molecular modelling of the A2 domain 
suggests it has a characteristic a/ß-fold with 6 stranded ß-sheet surrounded by 3 a- 
helices on each side. The A2 domain harbours the ADAMTSI3 cleavage site at 
Tyr1605-Met1606 (section 1.5.4). The peptide bond is buried within the ß-sheet and is 
predicted to require large conformational changes in the A2 domain to expose the 
scissile bond prior to proteolysis by ADAMTSI3. The crystal structure of the A3 
domain has a dinucleotide-binding fold that consists of a central ß-sheet with 6 strands 
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that are surrounded by 7 a-helices. It also generates a loop of identical length to the AI 
domain by a disulphide bond between residues Cys1686 and Cys1872. The A3 domain 
is important for binding type III or type I collagen, present in the sub-endothelium81. 
The C domains share sequence similarity to corresponding domains in 
thrombospondin and alpha-procollagen types I and III. The Cl domain contains a 
RGDS sequence, which is a typical recognition site for adhesion receptor of the 
integrin superfamily. The C domains also bind to the platelet GPIIbIIIa receptor on 
activated platelet surfaces82. The CK domain contains cysteine residues involved in the 
dimerisation process (section 1.4.2). 
The mature VWF subunit is extensively glycosylated. It contains 22 predicted 
glycosylation sites, 10 O-linked to serine or threonine residues and 12 N-linked to 
asparagine residues. Approximately 10% to 19% of the total molecular mass of the 
mature VWF subunit is made up of carbohydrate moieties. The N-linked 
oligosaccharides contain ABO blood group oligosaccharides83"84. It has been shown 
that ABO blood group antigens influence plasma VWF levels, whereby blood group 0 
individuals have lower VWF levels than non-blood group 0 (A, B, AB) individuals85. 
It seems that these carbohydrate structures not only influence VWF proteolysis but 
86 "88. also the clearance of the molecule from plasma 
1.4.2 VWF biosynthesis, storage and secretion 
VWF is primarily expressed in endothelial cells, but also by platelets89. VWF is 
initially synthesised as a prepropolypeptide before processing by sequential carboxyl 
(C) - and amino (N)-terminal disulphide-bond dimerisation and multimerisation in the 
rough endoplasmic reticulum (rER) and Golgi complex, respectively73. In the rER, 
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glycosylation and dimerisation of the pro-VWF subunits takes place. This is achieved 
by disulphide bond formation between cysteine residues in the C domains at the C- 
terminus of VWF, and is known as "tail-to-tail" dimerisation71. Also, the propeptide 
forms a disulphide-linked intermediate with the D'D3 domains at the N-terminus of 
VWF in the rER. This intermediate rearranges in the Golgi apparatus to make 
multimers9°. The propeptide may function as an endogenous pl-1-sensitive thiol- 
disulphide oxidoreductase, converting intrasubunit disulphide bonds into intersubunit 
disulphide-bonded multimers in the N-terminus of each mature subunit, this is termed 
"head-to-head" multimerisation73,91.92. Cysteine residues in the D1 (Cys159 and 
Cys162) and D2 (Cys521 and Cys524) domains promote VWF interdimer disulphide 
bond formation93. Subsequently, the propeptide is cleaved by furin in the Golgi and 
additional glycosylation take place. The propeptide remains non-covalently bound to 
VWF multimers due to the acidic pH and high calcium concentration of the Golgi94. 
Whilst proteolytic processing of VWF is not essential for multimer formation95, the 
outcome of this post-translational process results in the generation of "ultra large" 
VWF (UL-VWF) multimers that may exceed 20,000kDa96 (up to 40 VWF subunits) 
(Figure 1.3). 
The majority of VWF synthesised by endothelial cells is constitutively secreted into 
the plasma as polymers of varying size, ranging from 500kDa to 20,000kDa, but -5% 
is stored within the organelles of the Weibel-Palade bodies predominantly as UL- 
VWF . It has 
been 97. UL-VWF multimers are also contained in platelet a-granules98'99 
shown that VWF targeting to storage granules requires the propeptide region and its 
deletion causes constitutive secretion of VWF' 00-103. The stored VWF can be released 
upon activation of particular membrane surface receptors on the surface of platelets or 
endothelial cells by histamine, thrombin or vasopressin. This generates a specific 
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intracellular signal which ultimately leads to the secretion of the a-granule and/or 
Weibel-Palade bodies contents 104''05. After secretion, the propeptide dissociates from 
the VWF multimers and circulates in plasma as a non-covalent homodimer 
(vWAgII)106,107. VWF multirners circulate in plasma at a concentration of - 5-lOµg/ml 
with a half-life of -12 hours1°6, which may not change with multimeric size""'. 
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Figure 1.3. VWF multimerisation. 
(A) Newly synthesized VWF consists of a signal peptide, a propeptide, and a mature polypeptide. (B) 
Upon entry into the rER, the signal peptide is removed and pro-VWF forms a dimer by disulphide 
bonds at the carboxyl terminus. (C) In the golgi apparatus, VWF multimerises through disulphide bonds 
at the amino terminus. The largest VWF multimers are then stored in the Weibel-Palade bodies of 
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endothelial cells. Adapted from 
1.4.3 VWF function 
VWF has two principal roles in haemostasis. First, VWF acts as a carrier protein for 
FVIII110. Second, VWF mediates platelet adhesion to sites of vascular damage through 
the specific binding of VWF to exposed sub-endothelial collagens 1. Platelet tethering 
properties of circulating VWF are partly dependent upon its molecular size. Larger 
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VWF multimers not only bind circulating platelets more readily than smaller forms, 
but can also more readily undergo conformational changes in response to the shear 
forces exerted by the circulating blood112. Under low shear stress, VWF multimers 
circulate in a "globular" form whereby the GPIb platelet-binding site in the Al domain 
is concealed, but the collagen-binding site in the A3 domain is exposed. Consequently, 
globular VWF cannot readily bind platelets, but can bind collagen. When exposed to 
I 
high shear stresses, VWF unravels into a "string-like" conformation 113. This increases 
the number of exposed platelet/matrix binding sites and thus enhances the platelet 
aggregating potential of the VWF molecule. Smaller multimeric forms do not respond 
to shear stresses to the same extent as UL-VWF. 
1.4.4 Factor VIII stabilisation 
An important function of VWF is to stabilise FVIII and protect it from degradation by 
APC. FVIII binds VWF with a high binding affinity (KD 200pM to 400pM) and 
circulates in plasma in a non-covalently associated complex' 
10, but is very labile when 
(e nors , -SW OJcktzb, + 
Cocfiger4c%) 
not bound to VWIn. VWF binds FVIII with similar affinity regardless of its multimeric 
size114. The FVIII binding site on VWF is located in the D' and D3 domains 
The N-terminal region of VWF contains an intrachain disulphide bond that is essential 
for FVIII binding' 17. The corresponding VWF binding site on FVIII is located near the 
N-terminus of the 80kDa light chain and in the C-terminal region of the C2 domain118- 
120 
. Inhibition studies showed that 
binding sites for APC and VWF on FVIII are 
overlapping 121. Thus, VWF protects FVIII from APC catalysis by direct inhibition of 
APC binding. It has also been shown that VWF binding to FVIII reduces the rate of its 
clearance by decreasing the efficiency of FVIII internalisation and degradation by the 
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liver lipoprotein receptor-related protein'22. During blood coagulation, FVIII is 
activated by thrombin cleavage after R372, R740 and R1689, causing the release of 
FVIII B domains. This cleavage disrupts the VWF binding site and releases FVIIIa, 
23''25 which can then take part in the coagulation cascade1. 
1.4.5 VWF binding to sub-endothelial surfaces 
At the site of a vascular lesion, platelets must adhere to the injured region and resist 
the rheological forces exerted by the flowing blood. The role of VWF in haemostasis 
involves establishing contact between circulating platelets and sub-endothelial 
components. Once VWF is immobilised on the sub-endothelium, the shear forces of 
the flowing blood unravel and expose platelet binding sites in the Al domain of VWF. 
Collagen is a major component of the extracellular matrix that is capable of binding 
VWF'11. There are different types of collagen that interact with VWF. However, the 
type that is exposed to the flowing blood depends on the degree of the vascular 
damage. The main types of collagen involved in anchoring VWF to sub-endothelial 
surfaces are types I, III and VI126-129. Collagen type I is located in the deeper layers of 
the vessel wall. and is exposed only after extensive injury; collagen type III and type 
VI are present in the sub-endothelium and can be revealed following limited injury. 
Alanine-scanning mutagenesis and the crystal structure of the Al and A3 domains in 
. 
81 VWF have been carried out to localise the collagen-binding sites in VWF'130'ý3ý 
These studies suggest the A3 domain in VWF is the main collagen-binding site for 
both collagen type I and type III. A minor collagen type I binding site and a collagen 
type VI binding site has also been identified in the Al domain132'133. Other structural 
matrix components may also be involved in the immobilisation of VWF to the sub- 
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endothelial surface. The Al domain contains a heparin binding site which may interact 
with matrix heparin-like GAG134,135. A lower affinity heparin binding site is also 
located in the D' and D3 domains76. 
1.4.6 Platelet binding to VWF in the sub endothelial layer 
The function of VWF is crucial to establishing platelet-surface contact at shear rates 
above 500-1000s'', but less so at lower shear rates. The consequence of shear stress 
upon VWF function is to increase its reactivity by creating a bridge between platelets 
and the sub-endothelial surface. In normal flow, plasma VWF exists in a globular 
conformation and cannot bind circulating platelets. However, once tethered to sub- 
endothelial collagen via its A3 domain at sites of endothelial disruption, globular 
VWF unravels and adopts a "stretched" conformation in response to shear stress 
conditions of the circulation. Further structural changes may also contribute to VWF 
unravelling. For example, it has been suggested that the neighbouring D' and D3 
domains shield the Al domain, which is only exposed when VWF is immobilised onto 
collagen 136. This process exposes the multiple sites that confer VWF affinity for the 
GPIb-IX-V receptor complex on the surface of circulating platelets113. The GPIb 
binding site on VWF has been mapped to a large number of charged residues on the 
Al domain surface 134,135. GPIb binding to VWF immobilised on collagen has a fast 
association and dissociation rate in addition to being highly resistant to tensile stresses, 
thereby slowing the movement of flowing platelets even at shear rates up to 6000s"l 
137. The initial contact facilitates other interactions, namely GPIIbIIIa expressed on 
activated platelet surfaces with the RGD motif in the Cl domain of VWF. This 
provides a tighter binding interaction, characterised by a slow association and 
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are secreted as active enzymes that possess one or more thrombospondin type I 
repeats (TSP) and variable additional C-terminal domains frequently involved in 
extracellular matrix binding'47"48. The signal peptide and propeptide domains of 
ADAMTS family members are predicted to ensure correct protein folding and 
maintain the enzyme in an inactive form during maturation within the cell (Figure 
1.4). There are currently 19 members in the ADAMTS family some of which have 
important roles against cancer and arthritis. ADAMTSI3 plays a unique role in 
haemostasis and is the most phylogenetically divergent member amongst the 
ADAMTS family14`'. 
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Figure 1.4. Domain structure of ADAM and ADAMTS metalloproteinases. 
SP, signal peptide; pro, propeptide; protease, metalloproteinase (location of zinc-binding motif shown in 
red); disintegrin, disintegrin domain; dis-like, disintegrin-like domain; cys-rich, cysteine-rich domain; 
TSP, thrombospondin type-1 motif; EGF, epidermal growth factor-like repeat; TM, transmembrane 
domain. Reproduced from"'). 
1.5.2 ADAMTS13 biosynthesis and secretion 
The Adamtsl3 gene is located on chromosome 9 at position 9q34, spans 
approximately 37kb, and contains 29 exons143 The cDNA is 4281 base pairs long, and 
encodes a precursor ADAMTS13 protein composed of 1427 amino acid residues with 
a predicted molecular weight of -145kDa. However, the observed molecular weight of 
purified ADAMTS13 from plasma is - 190kDa141. The increased molecular weight is 
attributed to glycosylation at 10 potential N-glycosylation sites (Asn-Xaa- 
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Thr/Ser)9'1s1'1s2 ADAMTS13 is expressed by a number of adult tissues including the 1 
prostate, brain, placenta, heart and skeletal muscle, but it is predominantly expressed 
and secreted into the blood as an active enzyme by hepatic stellate cells in the liver' 52- 
'5'. An additional source of ADAMTSl3 is also contained in platelets'55"56 and has 
also been reported within cultured endothelial cells' 57,158 Expression of ADAMTS13 
from hepatic cells was constitutive and does not appear to change dramatically under 
pathological conditions' 59. ADAMTS13 circulates in plasma as an active enzyme at a 
concentration of approximately 1µg/ml (-5nM) and has an estimated half-life of 2-3 
days' 60 
1.5.3 ADAMTS13 structure and function 
Members of the ADAMTS family share a similar N-terminal domain structure up to 
the spacer domain, but differ in the domains C-terminal to the spacer. Uniquely, 
ADAMTS13 is the only member to contain the C-terminal CUB domains (Figure 1.5). 
TSP-1 
Figure 1.5. Domain structure of ADAMTS13. 
MP - metalloproteinase domain, Dis - 
disintegrin-like domain; cys-rich - cysteine-rich domain; TSP-1 - 
thrombospondin type-I repeat motif, CUB - CUB domain. 
The propeptide domain (residues 34-74) of ADAMTS13 is flanked at its carboxyl end 
by a consensus cleavage site (RQRR) for furin. It is only 41 amino acids long in 
contrast to -200 amino acids in other ADAMTS and ADAM family members. 
Furthermore, the ADAMTS13 propeptide domain does not contain a potential 
"cysteine-switch" motif whose function in other metalloproteinases is to inhibit 
protease activity prior to its proteolytic removal by furin'61. Therefore, the function of 
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the propeptide domain in ADAMTS 13 is uncertain since its removal does not affect 
secretion or enzymatic activity, suggesting this domain does not confer latency or 
correct folding and secretion of ADAMTS13162. 
A common theme amongst the protease domain of metzincin family is the dependency 
upon zinc and calcium ions for catalytic activity. The metalloproteinase domain of 
ADAMTS13 (residues 75-289) contains a putative zinc ion-binding site coordinated 
by three histidine residues (H224EXXHXXGXXHD235), a predicted calcium-binding 
site coordinated by residues G1u83, Asp 173, Cys281, Asp284 and a conserved Met249 
that supports the active site zinc ion in a "Met-turn". The glutamate residue (E) 
following the first zinc-binding histidine residue has a catalytic role163 This residue is 
predicted to hydrogen bond and polarise a water molecule, stabilised by its 
coordination with the zinc ion, and nucleophilically attack the carbonyl group of the 
substrate scissile peptide bond. Calcium is also required for ADAMTS13 activity 
against VWF, but its exact functional role has not been determined139,1ao, 
t6a 
ADAMTS13 has an apparent KD of 0.5µM for zinc and 4.8µM for calcium164. Since 
the normal plasma concentrations of zinc and calcium are 12-18µM and 2.2-2.6mM, 
respectively, it is likely that ADAMTS13 binds free zinc and calcium in plasma and 
circulates as a fully active coordinated enzyme. ADAMTS13 is inhibited by metal ion 
chelators, such as ethylenediaminetetraacetic acid (EDTA), compatible with the 
139 
essential role of zinc and calcium in its activity against VWF 
The disintegrin-like domain (residues 290-385) shares sequence identity with snake 
venom proteins that bind integrins via its RGD sequence. ' Despite its name, the 
disintegrin-like domain in ADAMTS13 does not have an RGD integrin binding 
sequence 152. Its precise role in ADAMTS13 is unknown, although patients with 
mutations in this domain have reduced activity against VWF'43,165. Whether these 
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mutations actually affect activity or impair secretion is unclear. Potentially, the 
disintegrin-like domain may be involved in VWF binding166,167. 
The cysteine rich domain (residues 440-555) contains 10 cysteine residues and 
includes a potential integrin-binding RGD sequence. The importance of this sequence 
for ADAMTS13 secretion and activity is unclear as mutating it had no effect upon 
secretion or activity of ADAMTS 13168. However, a common ADAMTS13 
polymorphism located in this region, P475S, found in the Japanese population affected 
ADAMTSI3 activity but not secretion in vitro151. The precise role of this domain in 
ADAMTS13 is uncertain, but may be involved in VWF binding166,167. 
The spacer domain (residues 556-685) is important for the function of several 
ADAMTS family members, including ADAMTSI and ADAMTS4169,170. In 
ADAMTS13, the spacer domain is essential for VWF processing function since loss of 
this domain largely depletes ADAMTS13 activity171'172 . The ADAMTS 13 spacer 
domain may be involved in binding to VWF. ADAMTS13 truncated after the TSP1 
domain bound multimeric VWF with a KD of 206nM whereas ADAMTS13 truncated 
after the spacer domain bound with a KD of 23nM, which is comparable to full-length 
ADAMTS13 with a KD of 14nM173. Similar results were obtained using VWF73, 
suggesting this domain recognises VWF A2 domain residues 166. Furthermore, a 
majority of mutations located in the spacer domain and a number of autoantibodies 
directed against this region have been found to cause a loss of activity, suggesting this 
domain performs an important role in defining ADAMTS 13 function 174,175 
ADAMTS13 has 8 TSP domains. The first (residues 386-439) is located between the 
disintegrin-like and cysteine-rich domains and the remaining seven (residues 686- 
1131) are located C-terminal to the spacer domain. Like other ADAMTS members, 
TSP1 appears to be important for enzyme function. Recent findings suggest that TSP1 
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may be involved in VWF binding 166,173. The precise role of the C-terminal TSPs in 
ADAMTS13 is uncertain. Under static and flow conditions, loss of TSP2-8 had no 
impact upon activity against VWF'71. However, truncation after TSP8 reduced the 
binding affinity by -3-fold and truncation after TSP7 increased the affinity for VWF 
by -2-fold 173. Possibly, the C-terminal TSPs may modulate VWF binding and 
contribute to cleavage of VWF in vivo. 
Unlike other ADAMTS family members, ADAMTSI3 has two C-terminal CUB 
domains (Complement components Clr/Cls, Uegf (sea urchin fibropellins), and Bone 
morphogenic protein 1) (residues 1192-1408). CUB domains are found in many 
developmentally regulated proteins such as the dorsoventral patterning protein tolloid, 
bone morphogenetic protein 1, and spermadhesins that are involved in protein-protein 
interactions 16. Recently, it has been suggested the CUB domains are involved in the 
apical sorting of a soluble ADAMTS13 in polarised cells158. However, its precise role 
in ADAMTS13 activity against VWF remains unclear. Under static conditions, loss of 
the CUB domains had no effect upon activity against multimeric VWF or the VWF73 
substrate 166"71. Furthermore, several natural murine strains express an ADAMTS13 
variant lacking the CUB domains and TSP7 and TSP8 domains. This variant was 
active against multimeric VWF in vitro, suggesting these domains may not be critical 
for ADAMTS13 function in vivo'77. Nevertheless, mutations located in the CUB 
domain and autoantibodies directed against this region have been identified175'178. 
Potentially, the CUB domain may be involved in VWF binding 152. A recombinant 
CUB1 polypeptide inhibited cleavage of UL-VWF strings under flow, but not static 
ýýrs 
conditions. Additionally, an ADAMTS13 variant truncated up to the TSP8 domain 
reduced VWF binding by -3 fold, suggesting the CUB domains may modulate VWF 
interactions 173. Indeed, an ADAMTS13 variant truncated after the spacer domain 
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cleaved UL-VWF strings more efficiently compared to wild type ADAMTS13 under 
flow conditions, suggesting C-terminal domains from the spacer region may 
negatively regulate ADAMTS 13 activity' 72. 
1.5.4 Regulation of UL-VWF size by ADAMTS13 in the circulation 
The normal location of ADAMTS13 action in vivo is still unclear. Although 
ADAMTS13 circulates in plasma as an active enzyme, VWF adopts a globular 
conformation that is resistant to proteolysis180'181. Only when shear stress unravels 
VWF to expose the ADAMTS13 cleavage site does proteolysis occur. 
ADAMTSI3 may cleave UL-VWF multimers upon its release from the Weibel-Palade 
bodies of stimulated endothelial cells. In this case, UL-VWF is tethered to P-selectin 
through its D' and D3 domains 182.183. This anchoring to the cell surface may assist UL- 
VWF to undergo conformational changes once exposed to high shear stress in 
vitro 11'113. Selectins are cell surface carbohydrate-binding protein (lectins) that mediate 
a variety of transient, calcium dependent, cell-cell adhesion interactions in the 
bloodstream. However, recent data has demonstrated that P-selectin is not essential for 
platelet string formation in vivo since transient thrombi are formed in stimulated 
venules of P-selectin deficient mice, similarly seen in wild type mice venules, when 
ADAMTS13 activity is inhibited184. 
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Unravelling of UL-VWF most likely exposes binding sites for ADAMTS13. The 
stoichiometry of binding is one ADAMTS13 per two VWF monomers and the KD is 
approximately 14nM, which is comparable to the plasma VWF concentration, 73 . The 
A3 domains of VWF have been suggested to be involved in ADAMTS13 binding185. 
However, this binding does not appear to be important for proteolysis 186''87. Additional 
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charged amino acid residues within the A2 domain of VWF might also be important 
for the binding and cleavage by ADAMTS 13187'189. Recently, it has been demonstrated 
that residues Glu1660 to Arg1668 within the C-terminus of the VWF A2 domain are 
important for ADAMTSI3 to recognise and cleave its substrate190. The regions of 
ADAMTS13 involved in binding VWF are not known, but is likely to involve the 
. spacer domain since 
its loss reduces ADAMTS 13 activity'71.190 
Once ADAMTS13 is bound to unravelled VWF, it is able to proteolyse VWF in the 
Tyr1605-Met1606 bond in the A2 domain. This causes the conversion of VWF 
multimers into lower molecular weight forms that confer a diminished 
adhesive/prothrombotic potential because of the reduced number of platelet binding 
sites. Several lines of evidence support the requirement for VWF to unravel before it 
becomes susceptible to ADAMTS 13 proteolysis. In vitro, ADAMTS 13 is only able to 
cleave VWF in the presence of denaturants, such as urea or guanidine139,14o Under 
physiological flow conditions at arterial (20-50dyn/cm2) and venous (2.5dyn/cm2) 
shear stresses, UL-VWF strings secreted from stimulated endothelial cells are 
susceptible to proteolysis by ADAMTSI3 in the absence of denaturants, 85'191. Also, 
the Al domain is predicted to conceal the ADAMTS13 binding site in the A2 domain, 
which is only revealed when exposed to high shear stress 186. This is supported by the 
finding that proteolysis of an A2 domain polypeptide fragment by ADAMTSI3 was 
much faster when compared to a A1A2A3 VWF polypeptide fragment under 
physiological ionic conditions in the absence of denaturants1g7'188,192,193 
It seems that NaCI influences the rate of VWF proteolysis. In the absence of chloride 
ions, the catalytic efficiency (kC8t/Km) of ADAMTS13 for UL-VWF is 3.4 x 104 M'ss'', 
but this decreased -10-fold in the presence of physiological NaCl concentrations of 
150mM, suggesting that chloride anions inhibit proteolysis of UL-VWF by 
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ADAMTS13194. However, the presence of denaturants in these reactions may not 
accurately assess the kcat/K,,, of ADAMTS13 for UL-VWF. Nevertheless, it is 
hypothesised that anion binding to the Al domain may stabilise VWF in a `closed' 
conformation, denying access of ADAMTS13 to cleave the Tyrl605-Metl606 peptide 
bond in the A2 domain'95. When exposed to shear stress, VWF undergoes a 
conformational change that reduces the anion binding capacity and allows 
ADAMTS 13 to access the cleavage site. 
1.6 Thrombotic thrombocytopenic purpura 
Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening condition 
linked to UL-VWF function' 96. This condition is characterised by platelet-rich thrombi 
in the microvasculature causing haemolytic anaemia, thrombocytopenia, fever, renal 
failure, and neurological dysfunction 197. Such clinical manifestations are a direct 
consequence of the elevated levels of circulating UL-VWF detected in affected 
individuals 198. Increased circulating UL-VWF multimers promote platelet-rich 
thrombus formation by tethering/aggregating circulating platelets under normal shear 
conditions in the absence of collagen binding 197. The reported mortality for TTP is 
greater than 90%, but when diagnosed early and treated with plasma exchange, 
mortality is reduced to less than 20%199. The cause of TTP has been attributed to the 
loss of ADAMTS13 function in processing UL-VWF due to congenital or acquired 
defects. 
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1.6.1 Congenital TTP 
Congenital TTP is caused by Adamtsl3 gene mutations that affect secretion or VWF 
cleaving activity. A number of Adamtsl3 mutations affecting activity and 
ADAMTS13 plasma levels have been documented 143,151,200,201 . Approximately 60% of 
these mutations are missense single amino acid substitutions, and 40% are nonsense, 
frameshift, or splice site mutations that are predicted to result in a truncated protein. 
There are no apparent clustering or mutation hot spots, although roughly 75% of the 
missense mutations are found in the first half of the molecule (metalloproteinase 
domain through to the TSP2 domain). Although mutations in ADAMTS 13 can cause 
deficiency in VWF processing, there are no homozygous null patients suggesting 
ADAMTS13 activity is essential for life. Individuals suffering from congenital TTP 
show a varied age of onset, with most cases occurring during infancy, but some not 
occurring till the third decade of life202. In a murine study, ADAMTS13 deficient mice 
were viable and exhibited normal survival in the presence of UL-VWF multimers. 
Introduction of an ADAMTSI3 knock out into a CASA/Rk mouse background, a 
mouse strain with -10-fold elevated VWF levels, caused a subset of mice to develop 
TTP-like symptoms. Challenging these mice with shigatoxin resulted in TTP-like 
symptoms. However, no correlation between VWF levels and severity of TTP was 
observed, suggesting that environmental and/or additional genetic factors might 
influence such a TTP episode in an ADAMTS13 deficient murine setting203. Similar 
results were obtained in another murine study in which ADAMTS 13 deficiency alone 
was prothrombotic, but insufficient to induce a TTP episode204. Whilst additional 
factors are likely to be required to elicit a TTP episode in ADAMTS 13 deficient mice, 
fundamental differences exist between human and murine systems'77. Therefore, 
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results generated from murine models may not best represent the severity of TTP 
symptoms in humans and may account for the variations observed. 
1.6.2 Acquired TTP 
Acquired TTP is caused by the presence of inhibitory immunoglobulin (Ig) G 
autoantibodies against ADAMTS13. These autoantibodies can be generated after 
infection or result from the use of drugs such as clopidogre1205 and ticlopidine206. Both 
clopidgrel and ticlopidine are used to inhibit platelet aggregation and treat various 
conditions such as myocardial infarction, stroke, blood clots, and acute coronary 
syndrome. Whether the autoantibodies are always involved in enhanced clearance or 
blockage of enzymatic function, or both, is not clear. In a study with a patient 
suffering from acquired TTP, non-neutralising IgM and IgG autoantibodies against 
ADAMTS13 activity were found, suggesting these antibodies influenced ADAMTS13 
by reducing its plasma half-life207. Epitope mapping has shown that autoantibodies can 
bind to most domains in ADAMTS13, but those against the cysteine-rich and spacer 
regions are the most common17s, 
2os. 2o9 Interestingly, two identical sisters who did not 
have congenital defects in ADAMTSI3 suffered from acquired TTP suggesting a 
genetic predisposition to forming autoantibodies against ADAMTS13210. The current 
treatment to remove autoantibodies against ADAMTS13 involves periodic plasma 
exchange (2-4 weeks). An alternative to plasma exchange in treating acquired TTP is 
to use the anti-CD20 monoclonal antibody Rituximab, normally used for treating B 
cell lymphoma since this removes autoantibody producing B cells 211'212. Another 
alternative to plasma exchange may be to use ADAMTS 13 variants truncated after the 
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C-terminus of the cysteine-rich domain, which has been shown to eliminate 
autoantibody recognition without abolishing all VWF proteolytic activity213. 
1.6.3 TTP, haemolytic Ure mit Syndrome and other thrombotic 
microangiopathies 
TTP-like syndromes can also arise secondary to other conditions such as HIV 
infection214, bone marrow transplantation 215,216, pregnancy217 and systemic lupus 
erythematosus218. Furthermore, decreased ADAMTS13 activity has been associated in 
a wide range of conditions, including idiopathic thrombocytopenic purpura, 
haemolysis-elevated liver enzymes-low platelet syndrome219, disseminated 
intravascular coagulation (DIC)220'221, liver cirrhosis, chronic uremia, leukemia, the 
postoperative state, the neonatal period, and with advancing age222,223. Additionally, 
Haemolytic Ureamic Syndrome (HUS) presents similar symptoms to TTP such as 
acute renal failure, thrombocytopenia, neural impairment, intravascular haemolytic 
anemia with schistocytosis, and elevated serum lactate dehydrogenase levels. 
However, most cases of HUS are caused by infections from Shigatoxin-producing 
bacterial strains such as Escherichia coli and Shigella dysenteriae. HUS differs in the 
nature of the microvascular thrombi. Clots from patients with TTP are composed 
mainly of platelet-VWF rich thrombi whereas in HUS patients they are composed 
mainly of fibrin-platelet rich thrombi. Additionally, TTP is normally distinguished 
from HUS by a severe deficiency in ADAMTS13 activity (<5%), which is less 
224 deficient in HUS patients. 
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1.7 Aims of the thesis 
Although ADAMTS13 controls VWF multimeric size by enzymatic cleavage, it 
remains unclear how ADAMTS13 activity is regulated within the vascular system. 
Circulating plasma VWF is normally protected from proteolysis by ADAMTSI3 due 
to its complex tertiary structure. Plasma VWF undergoes conformational changes 
when tethered to various ligands, such as sub-endothelial collagen, and exposed to 
high shear forces of the flowing blood. At sites of vascular injury, this facilitates 
platelet tethering and subsequent platelet plug formation. However, this would be 
predicted to permit ADAMTS13 to both access and cleave the scissile bond in VWF. 
In the absence of a regulatory mechanism, such cleavage might oppose platelet 
adhesion and development of a stable platelet plug. Although it has been observed that 
high levels of interleukin-6 inhibit ADAMTSI3 activity under flow conditions, a 
mechanism and its physiological significance has not been established 
225. 
Additionally, haemolytic serum from a paediatric patient with TTP showed that 
plasma haemoglobin may inhibit ADAMTSI3 activity at 2mg/ml or higher226. Both of 
these inhibitory mechanisms might only be significant under extreme pathological 
circumstances. The aim of my thesis was to investigate the mechanisms that might 
normally regulate ADAMTS13 activity at sites of vessel injury. My working 
hypothesis was that ADAMTS13 activity might be locally regulated by serine 
proteases such as thrombin, FXa and plasmin involved in the coagulation and 
fibrinolytic cascades at sites of vascular injury. If demonstrated, this might represent a 
novel function of such serine proteases that ensures efficient development of the 
haemostatic plug. 
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2 MATERIAL AND METHODS 
2.1 Generation of ADAMTS13 and ADAMTS13 mutants 
2.1.1 ADAMTS13 vector 
Full-length ADAMTS13 cDNA lacking the stop codon (a kind gift from Dr Friedrich 
Scheiflinger, Baxter, Austria'42) was previously amplified and cloned in frame into the 
multiple cloning site of the pcDNA3. lmyc/His mammalian expression vector 
(Invitrogen, UK) by Dr. James Rance (Figure 2.1). This construct was used for 
expression of wild type ADAMTS13 in mammalian cells and as template for the 
generation of ADAMTS13 mutants. 
EcoRI XbaI 
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5.5 kb 
Figure 2.1. Schematic representation of pcDNA 3.1/myc-His vector. c ýýýýuS 
Salient features of the vector encoding recombinant full length ADAMTS13 include the oytomogol irus 
promoter to drive gene transcription, a C-terminal myc-epitope for detection of recombinant protein by 
Western blotting, a C-terminus polyhistidine tag for protein purification, a SV40 promoter for efficient 
expression of the neomycin resistance gene used for selecting mammalian clones, a pUC origin for 
high-copy number replication of the vector in E. coli and an ampicillin resistance gene for selection of 
bacterial clones. 
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2.1.2 Site directed mutagenesis 
The QuikChange® XL site-directed mutagenesis kit (Stratagene, USA) was used to 
a 
introduce mutations into the ADAMTS13 cDNA vector using polymerise chain 
reaction (PCR) that was carried out on the GeneAmp PCR System 2700 (Applied 
Bioscience, UK). Primers (Thermo Electron Corporation, UK Electron Corporation, 
Germany) containing the desired base change(s) were purchased and their purity 
assessed by high performance liquid chromatography (HPLC) analysis (Table 9.1). 
The pcDNA3.1 ADAMTS13 myc/His vector construct was used as template to 
generate ADAMTS13 mutant constructs. PCR reactions were set up according to 
Table 2.1. 
Reagents Strata ene Volume II 
pCDNA3.1 ADAMTS13 myc/His 50n I 
Sense oligonucleotide primer (125ng) 1 
Antisense oli onucleotide primer (125ng) 1 
dNTP mix 1 
lOx reaction buffer 5 
Double distilled deionised (dd) H2O 41 
P fu Turbo DNA polymerase 2.5U/ 1 1 
Total volume 50 
Table 2.1. PCR reaction for generating ADAMTS13 mutant constructs 
The PCR cycling parameters were followed according to manufacturer's instructions 
except the extension time was lengthened from 1 min/kb to 2.5mins/kb to enhance 
generation of mutant constructs. PCR conditions are outlined in Table 2.2. 
Segment Temperature °C Time Cycles 
1 95 1 min 1 
2 95 1 min 18 
45-67 50 seconds 
68 25 minutes 
3 68 7 minutes 1 
Table 2.2. PCR conditions used to generate ADAMTS13 mutant constructs 
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Following PCR, the reaction mix was treated with 1µl Dpnl (IOU/µl) for 2 hours at 
37°C to digest the methylated parental DNA strands. DpnI digested vector was then 
transformed into XL10-gold ultra competent E. coli cells (Stratagene, USA). Briefly, 
45µl XL-10-gold E. coli cells were thawed slowly on ice and pre-incubated with 2µl ß- 
mercaptoethanol (Stratagene, USA) for 10 minutes to enhance cell membrane 
permeability. 4µl of the DpnI treated plasmid DNA was then added to the mixture and 
incubated on ice for 30 minutes. Thereafter, cells were heat shocked at 42°C for 30 
seconds, rapidly chilled once for 2 minutes before incubating with 500µl of pre- 
warmed SOC complete medium (Invitrogen, UK) for 1 hour at 37'C in a rotating 
incubator (250rpm). 250µl of the liquid culture was then spread onto a Luria Bertani 
(LB) agar plate containing 100µg/ml ampicillin (Sigma, UK) and incubated at 37°C 
overnight. 
2.1.3 Isolation of plasmid DNA from E. co/i cells - Plasmid Miniprep 
For small-scale plasmid extractions, isolated transformed bacterial colonies were 
added to 5ml liquid LB containing 100µg/ml ampicillin with shaking at 250rpm 
overnight at 37°C. After incubation, the culture was centrifuged for 5 minutes at 
3000rpm and the supernatant decanted. Vector DNA was then purified using the 
plasmid miniprep kit (Qiagen, UK). Briefly, the cell pellet was resuspended in 250µl 
Pl lysis buffer containing RNase A before being mixed gently with 250µl P2 buffer 
for 5 minutes. During this step, bacterial phospholipids and cell membrane proteins are 
solubilised in sodium dodecyl sulphate (SDS) whilst chromosomal/plasmid DNA and 
proteins are denatured by the alkali conditions of the P2 buffer. 350µ1 N3 buffer was 
added to neutralise the alkali conditions and reconstitute the cell lysate in a high salt 
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environment. This resulted in a white precipitate consisting of denatured proteins, 
chromosomal DNA, cellular debris and SDS. After centrifugation at 13000rpm for 10 
minutes, the supernatant was passed over the QlAprep spin column and centrifuged 
for 1 minute. The flowthrough was discarded and 750µ1 PE buffer containing ethanol 
was centrifuged through the column for l minute at 13000rpm. The flowthrough was 
discarded and residual PE buffer removed by centrifugation as before. To elute the 
plasmid DNA from the mini-column, S0µ1 EB buffer was added to the column and left 
to stand for 1 minute before eluting the plasmid DNA by centrifugation as before. 
2.1.4 DNA sequencing 
Sequencing of ADAMTS13 cDNA was carried out with specific sequence primers 
(Table 9.2). 1µg plasmid DNA was added to 3.2pmol sequencing primer and the final 
reaction volume made up to 10µl.. DNA sequencing was performed at the 
Hammersmith Hospital's Genetics Core Facility using an ABI 3700 DNA analyser 
(Perkin-Elmer, UK). Alignment and analysis of the sequencing results were performed 
using the Seqman (DNAstar, USA) software. 
2.1.5 Restriction enzyme digestion 
To digest plasmid DNA, 1µg DNA was added to IU restriction enzyme (New England 
Biolabs, USA) with restriction enzyme buffer and bovine serum albumin (BSA) as 
appropriate. The reaction volume was brought up to 20µl with ddH2O and incubated at 
37°C for 1 hour. The restriction enzyme was then heat inactivated at 65°C for 30 
minutes. 
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2.1.6 Dephosphorylation of DNA 5' and 3' ends 
To prevent self-religation of complementary ends following restriction enzyme digest, 
1µg vector DNA was treated with 5U calf intestinal alkaline phosphatase (Invitrogen, 
UK) in 50mM Tris-HCI (pH8.5), 0.1mM EDTA and incubated at 37°C for 10 minutes. 
The reaction was then stopped by heat inactivation at 65°C for 30 minutes. As 
necessary, DNA was separated and purified (sections 2.1.7 and 2.1.8). 
2.1.7 Agarose gel electrophoresis 
To visualise and separate DNA fragments according to their size, agarose gel 
electrophoresis was used. Agarose (Biomed, UK) (0.8% w/v) was dissolved in Tris- 
Borate-EDTA buffer (89mM Tris, 89mM boric acid and 2mM EDTA) containing 
10µg/ml ethidium bromide (Sigma, UK) and allowed to polymerise. DNA was mixed 
with 5x DNA loading buffer (40% w/v sucrose and 0.25% w/v bromophenol blue), 
loaded onto the gel and run at 90V for 30 minutes. DNA bands were visualised using a 
UV lightbox (fotoprep II) Fotodyne. 
2.1.8 Extraction of DNA from an agarose gel 
To purify DNA from agarose gel slices, a gel extraction kit (Qiagen, UK) was used. 
Gel slices were resuspended in 3 volumes QG buffer to I volume of gel (I volume = 
100mg/100µl QG buffer) and incubated at 50°C for 10 minutes. One volume of 
isopropanol was added to DNA fragments larger than 4kb or smaller than 0.5kb to 
improve recovery. The entire sample was centrifuged through a QlAquick spin column 
(Qiagen, UK) for 1 minute at 13,000rpm and the flowthrough discarded. During this 
step, DNA is adsorbed onto a silica-membrane on the column whilst contaminants 
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pass through. 500µl QG buffer was added to remove traces of agarose and centrifuged 
at 13,000rpm for 1 minute. The flowthrough was discarded and the column washed 
with 750µl PE buffer by centrifugation as before. The flowthrough was discarded and 
residual PE buffer removed by centrifugation as before. DNA was then eluted with 
30µI EB Buffer and the approximate concentration determined by comparing the band 
intensity with a 1kb ladder (New England Biolabs, USA) on a 0.8% w/v agarose gel. 
2.1.9 Ligation of DNA 
To ligate DNA fragments, 5: 1 insert: vector molar ratio was incubated in the presence 
of 1U T4 DNA ligase (Invitrogen, UK) in 50mM Tris-HCI (p117.5), 10mM 
dithiothreitol, 1mM adenosine triphosphate and 25µg/ml BSA. The reaction volume 
was brought up to a final volume of 20µ1 with ddH2O and incubated at room 
temperature for 1 hour or 4°C overnight as appropriate. 
2.1.10 Transformation of DH5a cells 
After ligation of DNA fragments into the plasmid vector, 1µl of ligation mix was 
added to 50µl chemically competent DH5a Eco1i cells (Invitrogen, UK) on ice for 30 
minutes, heat shocked at 37°C for 20 seconds and placed back on ice for 2 minutes. 
The cells were suspended in 490µl SOC medium and incubated at 37°C shaking at 
250rpm for 1 hour. The entire cell suspension was centrifuged, resuspended in 100µl 
SOC medium and plated on LB agar plates containing 100µg/ml ampicillin. The 
pUC18 vector (Invitrogen, UK) was used as a positive control for transformation 
efficiency. The restriction enzyme digested backbone vector lacking the insert was 
transformed as a negative control. 
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2.1.11 Preparation of glycerol stock 
To store transformed bacterial Ecoli cells, 700µt liquid cultures was mixed and 
vortexed with 300µl glycerol (Sigma, UK) to prevent ice crystals forming and stored 
at -70°C. 
2.1.12 Large scale preparation of plasmid DNA from E. coll - Plasmid maxi prep 
For stable or transient transfection of mammalian cells, increased amounts of plasmid 
DNA were required. For this, larger cultures (50ml to 100ml) were grown. The vector 
containing the desired construct was streaked onto a LB agar plate containing 
100pg/ml ampicillin and incubated overnight at 37°C. An isolated colony was 
inoculated into 5ml liquid LB containing 100µg/ml ampicillin and incubated for 8 
hours shaking at 250rpm at 37°C. 500µ1 was then taken, placed into 100ml liquid LB 
containing 100µg/ml ampicillin and grown overnight at 37°C shaking at 250rpm. The 
Endofree plasmid maxi-prep kit (Qiagen, UK) was then used to obtain endotoxin free 
plasmid DNA. The culture was centrifuged at 9000rpm for 15 minutes at 4°C, the 
supernatant decanted and the pellet resuspended in 10ml P1 buffer containing RNase 
A. The cells were lysed with 10ml P2 buffer and incubated at room temperature for 5 
minutes. 10ml chilled P3 buffer was added to neutralise the alkaline conditions and 
mixed gently. This precipitated proteins, genomic DNA and detergent whilst plasmid 
DNA remained in solution. This was poured into the QlAfilter cartridge and incubated 
at room temperature for 10 minutes. The lysate was filtered through the cartridge and 
2.5ml ER buffer added for 30 minutes on ice to prevent lipopolysaccharide (LPS) 
molecules from binding to the anion-exchange resin of the Qiagen-tip 500 column. 
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Plasmid DNA under low-salt (p117.0) conditions binds to the column. The column was 
equilibrated with 10ml QBT buffer under low salt (p11 7.0) conditions before the 
filtered lysate was applied to the column and allowed to enter by gravity flow. The 
Qiagen-tip was washed with 60m1 QC buffer and the DNA eluted with 15ml high salt 
QN buffer. DNA was then concentrated and desalted with 10.5ml isopropanol and 
centrifuged at 15000xg for 30 minutes at 4°C. The supernatant was discarded and the 
DNA pellet washed with 5m1 endotoxin free water containing 70% ethanol. The DNA 
pellet was centrifuged at 15000xg for a further 10 minutes and the supernatant 
discarded. The DNA pellet was air-dried for 5 minutes and resuspended into Iml 
endotoxin free ddH2O. Plasmid DNA was then stored at -20°C. 
2.1.13 Determination of DNA concentration 
Plasmid DNA concentration was quantified using the UV-1601 Shimadzu 
spectrophotometer (Shimadzu, Japan). In general, DNA was diluted 50-fold in ddH2O 
and the optical density (OD) was read at 260nm and 280nm to measure DNA 
concentration and purity. DNA concentration was calculated using the equation DNA &C' S 64- 4bsocpt i; % 03r l't 
(µg/ml) = OD at 260nm x 50 ()x dilution factor. The DNA purity 
was measured by determining the absorbance ratio of 260nm/280nm. A ratio of 1.8 
corresponded to a pure DNA preparation, whilst a lower ratio suggested protein 
contamination and a higher concentration of RNA. 
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2.1.14 Generation of ADAMTS13 mutants at the predicted thrombin cleavage 
sites 
The QuikChange® XL site-directed mutagenesis kit (Stratagene, USA) was used to 
alter the predicted P1 arginine residue in the pcDNA3.1 ADAMTS13 myc/His 
expression vector to inhibit the proteolysis by thrombin (section 2.1.2). After 
transforming in XL-10 gold ultra competent E. coli cells, plasmid minipreps were 
performed and the ADAMTS13 region sequenced to ensure no unwanted mutations 
were introduced (sections 2.1.3 and 2.1.4). Each ADAMTS13 mutant construct was 
digested with EcoRI (NEB, USA), BmgBI (NEB, USA) or XbaI (NEB, USA) and run 
on a 0.8%w/v agarose gel (sections 2.1.5,2.1.6 and 2.1.7). Digestion with EcoRI and 
BmgBI would generate a -3.2kb insert band and -6.8kb vector backbone. Digestion 
with BmgBI and XbaI generated a -1. Ikb insert band and -8.9kb vector backbone. 
Digestion with EcoRI and BmgBI generated a -3.2kb insert band and -6.8kb vector 
backbone. The various insert fragments were isolated by gel extraction and ligated into 
a wild type pcDNA3.1 ADAMTSI3 myc/His expression backbone vector that had 
been dephosphorylated and treated with the appropriate restriction enzymes (sections 
2.1.6,2.1.8 and 2.1.9). This was transformed into chemically competent DH5a E. coli 
cells (section 2.1.10). Isolated colonies were then verified for incorporation of the 
insert fragment and a plasmid maxiprep prepared for transient transfection into 
HEK293T cells (sections 2.1.12 and 2.2.5). 
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2.2 Expression of ADAMTS13 
2.2.1 Cell culture 
All cell culture was carried out in a class II flow cabinet and all surfaces and flasks 
used in the flow cabinet thoroughly cleaned with 70% ethanol to prevent 
contamination of cell lines. 
2.2.2 Reviving human embryonic kidney 293 cells from liquid nitrogen 
Human Embryonic Kidney (HEK) 293 or HEK293T (transformed with the SV40 large 
T antigen) cell lines (American Type Culture Collection, USA) stored in liquid 
nitrogen were thawed and centrifuged at 800rpm for 5 minutes. The medium was 
decanted and the cell pellet resuspended in growth medium (minimal essential 
medium eagle (Sigma, UK) supplemented with 10% fetal bovine serum (Biosera, UK), 
5mM Penicillin/Streptomycin (Invitrogen, UK), 5mM L-glutamine (Invitrogen, UK) 
and non-essential amino acids (Sigma, UK)). HEK293 cells were then incubated at 
37°C and 5% CO2 until cells had reached the desired confluency. 
2.2.3 Cell Passage/maintenance 
Once HEK293 cells had reached full confluency on the flasks/plate, adherent cells 
were "split" into larger tissue culture flasks. Cells were washed twice with autoclaved 
phosphate buffered saline (PBS) buffer (Sigma, UK), cells detached from the surface 
using 0.25% trypsin/EDTA (Sigma, UK) for 30 seconds, the excess trypsin removed 
and the flask incubated for 5 minutes at 37°C. Trypsin was inactivated by addition of 
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complete growth medium (section 2.2.2) and seeded into a larger tissue culture flask 
(Nunc, Germany). 
2.2.4 Stable transfection of IIEK 293 cells 
Plasmid DNA was stably transfected into HEK293 cells using the Lipofectin reagent 
(Invitrogen, UK). 4x105 HEK293 cells were seeded into a 35mm2 (6 well) dish and 
grown for 24 hours at 37°C with 5% CO2 until cells were 50-60% confluent. The 
transfection mixes were prepared by diluting 4µg plasmid DNA with 100µl Optimem 
(Invitrogen, UK) medium and in a separate reaction 1µg Lipofectin in l00µ1 Optimem. 
Both plasmid and Lipofectin were incubated at room temperature for 30 minutes 
before the two mixtures were combined and incubated at room temperature for 15 
minutes. During this period, HEK293 cells were washed twice with 2ml sterile PBS 
buffer and 1.8ml Optimem added. The Lipofectin/DNA mix was then placed onto the 
cells and incubated overnight at 3,7°C with 5% CO2. The following day, the 
transfection mix was removed and replaced with fresh Optimem and cells incubated 
with growth medium (section 2.2.2) until fully confluent. HEK293 cells were then 
trypsinised and seeded onto a 10cm2 dish with growth medium containing 50µg/ml 
Geneticin G418 (Sigma, UK), a neomycin analogue that selects for transfected 
mammalian cells. The growth medium was replaced every 2 days to maintain the 
selective pressure. Non-transfected cells were used as a negative control to indicate 
when transfected clones could be selected. An ADAMTS13 enzyme linked 
immunosorbent assay (ELISA) was used to detect high expressing clones by assessing 
ADAMTS13 antigen levels in the cell culture medium (section 2.5.2). This was 
verified by Western blotting ADAMTS13 using the anti-myc monoclonal antibody 
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(mAb) (section 2.5.5). Clones expressing the highest levels of ADAMTS 13 were 
selected and expanded into 500cm2 triple flasks (Nunc, Germany) using growth 
medium until cells were 80-90% confluent. The growth medium was then replaced 
with Optimem (Invitrogen, UK) with or without a protease inhibitor cocktail (Sigma, 
UK) containing inhibitors against serine proteases, (aprotinin and leupeptin 
hemisulphate salt), aminopeptidases (bestatin hydrochloride), cysteine proteases 
(leupeptin hemisulphate salt and E-64 - [N-(trans-Epoxysuccinyl)-L-leucine 4- 
guanidinobutylamide]) and acid proteases (pepstatin A) and incubated for 2 days at 
37'C with 5% CO2. This was collected and filtered through a 0.5mm (Nalgene, UK) to 
remove cell debris. The conditioned medium was then concentrated using the 
LabscaleTM TFF system (Millipore, UK) with a Pellicon XL lOkDa filter (Millipore, 
UK). 
2.2.5 Transient transfection of HEK293T cells 
Plasmid DNA was transfected into HEK293T cells using Lipofectamine 2000 
(Invitrogen, UK). HEK293T cells were seeded at a cell density of 2x 106/ml 
HEK293T cells onto a 10cm2 dish in growth medium until they reached 80-90% 
confluency. The transfection mixes were prepared by diluting 24µg plasmid DNA in 
1.5m1 Optimem and in a separate reaction 6Oµl Lipofectamine 2000 in 1.5ml 
Optimem. Both mixtures were left at room temperature for 5 minutes before 
combining them and mixing at room temperature for 20 minutes. During this 
incubation, the growth medium (section 2.2.2) was removed and replaced with 7ml 
Optimem. The mix was then added to the cells and incubated at 37°C and 5% CO2 for 
6 hours. 10ml fresh Optimem was replaced 6 hours post-transfection and left for 3 
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days at 37°C and 5%C02. The medium was collected and concentrated 10-fold using a 
lOkDa cut off spin filter (Amicon, UK) by centrifugation at 4000xg for 15 minutes. 
The medium was then dialysed into 20mM Tris-IICI (p117.8) and quantified by the 
ADAMTS13 ELISA (section 2.5.2). 
2.2.6 Cryopreservation of cell lines 
For long-term storage of mammalian cell lines, cells were trypsinised and resuspended 
in growth medium without 5mM Penicillin/Streptomycin (section 2.2.2). 10% 
dimethyl sulphuroxide (v/v) (Sigma, UK) was added to protect cells from rupturing by 
preventing formation of ice crystals at low temperatures. The cell suspension was 
aliquoted into Iml cryovials (Nunc, Germany), placed in a container with 200ml 
isopropanol and stored at -70°C overnight. These were then transferred and stored in 
liquid nitrogen. 
2.3 Purification of ADAMTS13 
2.3.1 Desalting of conditioned medium 
The concentrated conditioned medium was desalted in 20mM Tris-IICI (pH7.8), 
500mM NaCI and 20mM imidazole using a 26/10 desalting column (Amersham 
Pharmacia, UK) coupled to an ÄKTA Fast Pressure Liquid Chromatography machine 
(Amersham Pharmacia, UK). The column is composed of a cross-linked dextran 
matrix, in which high molecular weight compounds (>5kDa) and salts could be 
separated. This is done using gel filtration, which separates molecules according to 
their molecular weight. High molecular weight proteins are able to pass through the 
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interstitial spaces of the dextran matrix and travel faster through the column. Low 
molecular weight (<lkDa) molecules, such as salts and amino acids, are distributed 
between the mobile and stationary phases and pass through more slowly. After 
equilibrating with 20mM Tris-HCI (pH7.8), 500mM NaCl and 20mM imidazole, 
conditioned medium was passed over the column. The first major peak observed 
represented proteins >5kDa and these fractions were collected and pooled. The second 
major peak represented small molecules <IkDa that were discarded. 
2.3.2 Nickel chelating chromatography 
ADAMTSI3 was purified using a 5ml Ni2+ HiTrap chelating column (Amersham 
Pharmacia, UK). After equilibrating with 20mM Tris-HCI (pH7.8), 500mM NaCl and 
20mM Imidazole, the desalted conditioned medium was passed over the column, 
washed with 20mM Tris-HCI (pH7.8), 500mM NaCI and 35mM imidazole and eluted 
with 20mM Tris-HCI (pH7.8), 500mM NaCI and 500mM imidazole. Peak fractions 
during the elution were collected, pooled and dialysed in 20mM Tris-HCI (pH7.8) 
overnight at 4°C. This was analysed by SDS-PolyAcrylamide Gel Electrophoresis 
(SDS-PAGE) with Coomassie staining and Western blotting using the anti-myc mAb 
(Invitrogen, UK) under reducing and non-reducing conditions (sections 2.5.4 and 
2.5.5). 
2.3.3 Gel filtration chromatography 
Following purification of ADAMTS13 from the Ni2+ chelating column, ADAMTS13 
was purified further by using the gel filtration SuperdexTM 200 HR 10/30 column 
(Amersham Pharmacia, UK). Superdex 200 is composed of cross-linked porous 
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agarose beads and dextran, which is able to separate proteins in the range of 10- 
600kDa. After equilibrating the column with 20mM Tris-UCI (p117.8) and 150mM 
NaCl, a 500µl sample was passed over the column at a flow rate of 0.25ml/min and 
fractions collected when peaks were observed at the OD 280nm. Samples were 
analysed by SDS-PAGE followed by Coomassie staining (section 2.5.4). Western 
blotting using an anti-myc mAb (Invitrogen, UK) under reducing and non-reducing 
conditions was also used for analysis (section 2.5.5). The concentration was then 
determined using an ADAMTSI3 ELISA (section 2.5.2). 
2.4 Purification and plasma VWF and VWF115 
2.4.1 Purification of VWF from human plasma 
Plasma VWF purification was performed in the lab by Tom Mckinnon, as previously 
described86. Briefly, 600ml fresh frozen multidonor plasma was cryoprecipitated and 
the pellet dissolved in 20mM Tris-HCI (pH 8.0). Samples were cleared by 
centrifugation and sterile-filtered before passing over a Sepharose CL-2B HiPrep 
26/60 gel filtration column (Amersham Pharmacia, UK). Peak fractions were detected 
at 280nm in 5m1 aliquots and the VWF concentration in each fraction determined by a 
VWF ELISA (section 2.5.3). SDS-PAGE and Coomasie staining assessed the VWF 
purity and multimeric composition checked by Western blotting using the anti-VWF 
conjugated horseradish peroxidase (HRP) antibody (DakoCytomation, Denmark) 
(section 2.5.5). 
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2.4.2 VWF115 expression and purification 
Cloning and bacterial expression of VWF115 (E1554-R1668), a short A2 domain 
fragment spanning the ADAMTS13 cleavage site, was performed by Sara 
Zanardelli187. Briefly, VWF115 was amplified with appropriate primers from human 
VWF cDNA and cloned into the pETIOO/D-TOPO (Invitrogen, UK) bacterial 
expression vector, which fused an N-terminal poly histidine and Xpress epitope tag. 
This was transformed into Rosetta E. coli cells (Novagen, UK) and grown to log phase 
growth in 1 Litre culture of 2x YT medium. Expression was then induced with 1mM 
isopropyl-ß-D-thiogalactoside for 16 hours at 37°C. Thereafter, cells were lysed with 
Bugbuster reagent (Novagen, UK) and the inclusion body fraction solubilised in 8M 
urea, 20mM Tris-HCI (pH7.8) and 50mM imidazole. The solubilised inclusion bodies 
were then bound onto a 5ml Ni2+ chelating column and the protein refolded using an 
8M to OM urea linear gradient. Elution was performed with 500mM imidazole and 
SDS-PAGE and Coomassie staining then assessed the purity of VWF115 (sections 
2.5.4 and 2.5.5). VWFI 15 was subsequently dialysed in 20mM Tris-HCI (pH7.8) and 
its concentration determined using the bicinchoninic acid (BCA) Total Protein Assay 
Kit (Perbio, UK) (section 2.5.1). 
2.5 Analysis of ADAMTS13 and VWF 
2.5.1 BCA total protein assay 
For highly purified protein preparations, a total protein assay was performed to assess 
the protein concentration. This method is based on the reduction Cu 2+ to Cu+ by 
proteins in an alkaline medium. The colorimetric reaction is formed by the chelation of 
two molecules of BCA with one cuprous ion. The intensity of the colorimetric reaction 
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is proportional to the protein concentration. Serial dilutions of a BSA protein standard, 
ranging from 2mg/ml to 25µg/ml, were prepared and 25µl of each concentration 
loaded into microtiter wells. Different dilutions of unknown protein samples (25µI) 
were loaded for comparison. BCA solution B was added at a 1: 50 dilution of BCA 
solution A and 200µl of this mixture loaded into wells containing the samples. The 
reactions were incubated at 37°C for 30 minutes and the absorbance read at 540nm 
using an automated iEMS plate reader (LabSystems, USA). 
2.5.2 ADAMTS13 ELISA 
Polyclonal antibodies (pAb) raised in rabbits against recombinant ADAMTSI3 were 
purified and prepared by Dr James Crawley227. For the purpose of a specific ELISA, 
anti-ADAMTS13 TSP2-4 pAb were affinity purified and biotinylated for use as the 
detection antibody. Anti-ADAMTS13 pAb that had been fully depleted of anti-TSP2-4 
pAb (5pg/ml) were used as capture antibody, immobilised onto polyvinyl-coated wells 
(Nunc, Germany) in carbonate buffer (50mM NaHCO3 and 20mM Na2CO3) (p119.6) 
and incubated overnight at 4°C. The plate was washed 3 times with 2O0µ1 PBS-0.1% 
Tween (Sigma, UK), and the wells "blocked" with 200µl PBS 2% BSA (w/v) (Sigma, 
UK) for l hour with shaking at room temperature to prevent non-specific binding of 
proteins to the wells. Samples containing ADAMTSI3 were diluted in PBS with 
2%BSA, loaded onto the wells and incubated at room temperature for 2 hours. Serial 
dilutions of normal pooled plasma (Technoclone, UK) and purified ADAMTSI3 were 
used as a standard curve. The plasma concentration of ADAMTS 13 is -1 pg/ml160. The 
plate was then washed 3 times with 200µI PBS-0.1% Tween. O. Ipg/ml biotinylated 
anti-ADAMTSI3 TSP2-4 pAb diluted in PBS 2%BSA, was added to the wells and 
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incubated for 2 hours at room temperature. The plate was washed 3 times with 200µ1 
PBS-0.1% Tween. Streptavidin-HRP (Amersham Pharmacia, UK) in PBS 2% BSA at 
a 1: 2000 dilution was incubated for 1 hour at room temperature. The wells were then 
washed with 200µI PBS-0.1% Tween and the chromogenic solution prepared. O- 
phenylenediamine dihydrochloride (OPD) and 11202 tablets (Sigma, UK) were 
dissolved in 20m1 ddH2O and 200µl added to the microtiter wells. The reactions were 
stopped with 100µl 1.4M H2S04 and the absorbance read at 492nm using an 
automated iEMS plate reader (LabSystems, USA). 
2.5.3 VWF ELISA 
Anti-VWF capture pAb (DakoCytomation, Denmark) (1: 500 dilution) in carbonate 
buffer was immobilised onto polyvinyl-coated wells overnight at 4°C as previously 
described228. Samples containing VWF were diluted in PBS containing 2%BSA (w/v) 
and incubated for 1 hour with shaking at room temperature. Normal pooled plasma 
was used to determine the VWF concentration in the sample. The VWF plasma 
concentration is -'10µg/ml106. VWF was detected by incubating with the anti-VWF 
HRP pAb (1: 2000 dilution) (DakoCytomation, Denmark) for 1 hour with shaking at 
room temperature. As before, 200µl OPD chromogenic substrate was added. The 
reactions were stopped with 100µl 1.4M sulphuric acid and the absorbance read at 
492nm using an automated iEMS plate reader (LabSystems, USA). 
2.5.4 SDS-PAGE and Coomassic staining 
SDS-PAGE was used to separate proteins based on their molecular weight. SDS is an 
anionic detergent, which unfolds proteins and confers a negative charge proportional 
60 
to their size. Protein samples were diluted in 2x loading buffer (65mM Tris-1: UCI 
(pH8.0), 0.1% SDS w/v, 0.01% 13romophenol blue w/v) and heated at 95°C for 10 
minutes to denature the protein. When necessary, 4% v/v ß-mercaptoethanol was 
added to the 2x loading buffer to reduce disulphide bonds. Protein samples were 
added to precast SDS-PAGE gels (BioRad, USA) and electrophoresed at 120V for 70 
minutes in running buffer (25mM Tris (pH 8.3) 192mM glycine, 0.1% SDS). The gel 
was then used for either Western blot analysis or stained with Simplyßlue Coomassie 
stain (Invitrogen, UK). For Coomassie Staining, the gel was rinsed 3 times with 100ml 
ddH2O for 5 minutes before applying 25m1 SimplyBlue Coomassie stain for 1 hour. 
The gel was then destained by washing the gel for 1 hour with 100ml ddH2O before 
the gel was dried using Model 583 gel dryer (BioRad, USA). 
2.5.5 Western blotting 
Following SDS-PAGE analysis, the precast gel, nitrocellulose membrane (Amersham 
Pharmacia, UK) and filter paper were soaked in transfer buffer (25mM Tris Base, 
192mM Glycine 20% Methanol (v/v)) for 10 minutes. These were then assembled into 
a sandwich and transferred at 90V for 60 minutes. Following transfer of proteins from 
an SDS-PAGE gel to a nitrocellulose membrane, the membrane was incubated with 
5% blocking reagent (Amersham Pharmacia, UK) in PBS-0.1%Tween for 1 hour 
shaking at room temperature to prevent non-specific binding. The primary recognition 
antibody (Table 9.3) diluted in PBS-0.1% Tween with 5% blocking reagent was then 
added for 1 hour shaking at room temperature. The membrane was washed 3 times 
with PBS-0.1%Tween for 5 minutes and a secondary detection antibody conjugated 
with HRP (DakoCytomation, Denmark) (1: 2000 dilution) in 5% blocking reagent 
61 
added for 1 hour shaking at room temperature. The membrane was washed 5 times 
with PBS-0.1% Tween for 5 minutes and proteins detected using the ECL 
chemiluminescent kit (Amersham Pharmacia, UK) according to manufacturer's 
instructions. The membrane was exposed on to chemiluminiscent film (Amersham 
Pharmacia, UK). 
2.6 Proteolysis of ADAMTS13 by serine proteases 
Recombinant ADAMTS 13,250nM, was incubated with 0.9nM to 90nM human alpha 
thrombin (Sigma, UK), 0.9nM to 90nM human plasmin (Calbiochem, UK), 5OnM to 
250nM human FXa (Calbiochem, UK) or 1nM to 5OnM granulocyte elastase (Elastase 
Products, USA) in 20mM Tris-HC1 (pH7.8), 5mM CaCl2 and 150mM NaCl at 37°C. 
Sub-samples were removed at time points between 0 to 6 hours and ADAMTSI3 
proteolytic fragments analysed by SDS-PAGE with Western blotting using the various 
antibodies (Table 9.3), under reducing and non-reducing conditions (sections 2.5.4 and 
2.5.5). To determine sites of proteolysis by thrombin, 1µM ADAMTS13 was 
incubated with 100nM thrombin for 6 hours and subjected to SDS-PAGE and 
Coomassie staining under reducing conditions. Bands were excised and subjected to 
N-terminal sequencing (Alta Bioscience, UK). 
To assess the role of thrombin exosites upon ADAMTS 13 proteolysis, the competitive 
effect of heparin and TM was studied. Experiments were performed as above, except 
50nM thrombin was pre-incubated for 5 minutes with 50nM and 500nM 
unfractionated heparin (CP Pharmaceuticals, UK) or soluble rabbit TM (Haematologic 
Technologies Incorporated, USA). 
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To determine thrombin residues that facilitate ADAMTSI3 cleavage, 250nM 
ADAMTS13 was incubated at 37°C with I00nM thrombin or various thrombin exosite 
I variants (provided by Dr L Leung, Stanford, CA) and reactions taken at 0 and 2 
hours for Western blot analysis (section 2.5.5). 
To assess the relative specificity of thrombin for ADAMTS13 compared with other 
ADAMTS family members, parallel experiments were conducted in which 833nM 
ADAMTS4 was treated with 9nM thrombin and analysed by Western blotting using an 
anti-ADAMTS4 metalloproteinase domain mAb (provided by from Dr H. Nagase, 
Imperial College London). 
For reactions that assessed the influence of VWF upon ADAMTS 13 proteolysis by 
thrombin, 50nM ADAMTS 13 was pre-incubated at 37°C for 20 minutes with or 
without 500nM multimeric VWF. Thereafter, 100nM thrombin was added and 
proteolysis assessed using the anti-ADAMTS13 pAb under reducing conditions. In 
similar experiments that examined the ability of fibrinogen to compete with 
ADAMTS13 for thrombin, reactions containing 44nM ADAMTS13 and -7µM 
fibrinogen (Hyphen Biomed, France) were set up and analysed using the anti- 
ADAMTS13 pAb. 
2.7 ADAMTS13 activity assays 
2.7.1 ADAMTS13 activity assay using multimeric VWF 
lOnM ADAMTS13 or proteolysed ADAMTS 13 (treated with thrombin, plasmin or 
granulocyte elastase and inhibited with a 10-fold molar excess of hirudin (Calbiochem, 
UK), aprotinin (Sigma, UK) or McOSuc-Ala-Ala-Pro-Val chloromethyl ketone 
(CMK) (Sigma, UK) respectively) was pre-incubated with 15mM BaCI2,20mM Tris- 
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IICl (p117.8) and 1.5M urea for 10 minutes at 37°C. Purified high molecular weight 
VWF (IOnM) was then added to the reaction and samples taken at time points between 
0 to 6 hours. Reactions were stopped with 5mM EDTA and VWF proteolysis 
determined by collagen-binding assay (CBA) or Western blotting (sections 2.7.1.1 and 
2.7.1.2). For competition experiments, activity assays containing 6nM ADAMTS 13, 
60nM thrombin-cleaved ADAMTSI3, or a mixture of 6nM ADAMTS13 and 60nM 
thrombin-cleaved ADAMTS 13 was incubated with lOnM high molecular weight 
multimeric VWF as above. Reactions were taken at 0 to 4 hours and stopped with 
5mM EDTA for analysis by CBA or Western blotting. 
2.7.1.1 Collagen binding assay 
The CBA assesses changes in VWF affinity for collagen as larger VWF multimers 
bind more efficiently to collagen-coated wells than smaller multimers229. Lyophilised 
collagen type III (Sigma, UK) was reconstituted in 0.2M acetic acid by stirring 
overnight at 4°C. Subsequently, 100µl 0.2mg/mI collagen in carbonate buffer (pH9.6) 
was immobilised on microtiter wells by overnight incubation at 4°C. To detect VWF 
binding to collagen, samples containing --50ng VWF were loaded onto the wells for 1 
hour at room temperature and bound VWF detected with an anti-VWF HRP pAb 
(1: 2000) for 1 hour at room temperature. After washing, 200µl OPD of the 
chromogenic substrate was added, reactions stopped with 100µl 1.4M sulphuric acid 
and the absorbance read at 492nm using an automated iEMS plate reader 
(LabSystems, USA). 
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2.7.1.2 Western Not of VWF 
The proteolysis of multimeric VWF following ADAMTS13 treatment was assessed by 
Western blotting. For multimer analysis, a 1% (w/v) Seakem® HOT agarose gel 
(BioWhittaker Molecular Applications, USA) was prepared. The agarose was 
dissolved in 200mM Tris-HCI (pH 9.0), 100mM glycine and 0.1% SDS and the gel 
cast on a 1.5mm thick glass plate (BioRad, USA). lOng VWF in denaturing buffer 
(10mM Tris-HCI, pH8.0,1mM Na2EDTA, 2%SDS and 8M urea) was incubated at 
60°C for 30 minutes. 
For visualization of the 176kDa and 140kDa degradation fragments following 
cleavage at the Tyr1605-Metl606 scissile bond, IOng VWF samples were mixed with 
2x loading buffer containing 4% v/v ß-mercaptoethanol, denatured for 20 minutes at 
95°C and separated on a 5% polyacrylamide gel (Biorad, USA). In both cases, samples 
from the gels were transferred onto an ECL membrane, probed with the anti-VWF 
HRP pAb (1: 2000) for 1 hour and proteins detected using the ECL chemiluminescent 
kit as described earlier (section 2.5.5). 
2.7.2 ADAMTS13 activity assay using VWF115 
I OnM ADAMTS 13 or proteolysed ADAMTS13 (treated with thrombin, plasmin or 
granulocyte elastase and inhibited by a 10-fold molar excess of hirudin, aprotinin and 
CMK respectively) was pre-incubated with 5mM CaC12,150mM NaCI and 20mM 
Tris-HCI (pH 7.8) at 37°C for 30 minutes followed by addition of 6.2µM VWFI 15. 
For visualisation of VWF115 cleavage products, samples were taken at time points 
between 0 to 3 hours, mixed with 2x Tris Tricine loading buffer (200mM Tris-HCI 
(pH 6.8), 2% SDS, 40% glycerol, 0.04% Coomassie Blue G-250) (BioRad, USA) and 
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assessed by SDS-PAGE with Simply Blue Coomassie stain using a 16.5% Tris-Tricine 
SDS-PAGE gel (BioRad, USA) in Tris-Tricine running buffer (100mM Tris (pII 8.3), 
100mM Tricine, 0.1% SDS). 
To determine the kinetic parameters (kcal, Km and kCat/K,,, ), 8.5nM ADAMTS13 or 
thrombin-treated ADAMTS 13 was pre-incubated with 5mM CaCI2,150mM NaCl and 
20mM Tris-HCI (pH 7.8) at 37°C for 30 minutes before adding 0.5µM to 20µM 
VWFI 15. Initial rates (nM/sec) of VWFI 15 cleavage were then derived by taking 
samples between 0 to 30 minutes and terminating the reaction with 5mM EDTA for 
HPLC analysis (section 2.7.2.1). For deriving the catalytic efficiency (kcac/K, ), 8.5nM 
ADAMTS13 or thrombin-treated ADAMTS13 was incubated with 0.25µM or 0.5µM 
VWF115, as describe above, and samples taken between 0 to 3 hours for HPLC 
analysis (section 2.7.2.1). 
2.7.2.1 HPLC analysis of VWF11S cleavage 
To quantify the rate of cleavage of VWF115 by ADAMTS13, HPLC was employed. 
The technique is based on the separation of molecules through a chromatography 
column under high-pressure conditions. The stationary phase is defined as the 
immobile packing material in the column. The mobile phase refers to the solvent, in 
which the sample has also been dissolved, prior to being applied to the column. The 
chemical interactions of the mobile and stationary phases determine the degree of 
migration and separation of components contained in the sample. The mobile phase 
can be altered to manipulate the interactions between the sample and the stationary 
phase, leading to different grades of resolution of the molecules contained in the 
sample. In reverse phase chromatography, the stationary phase is hydrophobic, 
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whereas the mobile phase is polar. Biomolecules are then adsorbed to the surface of a 
reverse phase matrix under aqueous conditions. Subsequently, the mobile phase 
composition is modified by adding organic modifiers, such as acetonitrile, which is 
apolar, which favour desorption of the solute from the stationary phase back into the 
mobile phase. Proteins or protein fragments are eluted at different points of the 
acetonitrile gradient based on their hydrophobic properties. Ion-pairing agents, such as 
trifluoroacetic acid, are also added to the mobile phase to maintain a pH <7.5. The 
AKTA Basicl0 HPLC machine (AmershamPharmacia, UK) with a Biol3asic C4 
column (Thermo Electron Corporation, UK) was used to assess VWFI 15 cleavage by 
ADAMTS13. At each time point, 50µl samples were loaded at a flow rate of 
1.5ml/min. VWF115 and its cleavage fragments were then eluted using a 25-50% 
acetonitrile-0.1% trifluoroacetic acid gradient. Each fragment had a specific retention 
time, based on its hydrophobic properties. Separation and calculation of the areas 
under the peaks of the peptide fragments were assessed using UNICORNTM software 
(AmershamPharmacia, UK). To confirm the identity of the peaks eluted from the C4 
column, mass spectrometry of each peak was performed (Imperial College-MRC 
Clinical Sciences Centre Proteomics Facility). Since the peak area of the intact 
VWF 115 was equal to the peak areas of the cleavage fragments generated, percentage 
proteolysis of VWFI15 was plotted against time enabling the rate kinetics to be 
determined. 
2.7.2.2 Kinetic analysis of VWFIl S proteolysis by ADAMTSI3 
To derive the kinetic constants kcal, Km and kCet/K,, the initial rates (nm/sec) of 
VWF115 proteolysis by ADAMTS13 was plotted against VWF115 concentration and 
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the results fitted using the Michaelis-Menten equation in the Prism 4 software 
(Graphpad, USA): 
Vmac X [S] 
K. + [S] 
Where V is the initial velocity, V, na,, is the maximal velocity reached at high substrate 
concentrations when the enzyme is saturated, [S] is the substrate concentration and K,,, 
(Michaelis constant) is the substrate concentration at which the reaction velocity is 
half-maximal. In this way, K., and V, na,, were determined and therefore the turnover 
number, kcat (in sec''), calculated from the ratio Vmax/[E], where [E] refers to 
ADAMTS 13 concentration. The catalytic constant kCat represents the number of 
reactions that each active site catalyses per unit time. The kcat/Km could then be 
calculated. This is a second order rate constant which measures the overall catalytic 
efficiency of free enzyme. Alternatively, the kcat/Km was also determined using low 
substrate concentrations and fitting the percentage of VWFI15 proteolysis against 
time to the equation using Enzfitter software: 
- in(1- [AP]/[APf)) kcaJKm _ [E]t 
Where [AP] is the area under the first major cleavage product peak curve that eluted at 
time t, [APfJ is the area under the first major cleavage product peak curve after 
complete cleavage and t is time. 
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2.8 Characterisation of the influence of ADAMTS13 proteolysis by 
thrombin 
2.8.1 ADAMTS13 plate binding assays 
To assess the influence of thrombin-mediated proteolysis upon ADAMTS13 binding 
to its substrates, plasma-derived VWF (750ng) or VWFI 15 (250ng) in carbonate 
buffer (pH9.6) was immobilised onto wells overnight at 4°C. To characterise the 
binding of ADAMTS13 to thrombin, biotinylated-PPACK human a-thrombin 
(Haematologic Technologies Incorporated, USA) (300ng) was similarly immobilised 
onto the wells. Thereafter, various concentrations of ADAMTS 13 or thrombin-treated 
ADAMTS13 in PBS 2%BSA (w/v) was loaded onto microtiter wells and incubated for 
2 hours at room temperature. Bound ADAMTS 13 was detected with the rabbit anti- 
ADAMTS13 pAb (1: 5000) and incubated for 2 hours at room temperature. The anti- 
rabbit HRP conjugate (DakoCytomation, Denmark) (1: 2000) was then added and 
incubated for 1 hour at room temperature. After washing, 200µl OPD of the 
chromogenic substrate was added, reactions stopped with 100µl 1.4M sulphuric acid 
and the absorbance read at 492nm using an automated iEMS plate reader 
(LabSystems, USA). Absorbance at each ADAMTS13 concentration was plotted and 
then fitted using a one binding site model equation using the Prism 4 software 
(Graphpad, USA): 
B_ 
Bmax x [X] 
KD+[X] 
Where Bmax is the maximal binding capacity, [X] is the ADAMTS13 concentration 
and KD is the ADAMTS 13 concentration required for half maximal binding. 
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2.8.2 Defibrinating plasma for Western blot analysis 
Normal pooled citrated plasma (950µl) was incubated with 50µl Reptilase Reagent 
(Pentapharm, Switzerland) and incubated at 37°C for 10 minutes. Plasma samples 
were then placed on ice for 10 minutes and centrifuged at 20,000xg at 4°C for 20 
minutes to precipitate the fibrin pellet formed. The defibrinated plasma supernatant 
was used for subsequent experiments. Fibrinogen deficient plasma was also obtained 
from afibrinogenemic human plasma donors (George King Bio-medical Inc, USA). 
2.8.3 Proteolysis of recombinant ADAMTS13 in human plasma 
To assess ADAMTS13 proteolysis in plasma, recombinant ADAMTSI3 (80nM) was 
added to 800µl defibrinated plasma. Thereafter, lipidated human tissue factor (8pM) 
(Baxter, Austria), phosholipids (4µM) (PS: PC: PE - 20: 60: 20) (Avanti, USA) and the 
fluorogenic thrombin substrate, Z-GIy-Gly-Arg-AMC-HCI (0.4mM) (Bachem, UK) 
was subsequently added. Thrombin generation was then initiated with 16.6mM CaCI2 
and monitored in real-time using a fluoroscan plate reader (Thermolabs, UK) and 
quantified by comparison to a standard curve generated at the same time. In parallel, 
thrombin generation was initiated in defibrinated plasma samples to which 
ADAMTS13 was added, but in the absence of the thrombin substrate. Sub-samples 
were removed at time points between 0 to 30 minutes for Western blot analysis using 
the anti-ADAMTS13 metalloproteinase domain mAb (section 2.5.5). Similar 
experiments were set up using whole human plasma. GlyProArgPro-amide (Sigma, 
UK), 5mg1ml, was added to each plasma sample to prevent polymerisation of fibrin. In 
these experiments, hirudin (Calbiochem, UK) was added to a final concentration of 
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3µM to one sample to specifically inhibit thrombin. Each sample was incubated at 
37'C for 30 minutes and then analysed by Western blotting as before. 
2.8.4 Detection of endogenous ADAMTS13 in plasma 
To improve detection of ADAMTSI3, which is not abundant in plasma (-5nM), the 
ProteoprepTM Blue Albumin Depletion Kit (Sigma, UK) was used prior to Western 
blotting. This removed 85% serum albumin and 75% IgG antibodies that represent 60- 
70% and 10-20% of the total serum protein, respectively. Slurry medium from the kit 
(400µl) was placed into a spin column and equilibrated twice using 400µI equilibration 
buffer (Tris-buffered urea solution pH7.8) by centrifuging at 8000xg for 40 seconds. 
100µl of whole plasma before/after initiating coagulation was added to the medium 
and incubated for 5 minutes at room temperature. The spin column was centrifuged at 
12,000xg for I minute. The flowthrough was then reapplied to the medium for another 
5 minutes to remove remaining albumin. The spin column was centrifuged again as 
before and 100µ1 equilibration buffer was added to the medium and pooled with the 
flowthrough of the "two times" serum depleted plasma. Samples were analysed by 
Western blotting using the anti-ADAMTS13 pAb under reducing conditions (section 
2.5.5). 
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3 PROTEOLYSIS OFADAMTS13 BY THROMBIN AND 
PLASMIN 
3.1 Introduction 
Prior to this investigation, there were no reports of direct inhibitors of ADAMTS13. 
However, regulation of its VWF-cleaving function may be important at sites of 
vascular perturbation since uninhibited ADAMTS13 activity would be predicted to 
counteract the necessary VWF dependent recruitment of platelets to exposed collagen. 
Since a number of serine proteases, such as thrombin, plasmin and FXa, are locally 
activated after vessel injury, these were investigated as potential regulators of 
ADAMTS 13 function using purified proteins. 
3.2 Results 
3.2.1 Purification of recombinant ADAMTS13 
To provide a continual source of ADAMTS 13, the pcDNA3.1/ADAMTS13/myc/His 
vector was stably transfected into HEK293 cells and recombinant ADAMTS13 with a 
C-terminal myc/6xHis-tag expressed into conditioned medium (section 2.2.4). After 
concentrating and desalting the conditioned medium, recombinant ADAMTS13 was 
purified by Ni2+ chelating affinity chromatography (section 2.3.1 and 2.3.2). Both 
SDS-PAGE with Coomassie staining and Western blotting using an ADAMTS 13 anti- 
metalloproteinase domain mAb demonstrated the presence of a prominent -200kDa 
band, in accordance with a previous report142 (Figure 3.1A - lane I and 2). However, 
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an anti-myc epitope mAb that recognised the C-terminal tag revealed the presence of 
both a -200kDa band and a lower intensity -4OkDa band. This minor species was 
believed to be a myc/His tagged C-terminal ADAMTS13 degradation fragment that 
was co-purified with the full-length enzyme (Figure 3.1A - lane 3). 
To obtain a more highly purified preparation of ADAMTS 13, the Ni2+ affinity purified 
material was concentrated and loaded onto a gel filtration column (section 2.3.3). The 
different peak fractions were collected separately for analysis by SDS-PAGE with 
Coomassie staining and Western blotting using the anti-myc mAb under reducing 
conditions. After Coomassie staining, a single -200kDa band was eluted in fractions 
Al and A2 (Figure 3.1 B- inset I). In fraction A3, the -200kDa band was eluted along 
with an additional slightly lower molecular weight band (Figure 3.1B - inset I). The 
presence of this band is due to variable glycosylation during processing and secretion 
from HEK293 cells'51. The activity of this variable glycosylated form of ADAMTS13 
was shown to be comparable to the activity of the -2OOkDa ADAMTS13 band 
(performed by Dr James Rance, data not shown). In fraction AS, a single -65kDa band 
was observed. No bands were observed in fraction A4 (Figure 3.113 - inset I). Western 
blotting of the same samples using the anti-myc mAb showed that the majority of the 
ADAMTS 13 eluted in fractions Al to A3, with very little in fraction A4 (Figure 3.1 B 
- inset II). The -65kDa band observed in the AS fraction after Coomassie staining was 
not detected by Western blotting, suggesting that this was a contaminant not 
ADAMTS13 related and was most likely BSA from the growth medium. However, a 
number of minor lower molecular weight species of ADAMTS13 were present in 
fractions Al and A3, suggesting that some degradation of ADAMTSI3 had occurred 
(Figure 3.1B - inset II). Although the use of the anti-metalloproteinase domain mAb 
revealed no lower molecular weight species after Ni2+ chelating affinity 
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chromatography, this may have been due to the amount loaded onto the SDS-PAGE 
gel and length of exposure of the Western blot (Figure 3.1A - lane 2). Since a single 
-200kDa band was eluted in the Al fraction after Coomassie staining and most of the 
ADAMTS13 remained intact, this was used for determining the ADAMTS13 
concentration (section 3.2.2). 
To inhibit proteolytic degradation of ADAMTS 13, a protease inhibitor cocktail was 
added during cell culture. It has been demonstrated that ADAMTS13 was not inhibited 
by these inhibitors 139'230. SDS-PAGE with Coomassie staining revealed the same 
molecular weight species observed in the A3 and A5 fractions after gel filtration 
(Figure 3.1C). Western blotting of the same samples with the anti-myc mAb showed 
only a single -200kDa band (Figure 3.1D). Thus, the protease inhibitor cocktail 
prevented the degradation of ADAMTS13 without affecting the expression or 
secretion of ADAMTS13 from HEK293 cells. This was then used in subsequent 
experiments. 
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Figure 3.1. Purification of recombinant ADAMTS13. 
The pcDNA3.1/ADAMTSI3/myc/His expression vector was stably transfected into HEK293 cells and 
recombinant ADAMTS13, with a C-terminal myc 6xHis tag, expressed into the conditioned medium. 
(A) ADAMTS13 was initially purified from conditioned medium using a Ni`+-HiTrap column and 
electrophoresed on a 7.5% polyacrylamide gel. Lane 1- Coomassie stain under non-reducing 
conditions. Lane 2&3- Western blot analysis under reducing conditions with the anti-ADAMTS 13 
metalloproteinase domain and anti-myc mAbs, respectively. Lad - marker ladder. (B) This material was 
then applied to a SuperdexTm 200 HR 10/30-gel filtration column to remove impurities. Fractions were 
collected at set intervals for analysis by SDS PAGE with Coomassie staining (1) and Western blotting 
using the anti-myc epitope antibody (II) under reducing conditions. A protease inhibitor cocktail was 
added to conditioned medium for 3 days. The conditioned medium was then collected and purified for 
analysis by SDS-PAGE with Coomassie staining (C) or Western blotting with the anti-myc mAb (D) 
under reducing (R) and non reducing conditions (NR). 
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3.2.2 Quantification of purified recombinant ADAMTSI3 
The ADAMTSI3 concentration was measured using the BCA total protein assay 
(section 2.5.1), since the ADAMTS13 preparation of the Al fraction after gel filtration 
was of high purity (Figure 3.1B, inset I). Using BSA to generate a standard curve, the 
ADAMTSI3 concentration of this preparation was -220nM (Figure 3.2A). This 
material was subsequently used to generate a standard curve for the ADAMTS13 
ELISA (section 2.5.2). In the ADAMTS13 ELISA, the ADAMTS 13 concentration in 
normal pooled plasma was determined to be -0.9µg/ml, essentially the same as the 
reported ADAMTS I3 plasma concentration of -l µg/m1144,167 (Figure 3.2B). Thus, the 
ADAMTS13 concentration determined by the BCA assay was used to determine the 
ADAMTS13 concentration in Ni2+ affinity purified preparations. The yield obtained 
after Ni2+ purification was -lmg ADAMTS13 from I litre of Optimen. Together, 
these systems provided me with the means to efficiently express, purify and quantify 
ADAMTS 13 for subsequent analysis. 
Figure 3.2. Determination of purified recombinant ADAMTS13 concentration. 
(A) The Al fraction of the gel filtered ADAMTSI3 preparation (Figure 3.1) was quantified by the BCA 
assay using BSA as a standard. (B) Based on the concentration determined by the BCA assay, this was 
used to generate a standard curve for the ADAMTSI3 ELISA to assess the concentration of Ni2+ 
purified ADAMTS13 preparations. 
76 
3.2.3 Thrombin cleaves ADAMTS13 at several sites 
To establish whether ADAMTS13 was susceptible to proteolysis by thrombin, Ni2+ 
affinity purified ADAMTS13 was incubated with and without 9nM human thrombin 
for 16 hours and subjected to SDS-PAGE with Coomassie staining and Western 
blotting. Coomassie staining revealed that without the addition of thrombin, full-length 
ADAMTS 13 was clearly visible as a band of -200kDa (Figure 3.3A). Under reducing 
conditions, the full-length ADAMTS13 band disappeared completely following 
incubation with thrombin. Moreover, lower molecular weight bands that were not 
readily visualised in either the thrombin, or ADAMTS13 preparations alone, became 
evident (Figure 3.3A). This demonstrated that ADAMTS13 is proteolysed by 
thrombin, and that cleavage occurs at several sites. Under non-reducing conditions, 
thrombin treatment caused the full-length ADAMTS13 band to disappear. Two major 
ADAMTS13 proteolytic fragments were resolved (-l50kDa and -4OkDa) (Figure 
3.3B), suggesting that the ADAMTS 13 cleavage fragments, with the exception of the 
-4OkDa fragment, remained covalently associated by disulphide bond linkages. 
Western blot analysis of these same samples using the anti-metalloproteinase domain 
mAb corroborated this contention. Under reducing conditions, the metalloproteinase 
domain was present within a -28kDa band, but under non-reducing conditions the 
metalloproteinase domain was present in the -150kDa band (Figure 3.3C). Analysis 
using the anti-myc mAb revealed that a -4OkDa C-terminal fragment of ADAMTSI3 
was generated after thrombin treatment under both reducing and non-reducing 
conditions (Figure 3.3D). This implied thrombin proteolyses ADAMTS13 at a site 
between unpaired cysteine residues to release a -4OkDa C-terminal fragment. 
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Figure 3.3. Purified Al) I I'S13 is clawed by thrombin. 
400nM purified ADAMTS13 was incubated with and without 9nM thrombin (Ella) in 20mh1 'Iris-110 
(pll 7.8) containing I50mM NaCl and 5mM Ca- at 37'C for 16 hours. Samples were electrophoresed 
on a 4-15% polyacrylamide gel under both reducing (; 1) and non-reducing (13) conditions followed by 
Coomassie staining. Thrombin was detected as a 36kDa band (white arrowhead), full-length 
ADAMTS13 and its proteolytic fragments are identified by arrows. Western blot analysis of 
ADAMI'S 13 with and without complete thrombin proteolysis (under reducing and nonreducing 
conditions) using the anti-ADAM'I'S13 metalloproteinase domain (C) or anti-myc epitope (ID) 
antibodies. 
3.2.4 CU13 domains remain ionically associate(] with AUAMTSI3 after 
proteolysis by thrombin 
Whilst the -40kDa C-terminal fragment vvas not covalently associated with the rest of 
the ADAMTS 13 molecule alter thrombin treatment, it is unknown whether this 
fragment was either separated from AD. AMTSI3 or still maintained an ionic 
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interaction with ADAMTS 13. Therefore, ADAMTS 13 or thrombin-treated 
ADAMTS13 was passed over the gel filtration column. Peak fractions were collected 
and subjected to Western blotting using the anti-myc mAb under non-reducing 
conditions. ADAMTS13 and thrombin-treated ADAMTSI3 exhibited similar 
chromatogram traces, each with four peak fractions of similar size (A2 to A6) (Figure 
3.4A and B). Western blotting showed that the -200kDa full-length ADAMTS13 band 
was present in fractions A2 to A5, with the majority eluting in fraction A4. Small 
degradation fragments were also detected, as before (Figure 3.4A, inset and Figure 
3.1 B, inset II). Western blotting of thrombin-treated ADAMTS 13 preparations showed 
that the -4OkDa C-terminal fragment was detected in fractions A2 to A4 (Figure 3.4B, 
inset). Although some full-length ADAMTS13 remained in fraction A4, appearance of 
the -4OkDa C-terminal fragment in the early fractions suggests that the CUB domains 
remain ionically associated with ADAMTS13 after proteolysis by thrombin. 
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Figure 3.4. CUB domain may remains associated to ADAMTS13 after thrombin treatment. 
ADAMTS13 (A) or thrombin treated ADAMTS13 (B) was passed over the SuperdexTM 200 HR 10/30 
gel filtration column at a flow rate of 0.25m1/min. Fractions were collected at set intervals and analysed 
by Western blotting using the anti-myc mAb under non reducing conditions (Inset). 
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3.2.5 Characterisation of ADAMTS13 cleavage fragments after thrombin 
treatment 
To estimate the number and position of thrombin cleavage sites, Ni2+ affinity-purified 
ADAMTS13 was proteolysed for 30 minutes at 37°C by thrombin and fragments 
visualised by Western blotting (Figure 3.5A and B). N-terminal containing fragments 
were detected with an ADAMTS 13 anti-metalloproteinase domain mAb (Figure 
3.5A). Limited treatment of ADAMTS 13 with thrombin revealed at least three 
metalloproteinase domain containing fragments of -150kDa, -4OkDa and -. 28kDa 
(designated Frag 1,5 and 6, respectively) of which Frag I and 6 were the major 
species (Figure 3.5A, lane 2). Proteolysis using increased quantities of ADAMTSI3 
and extended exposure of the blots aided the identification of three low abundant 
proteolytic intermediate species (Frag 2,3 & 4), suggesting the presence of less 
favoured cleavage sites (Figure 3.5A, lane 3). Analysis of myc epitope-containing C- 
terminal fragments revealed a fragmentation pattern that complemented the data 
obtained with the ADAMTS13 anti -metal I oprote i nase domain mAb (Figure 3.5B). 
The major species generated by thrombin were Frag A (-160kDa) and Frag D 
(-4OkDa), again suggesting the preference for proteolysis at the most C-terminal and 
N-terminal sites. Interestingly, the '-4OkDa C-terminal fragment that was co-purified 
with ADAMTS13 was of similar size to Frag D possibly through cleavage at the same 
proteolytically sensitive site. Due to the predicted molecular mass, the -170kDa, 
-160kDa and -150kDa fragments corresponding to the predicted C-terminal aspects of 
Frag 4,5 and 6 could not be resolved. These species probably migrated as Frag A. 
Proteolysis with increased quantities of ADAMTS13 indicated two additional 
intermediate species (Frag B and C), possibly representing the C-terminal portion of 
Frag 2 and 3 (Figure 3.5B, lane 4). Based on the molecular masses of the proteolytic 
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fragments generated. the approximate location of thromhin cleavage sites was 
predicted (Figure 3.5C). 
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Figure 3.5. Identification of ADAM I"S13 fragments generated by thrombin. 
250n\1 recombinant A1)AMTS13 was incubated ý\ith 9n\1 human thrombin at 37'C for 30 minutes in 
20m, \1 Iris-I ICI (pl1 7.8). I50m\1 NA'I and 5m\1 CaCI2. Samples %\ere analysed by Western blotting 
under reducing conditions. (A) ADAMTS13 detected using the anti-ADANIFS13 metalloproteinase 
domain mAb. Lane I- ADAMMIS1 3. Lane 2 ADA\1'I"S13 incubated with thrombin. Lane 3- 400nM 
ADANITS13 incubated with thrombin and extended development of blots. (K) ADANITS13 detected 
using the anti-myc mAb. Lane I- AI)Ah1"I'S 13. Lane 2,3,4 - AD; AM1TS 13 treated vw ith thrombin. lane 
3 contains 25°6 of the volume loaded in lane 4. (C) Predicted identities of the cleavage fragments in 
panel A (Frag 1-6) and panel B (Frag A-U) based on the molecular weights calculated t"rom (A) and (B). 
The fragments generated by cleavage at favoured cleavage sites are shown in bold. 
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3.2.6 Thrombin cleaves ADAMTS13 in a time and concentration dependent 
manner 
To get an indication of the sensitivity of ADAMTS 13 to cleavage by thrombin, 0.9nM 
to 90nM thrombin was incubated with ADAMTS 13 for 0 to 6 hours. Samples were 
analysed by Western blot using the anti-metalloproteinase domain mAb. At 0.9nM 
thrombin, no cleavage of the -200kDa full-length ADAMTS13 band was observed 
after 1 hour incubation. At 2 hours, a faint -150kDa band became evident and by 6 
hours an additional -28kDa band was observed (Figure 3.6A). Using 9nM thrombin, 
full-length ADAMTS 13 was cleaved over time as shown by the disappearance of 
-200kDa band and the appearance of three major fragmentation bands (-150kDa, 
. 4OkDa and -28kDa). Over time the high molecular weight band disappeared and the 
intensity of the -28kDa band became stronger (Figure 3.6A). With 90nM thrombin, 
complete pröteolysis occurred within 30 minutes (Figure 3.6A). The increase in 
intensity of the -'28kDa band over time was not necessarily comparable to the decrease 
in intensity of the -200kDa band. One explanation might have been the presence of an 
additional less favoured cleavage site in the metalloproteinase domain that with time 
generated a fragment similar in size, causing the -28kDa band to spread. 
FXa is a serine protease that is also generated locally at sites of vascular injury, 
upstream of thrombin in the coagulation cascade. FXa is mainly involved in the 
prothrombinase complex that converts prothrombin into thrombin, but has a similar 
specificity to thrombin. Consequently, similar experiments were performed to assess 
whether FXa also cleaved ADAMTS13. Although FXa cleaved ADAMTS13 in a 
comparable fashion to thrombin by generating a similar fragmentation pattern, the rate 
of proteolysis was much slower. Full-length ADAMTSI3 was still present after 6 
hours in the presence of 50nM FXa (Figure 3.6B). 
83 
I') F Iial u. t/n\I Ella 9n\I FIia 900I I'Iia I; ) ; on\I F\a 
:ýIn tu' Ih 'h i II in' Ih 'h nIý tu' Ih 21ý bh I ad Ih 11ý ý, Iý 
211) I a" we M" .. ý 
((kI )i 
45ki rº 
S 
ý, i ý.,... , 411 lj". sea .. A"O -ý- 
Figure 3.1 'T'hrombin and FXa cleaves AI) 1I S13 in a concentration anti time ºIclºcn(lent 
manner. 
Thrombin (Lila) (0 to 90nM1) (A) and FXa (50nM) (B) were incubated with X &M ADAM INH 
37C for 0 to 6 hours in 20mh1 Iris-Il('I (pll 7.8), I50mM Na('I and 5rnM ('a('l. Samples "err 
analysed under reducing conditions by Western blotting using the AI); AMtl'S13 anti-metalloprotcinasc 
domain mAb. Lad Biotinylated protein ladder (ßioRad, USA) 
3.2.7 AUAMTS4 is not cleaved by thrombin 
As a control, the susceptibility of other AI)ANI S iämik members to fprotcolvvsis by, 
thrombin was considered since they share a certain degree of' amino acid sequence 
identity. For this, -800nM ADAM"1'S4, an aggrecanase that cleaves aggrccan Ibund in 
cart ilage23ý, was incubated at 37°C with 9nM thrombin and samples taken over 6 
hours. After Western blotting with an ADAMTS4 anti-metalloproteinasc domain 
mnb, ADAM"I'S4 remained uncleaved over 6 hours suggesting that the susceptibility 
of ADAMTS 13 to thrombin night he specific (Figure 3.7). 
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Figure 3.7.. I)A1ITS4 is not cleaved b) thrombin. 
SOOn\1 ; 11). \\II S-I was incubated kith 9n\l thrombin at 37"(' in 15Om\I NaCl, 5m\1 ('a('I, and 
20m \1 'Iris-II('I (pl17.8) fier 0 to 6 hours and suhjceted to Western blotting under reducing conditions 
using the Al)AsI FS-1 anti-metalloprotcinasc domain mAh. 
3.2.8 Al)AMTSI3 is rapidly protCOI\sccl hN' pplasmin 
I'hrombin and I' Xa are gcncratcd rapidly at the site of \ ascular injury .I Io\\ cv cr, other 
serine protcases are locally activated that might also protcolvsc . Al)AN1'I'S 13. For this 
reason. susceptibility of' Al)AM'IS13 to clcavaie by hlasmiil as ezaminrd. 
Incubation of ADAM"IS Iä with plasmin generated a similar, but not identical, 
fragmentation pattern to that observed fier protcolvsis by thrombin. consistent with its 
specificity for cleavage after certain argininc residues (Figure 3.81 and Figure 3.5A 
and E3). Ilo\\e\er. plasmin can also cleave after specific lysine residues, which may 
explain the presence of additional and alternative ADAM l'S 13 cleavage products. OI' 
particular interest was the additional cleavage site in the metalloproteinase domain that 
generated Frag p7. which was not generated by thrombin (Figure 3.8A). Plasmin 
cleaved AIAMTS I 'i more rapidly than thrombin as seen by the rapid loss of' full- 
length ADAM'FS 13 with 0.9nM plasmin m thin I hour, \v hieb was still present alter 6 
hours with 0.9nM thrombin (Figure 3.813 and Figure 3.6A). 
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Figure 3.8. Proteolytic inactiNation of ADAM I ti13 by plasmin. 
(A) 250n! \1 : 1UAM'I'S13 was incubated vvith 9n\1 human I lasniin in 20m\l Iris-I(('I (p11 7.8), I50m\1 
NaCl and SmM C'ad , at +7°(' for 30 minutes. Samples were anal\sed by \\'estern hlottinp, using, either 
ADAMI'SI S anti-metalloproteinase domain (lane 1) or anti-mve epitopc mAbs (lane 2). (13) 250nM 
. m)AMTS1 3 was incubated with 0-90nM plasmin at 
37"(' in 20mß-1 iris-I WI (pl1 7.8), 150m%l NaCl 
and 5mM CaC'I,. Samples were taken between 0 to 6 hours and analýscd hý Western blotting under 
reducing conditions using the ADAM'I'S1 3 anti-metalloproteinase domain mAb. 
3.2.9 In silico prediction of thrombin cleavage sites in A1)AM'1'S13 
Although ADAMIS13 was susceptible to cleavage by I \a, lovvcr concentrations o1' 
thrombin and plasmin were more able to cflicientlv cleave Al)AM'I'S13 (Figure 3.613 
and Figure 3.813). Despite ADAM I'S 13 being more sensitive to cleav arge by plasmin 
than thrombin, plasmin is classically generated during the later stages of' haemostatic 
plug formation. Since thrombin generation occurs very rapidly after vessel injury, it 
seemed that thrombin might represent the most likely enzyme capable of' cleaving 
ADAM I'S 13 during: the initial haemostatic process. I examined potential thrombin 
cleavage sites in the AUAMTS 13 amino acid sequence (Accession number: 
86 
AB069698) using PeptideCutter (http: //us. expasy. org/tools/peptidecutter/). This 
located sequences with either an arginine in position P1, glycine in position P2 and 
position Pl' or hydrophobic residues found in positions P4 and P3, and non-acidic 
amino acids in the position Pl' and P2'. Further potential sites in ADAMTS13 were 
provisionally identified by proline in the P2 position and arginine in the Pl position 232 
From this, the predicted sites seemed in good agreement with the estimated locations 
derived from experimental data (Figure 3.9 and Figure 3.5C). 
4a, 
D,. o'' ©0 ©" 12 
t 
TSP-1 repeats CUB tftt 
8287 8393 R. 115 R910 8968 
R257 R1176 
Figure 3.9. Predicted thrombin cleavage sites in ADAMTS13 
The ADAMTS13 amino acid sequence (Accession number: AB069698) was entered into the 
PeptideCutter programme (http: //us. expasy. org/tools/peptidecutter/) and thrombin cleavage sites were 
identified. Numbering includes the signal and propeptide, which are not displayed. Other sites were 
found by searching other thrombin recognition amino acid sequenceSI; 2. The locations of the two major 
potential cleavage sites are highlighted in bold. 
3.2.10 Identification of the primary thrombin cleavage sites in ADAMTS13 
To precisely identify the major cleavage sites in ADAMTSI3, proteolytic fragments 
were separated by SDS-PAGE under reducing conditions. Major bands were excised 
and analysed by sequencing the N-terminus using Edman degradation. The N-terminal 
sequence obtained for the - 40kDa fragment was PLLPGP, which demonstrated 
proteolysis after R1176 in-between the TSP8 and CUBI domain. This fragment was 
consistent with the favoured C-terminal cleavage fragment detected by the anti-myc 
mAb (Figure 3.5B). The N-terminal sequence of the -28kDa cleavage fragment 
detected by the anti-metalloproteinase domain mAb (Figure 3.5A) was GILHL that 
corresponded to the start of the metal loproteinase domain. Therefore, this band was 
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derived from mature ADAMTS13 lacking the N-terminal signal peptide and 
propeptide. The N-terminal sequence of a -24kDa fragment was AGLA, which 
demonstrated proteolysis after R257 in the metalloproteinase domain. Based on the 
molecular weight of the -24kDa fragment, another potential thrombin cleavage site 
may exist within the TSP1 domain. The C-terminus of the -24kDa fragment would 
need to be sequenced to locate the exact cleavage site. The N-terminal sequence of the 
other cleavage fragments could not be determined. Possibly, these fragments were in 
low abundance and below the detection limit for N-terminal sequencing, or were not 
completely separation and resolved from other fragments. 
3.2.11 Mutation of ADAMTS13 thrombin cleavage sites 
To corroborate the N-terminal sequence of the thrombin cleavage fragments and the 
predicted thrombin cleavage sites in ADAMTS13, cleavage site variants were created. 
The R257 residue was mutated to alanine. R287 residue was changed to glycine, 
which is the amino acid in the corresponding position in the murine and rat 
ADAMTS13. The R910 and R968 residue in TSP5 and TSP6 respectively were 
changed to glycine, as this was the amino acid in the corresponding location of other 
TSP domains. The R1176, R415 and R393 residues were all substituted for histidine to 
maintain the basic properties of the arginine R-group. It was hoped that each of these 
alterations would be tolerated without adverse effects upon the overall ADAMTS13 
secretion, structure or function. 
Mutagenic oligonucleotide primers encoding substitutions at R257A, R287G, R393H, 
R415H, R910G, R968G and R1176H were used to disrupt thrombin cleavage at the 
predicted sites in ADAMTS13 (Table 9.1). The pcDNA3.1 ADAMTS13 myc/His 
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vector was used as template for the mutagenesis reaction (sections 2.1.1 and 2.1.2). To 
date, R415H has not been generated most likely due to low primer specificity. After 
verifying the presence of the mutation, mutant regions were subcloned into wild type 
vector using the appropriate restriction enzyme (section 2.1.14) (Figure 3.10). 
(A) '-3.2kb '-1.1 kb 
I FcoRl 1 BlieOf t bal 
ADAMTS13 cDNA (-4.3kb) 
R257A R287G R393H R415H R910G R968G R1176H 
ýBý Xbal + BmgBI EcoRI + BmgBI (Cý 
-s. 9kb 
--b. skb 
--3? kb 
1.1kb 
Figure 3.10. Generation of ADAMTS13 thrombin cleavage site mutants. 
(A) Restriction map of predicted restriction enzyme cleavage sites and fragment sizes generated when 
the pcDNA3.1 ADAMTSI3 myc/His vector was digested with BmgBI, EcoRl and Xba1. Both I: coRl 
and XbaI are in the multiple cloning site of the pcDNA3.1 myc/His vector (yellow) and BmgBJ in the 
ADAMTS13 cDNA. The relative location of the predicted thrombin cleavage sites in relation to the 
cDNA sequence is shown below. (B) After double restriction enzyme digest, the reaction was 
electrophoresed on a 0.8%w/v agarose gel and specific fragments isolated by gel extraction. (C) 
Relative amounts of DNA after gel extraction were measured according to the band intensities 
compared to the 1 kb ladder. Lane 1-I kb Ladder, lane 2- wild type pcDNA3.1 ADAMTS 13 myc/his 
backbone vector digested with XbaI and BmgBI, lane 3- insert of mutant vector digested with Xbal and 
BmgB1, lane 4- wild type pcDNA3.1 ADAMTS13 myc/his backbone vector digested with F, coRl and 
BmgBI, lane 5- insert of mutant vector digested with EcoRl and BmgBl. 
3.2.12 Analysis of thrombin cleavage sites in ADAMTS13 
The ADAMTS13 mutants R257A, R287G, R393H, R91OG, R968G and RI176H and 
the wild type ADAMTS13 construct was transiently transfected into HEK293T cells 
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123ac L Mutant WT Mutant WT 
(section 2.2.5). Western blotting was then used to check the expression and secretion 
of each variant in conditioned medium. All ADAMTS 13 variants except the R91 OG 
variant were expressed in the conditioned medium at similar levels to wild type 
ADAMTSI3. This indicated that the mutations introduced did not significantly 
influence ADAMTSI3 folding or its secretion from HEK293T cells. Wild type 
ADAMTSI3 and the ADAMTSI3 variants were then incubated with thrombin and 
subjected to Western blot analysis under reducing conditions using different 
antibodies, depending on the position of the thrombin cleavage site (Figure 3.11). For 
the R287G, R393H, R91OG and R968G variants, increased thrombin concentrations 
were used to cleave at these less favourable sites. Successful disruption of a thrombin 
cleavage site would be predicted to yield a change in molecular weight of the cleavage 
fragments in the ADAMTSI3 variants when compared to those of wild type 
ADAMTS 13. 
Anti- Anti_dkiYtegrtn 
metalbproteliase like domain 
domain mAb mAb 
t 
R287 R393 R415 
R257 
Anti CUB 
domain mAb 
TSP-1 repeats 
trt 
R910 R968 
R1176 
Figure 3.11. Cleavage of ADAMTS13 thrombin cleavage site variants. 
The positions of the mutated residues and their relationship the antibodies used for immunoblotting are 
shown. 
3.2.12.1 R257A and RI176H 
After thrombin cleavage of ADAMTS 13(R257A) and detection with the anti- 
metalloproteinase domain mAb, -40kDa and - 50kDa cleavage fragments were 
Ao1I-TSP2-4 
domain p. ab 
observed in contrast to the single -28kDa fragment generated from wild type 
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ADAMTS13 (Figure 3.12A). This would suggest that cleavage after R257 was 
prevented and that the -4OkDa and -5OkDa bands (Frag 2 and 3 respectively) 
represent metalloproteinase domain containing fragments arising from proteolysis at 
the next available thrombin cleavage site(s), potentially in the TSP1 domain (Figure 
3.12B). This is in agreement with the N-terminal sequence result obtained from the 
-24kDa cleavage fragment, which identified the R257 site. A lower intensity band of 
-30kDa was also detected with ADAMTS13(R257A). This may represent cleavage 
after R287 (Frag 1). 
Aller thrombin cleavage of ADAMTSI3(R1176H) and detection with an anti-CUB 
domain mAb, major species of -80kDa and IOOkDa degradation fragments (Frag B 
and C respectively) were detected, in contrast to the single -4OkDa band in the wild 
type ADAMTS 13 (Figure 3.12C). However, a less intense -4OkDa band (Frag A) was 
still present in ADAMTSI3(R1176H). Alteration of the PI arginine to histidine in 
fibrinogen was previously shown to impair thrombin cleavage by -. 160-fold, rather 
than completely abolish proteolysis 233. Therefore, cleavage may still have occurred at 
R1176, but at a greatly reduced rate. The -8OkDa and -l00kDa CUB domain 
containing fragments may represent bands generated by cleavage at the next available 
thrombin cleavage sites in the TSP6 and TSPS domains respectively (Figure 3.12D). 
The additional bands observed in lanes without thrombin treatment represent 
proteolysis of ADAMTS 13 during cell culture. 
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Figure 3.12. Identification of the R257 and R1176 thrombin cleavage sites 
ADAMTS13 (WT), ADAMTSI3(R257A) and ADAMTSI3(R1176H) were incubated at 37°C for 16 
hours with or without (+/-) 9nM thrombin in 150mM NaCl, 5mM CaC12 and 20mM Tris-HCI (pH7.8). 
Samples were subjected to SDS-PAGE with Western blotting under reducing conditions using the anti- 
metalloproteinase (A) and anti-CUB domain mAb (C). (B and D) Based on the molecular weight of the 
fragments generated, the location of the cleavage sites was mapped upon the ADAMTS 13 domain 
structure. 
3.2.12.2 R287G and R393H 
To monitor proteolysis of ADAMTSI3(R287G) and ADAMTSI3(R393H), the anti- 
disintegrin-like domain mAb was used since proteolysis at these sites could not be 
readily assessed with the anti-metalloproteinase domain or anti-myc mAbs (Figure 
3.11). Using this mAb, -140kDa, -110kDa, - 90kDa and - 50kDa disintegrin-like 
domain-containing fragments (Frag A, B, C and D respectively) were identified after 
proteolysis of wild type ADAMTS13 with thrombin (Figure 3.13A and B). After 
proteolysis of the ADAMTS13(R287G) by thrombin, there was no noticeable 
difference in the molecular weight of the cleavage fragments generated by wild type 
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ADAMTS13 (Figure 3.13). Since the less favoured R287 thrombin cleavage site is 
located in close proximity to the R257 site in the metalloproteinase domain, it was 
difficult to accurately assess whether cleavage was disrupted at R287. After 
proteolysis of ADAMTSI3(R393H) by thrombin, Frag A to C was observed as in wild 
type ADAMTS13 with the exception of Frag D (Figure 3.13). The absence of this 
fragment may represent inhibition of proteolysis in the TSPI domain, indicative that 
the cleavage at R393 was disrupted. 
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Figure 3.13. Identification of the R287 and R393 thrombin cleavage sites 
(A) Wild type ADAMTS13 (WT), ADAMTSI3(R287A) and ADAMTSI3(R393H) were incubated 
with 240nM thrombin in 150mM NaCl, 5mM CaCI2 and 20mM Tris-HCI (pH7.8), samples taken 
between 0 to 3 hours and subjected to Western blotting using the anti-disintegrin like domain mAb 
under reducing conditions. (B) The cleavage fragments were then mapped upon the domain structure of 
ADAMTS 13. 
3.2.12.3 R91OG and R968G 
To more accurately monitor the proteolysis of the R910 and R968 cleavage sites, the 
anti-TSP2-4 pAb was used (Figure 3.11). After proteolysis of wild type ADAMTS 13, 
-140kDa, -100kDa and -80kDa TSP2-4 domain containing degradation fragments 
(Frag A, B and C respectively) were generated (Figure 3.14A and B). After proteolysis 
of ADAMTS13(R910G) and ADAMTSI3(R968G) by thrombin, the same -140kDa 
and -100kDa degradation fragments were also generated (Figure 3.14A). The 
-140kDa and -100kDa degradation fragments in ADAMTS13(R910G) may represent 
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Frag A and B in wild type ADAMTS 13 (Figure 3.14B). Whilst the l40kDa 
degradation fragment in ADAMTSI3(R968G) may correspond to Frag A in wild type 
ADAMTSI3, the -100kDa degradation fragment may be an alternative cleavage 
product (Figure 3.14B). Possibly, this fragment could be similar to Frag 3 after 
detecting with the anti-metalloproteinase domain mAb (Figure 3.5C). Frag C 
generated in wild type ADAMTSI3 was not observed in both ADAMTSI3(R910G) 
and ADAMTS13(R968G) (Figure 3.14A). The absence of frag C in 
ADAMTSI3(R910G) and ADAMTSI3(R968) may be due to the reduced levels 
expressed into the conditioned medium and low abundance of this cleavage product. 
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Figure 3.14. Identification of the R910 and R968 thrombin cleavage sites. 
(A) Wild type (WT) ADAMTSI3, ADAMTSI3(R910G) and ADAMTSI3(R968G) were incubated 
with 240nM thrombin in 20mM Tris-HCI (pH7.8), 150mM NaCl and 5mM CaCI2 and samples taken 
between 0 and 3 hours for Western blotting with the anti-TSP2-4 pAb under reducing conditions. (B) 
Based on the molecular weight of the fragments generated, the cleavage sites were mapped onto the 
domain structure of ADAMTS 13. 
3.2.13 TM, but not heparin, inhibits thrombin mediated cleavage of ADAMTS13. 
The activity of thrombin towards its physiological substrates is altered by its cofactors. 
TM and GAGs are two cofactors that are present on endothelial cell surfaces and 
interact with specific regions on the surface of thrombin, exosite I (TM) and exosite II 
(GAGs/heparin). To determine the potential role of these exosites in the recognition of 
ADAMTSI3, the influence of these cofactors on ADAMTS13 proteolysis was 
examined. For this, 50nM thrombin was pre-incubated for 5 minutes with 50nM or 
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500nM of soluble rabbit 'I'M or heparin. Al)AM'I'S 13 was then added, incubated fier I 
hour and the extent of' fragmentation determined by Western blotting using the anti- 
nietalloproteinase domain mnb. In the absence of FM, near complete proteolysis of 
the -200k1)a full-length AI)AM'I'S I; hand and generation ofthe 'XkI )a degradation 
fragment occurred after I hour incubation with thrombin. I low ver. IM dose 
dependently inhibited AI)AM"I'S 13 prutcolvsis b' thrombin as observed by the 
reduced rate of disappearance of the -2OOkI)a full -Icngth A DA MIS I) hand, and the 
diminished generation of the -23k1)a degradation product at'tcr I hour (I i ure 3.15A). 
This ma)' imply that exosite I ol'thrombin is involved in its binding to ADAM IS 13. 
In the presence of heparin. degradation of AI)AM'I'S I> by thrombin was similar to 
thrombin alone suggesting that exosite II is unlikely to he involved in AI)AM I'S 13 
recognition (Figure 3.1513). Interestingly. ADAM I'S 13 proteolysis by thrombin in the 
presence of 500nM heparin appeared slightly enhanced by comparison to the no 
heparin control. The reason for this moderate enhancement is uncertain, but may be 
due to bridging of AUAMTS 13 and thrombin by heparin. 
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Figure 3.15. Proteolysis of ADAMTS13 by thrombin is inhibited by 'I ! 11, but not by heparin. 
25OnM recombinant ADAM I'S13 was treated ""ith 50n\1 thrombin that was pre-incubated at 37°C for 5 
minutes with either 50nM or 50000 of soluble rabbit I'M (A) or heparin (13) in 20m11 "iris-I IC! (p11 
7.8), I50mM NaCI and 5mM CaCI2. ADANII'S1 3 fragmentation was monitored by Western blotting 
tinder reducing conditions with the anti-nmetalloproteinase domain antibody at 0.30 minutes and I hour 
and compared to the thrombin alone control. 
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3.2.14 Identification of thrombin residues involved in ADAMTS13 binding 
Since TM, and not heparin, impaired the ability of thrombin to proteolyse 
ADAMTSI3, surface residues located in exosite I of thrombin may be important for 
ADAMTSI3 recognition. To identify the specific surface residues on thrombin 
important for the interaction with ADAMTS 13, a number of thrombin variants with 
mutations of charged or polar surface residues were studied (section 2.6). 
Thrombin variants were active site titrated using a short substrate to confirm equal 
amounts of thrombin were used. Thereafter, proteolysis of ADAMTS 13 was examined 
by Western blotting and detecting with the anti-myc and anti -metal Ioproteinase 
domain mAbs. Those variants with a reduced ability to cleave ADAMTSI3 when 
compared to wild type thrombin were assumed to contain a mutation that directly 
interfered with ADAMTS 13 binding. Using the anti-myc mAb, a single -4OkDa 
fragment was observed with wild type thrombin as before. However, full-length 
ADAMTS13 remained intact with the following thrombin variants: R67A, H71A, 
R73A, T74A, Y76A, R77A and K81A (Figure 3.16B, red box), implying the 
involvement of these residues in the proteolysis of ADAMTS 13. 
Similar analysis of ADAMTS13 was performed using the anti-metalloproteinase 
domain mAb. Although a -'28kDa band was generated using wild type thrombin, 
several high molecular weight fragments remained demonstrating that proteolysis of 
the R257 site was incomplete in these experiments under these conditions (Figure 
3.16A, blue box). However, the -200kDa full-length ADAMTS13 band disappeared 
after 2 hours with wild type thrombin and the intensity of this band was used to 
compare the relative activity of the thrombin variants to proteolyse ADAMTS 13. The 
-200kDa full-length ADAMTS13 band was still present after 2 hours incubation with 
thrombin variants: H71 A, R73A, T74A, Y76A, and K81 A, corroborating the data 
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obtained using the anti-myc mAb. In addition, thrombin variant Q38A also exhibited 
slowed proteolysis of ADAMTS13 (Figure 3.16A, blue box). The differences in 
thrombin variants identified using the anti -in eta] loproteinase domain mAb (Q38A) or 
anti-myc mAb (R67A) may demonstrate that different exosite I residues of thrombin 
are involved in the cleavage at the R257 and R1176 sites, but that the majority are 
shared. 
Thrombin mutants 
w®f --200kDa 
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Figure 3.16. Identification of thrombin residues involved in ADAMTS13 binding. 
9nM thrombin or thrombin mutants were incubated with lOOnM ADAMTSI 3 at 37°C in 150mM NaCl, 
5mM CaCI2 and 20mM Tris-HCI (pH7.8). At 0 to 2 hours, samples were taken for Western blotting 
under reducing conditions with the anti-metalloproteinase domain () and anti-myc (1fi) mAb. 
6p 
3.3 Discussion 
Using purified proteins, thrombin cleaved ADAMTS 13 in at least 6 sites. Of these, 
proteolysis occurred preferentially at the metalloproteinase domain and after the TSP8 
domain (Figure 3.5C). Different approaches were employed to identify the cleavage 
sites. Edman degradation of the -28kDa and -40kDa degradation fragments identified 
the two favoured cleavage sites at R257 in the metalloproteinase domain and Rl 176 
after the TSP8 domain respectively. This was further supported by site directed 
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mutagenesis and the probing of proteolysis with the anti -metal Ioproteinase domain and 
anti-CUB domain mAbs (Figure 3.12). Other potential cleavage sites identified by an 
in silico method, could not be confirmed with such certainty. The R287, R393, R910 
and R968 sites could not be identified by Edman degradation, probably because the 
cleavage fragments arising from proteolysis at these sites were not abundant. 
Furthermore, identification of these sites by site directed mutagenesis proved to be 
more difficult (Figure 3.13 and Figure 3.14). This was in part because thrombin 
cleavage at these sites was less favoured when compared to R257 and RI 176. 
Therefore, an alternative method may be needed to determine cleavage at these sites. 
With the exception of the -40kDa CUB domain containing fragment, thrombin 
cleaved ADAMTS13 at sites located in between paired cysteine residues as under non- 
reducing conditions, only a -160kDa and -4OkDa proteolytic fragment were resolved 
(Figure 3.3A and B). Despite this, the -4OkDa CUB containing fragment co-eluted in 
the early fractions during gel filtration suggesting that it remained ionically associated 
to the rest of ADAMTS 13 after proteolysis by thrombin (Figure 3.4). 
The sensitivity of ADAMTS 13 to proteolysis by low thrombin concentrations suggests 
that this could potentially represent a regulatory mechanism for controlling 
ADAMTS 13 activity (Figure 3.6A). Although in vivo the rate of thrombin generation 
may vary depending on the size of the vessel injury, -800nM thrombin can be 
generated during the propagation phase in plasma in vitro48. At these concentrations, 
ADAMTS13 would be highly susceptible to proteolysis by thrombin. ADAMTS13 
was also shown to be proteolysed by FXa, but proteolysis was less efficient than seen 
with thrombin (Figure 3.6B). In vivo, local thrombin concentrations far exceed those 
of FXa at sites of vascular injury and any physiological effect of thrombin on 
ADAMTS13 would be expected to outweigh that of FXa. 
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Following plasminogen activation by tPA and uPA, plasminogen is converted to 
plasmin. I showed that plasmin cleaves ADAMTS 13 at a faster rate than thrombin, 
and gives a similar, but not identical fragmentation pattern (Figure 3.8A and B). 
Although ADAMTS13 was rapidly degraded by plasmin, I hypothesised that thrombin 
was more likely to be physiologically relevant within the context of normal 
haemostasis. This is because plasmin is only generated in appreciable quantities 
following fibrin deposition. 
Thrombin has multiple physiological substrates and roles234'235. Following the 
initiation of coagulation, thrombin confers its procoagulant activities by cleaving 
fibrinogen, feedback activation of upstream clotting factors and the activation of 
tethered platelets236. Together, these functions promote rapid haemostatic plug 
formation. The experimental data presented suggest that thrombin might also serve a 
novel procoagulant function that involves the cleavage of ADAMTS 13. 
Physiologically, the activity and specificity of thrombin is modulated, in part, by 
cofactors. Competition between cofactors for exosite binding has been proposed as a 
mechanism for directing the activities of thrombin237. In binding TM, the specificity of 
thrombin towards fibrinogen, PC and PAR molecules is dramatically altered238. This 
serves to restrict its procoagulant activities to the site of vascular injury. This arises 
partly due to the occupancy of exosite I on thrombin with TM239. After preincubating 
thrombin with TM, proteolysis of ADAMTSI3 was appreciably compromised, 
suggesting exosite I as a possible site of interaction with ADAMTS 13 (Figure 3.15A). 
Exosite I residues involved in TM binding are: K36, Q38, R67, K70, H71, R73, T74, 
Y76, R77, K81 and K109237 (Figure 3.17B). Further investigation using thrombin 
variants demonstrated that mutations of exosite I residues: Q38, R67, H71, R73, T74, 
Y76, R77, and K81 impaired ADAMTSI3 cleavage. Mapping of these residues 
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Sho\VL'd that binding of A1)AM ISI; to thrombin occupied a distinct subset oI exositr 
I residues (Figure 3.16 and Figure 3.1 7A). Some of these residues are also invuAed in 
interacting with other thrombin substrates, such as lihrinogcn, it) (R67,1171, R73, Y71+, 
AI R77 and K8I) and FXIa (1171,1473. Y74 R77)'ß'. In contrast, hreinruh, ºtion of 
thrombin with heparin had no rl'l'rct upon the cleavage of A1)AN1 I SI ±, suggesting 
exosite II is Lin Iikcly involved in the interaction \\ith ADA NI I'SI I (Fisgure 3. I513). 
A) Active B) Active 
site site 
aft 
ADAMTS 13 TM 
Figure 3.17. Exosite I residues in%ohcd in ADAu i'S13 recognition 
(: A) Space till model of the potential thrombin exosite I residues imohcd in ADAM I"S13 recognition. 
(13) Space fill model of thrombin residues in exosite I that are involvcd in 1'M1 binding '. 
TO surnmarise, ADAM TS I3 is protcolvscd by thrombin. plasmin and to a lesser extent 
by FXa. This supports a model in \\hich the initial thrombin generated might 
proteolyse AI)AMTS 13 to prevent destabilisation of the platelet plug. Any thrombin 
that has escaped from the site of injury and onto the surface of' adjacent uninjured 
endothelial cells, mll bind TM. Consequently. thrombin-dependent ADAMTS13 
proteoI sis would he inhibited over intact endothelial cells, thereby restricting platelet 
aggregation to the growing haemostatic plug. I Iowwever, for this model to be credible. 
proteolysis of ADAMTS13 by these enzymes must also inactivate its VWF cleaving 
function. This will be considered in chapter 4. 
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4 INFLUENCE OF PROTEOLYSIS BY THROMBIN AND 
PLASMIN UPON ADAMTS13 FUNCTION 
4.1 Introduction 
The susceptibility of ADAMTSI3 to proteolysis by low concentrations of thrombin 
and plasmin, shown in chapter 3, suggested that proteolysis might represent a 
physiological mechanism by which ADAMTS13 activity could be locally regulated. 
For this hypothesis to be viable, it is necessary for proteolysis to inactivate 
ADAMTSI3. Therefore, the consequence of proteolysis upon ADAMTS13 activity 
was studied using both full length VWF and recombinant VWF substrates. 
4.2 Results 
4.2.1 Purification and quantification of multimeric VWF 
In order to have a ready source of multimeric VWF, it was necessary to purify VWF 
from normal human pooled plasma. This was done with a combination of 
cryoprecipitation followed by gel filtration (section 2.4.1) (Figure 4.1A). By reducing 
SDS-PAGE and silver staining, a single -250kDa band was seen in fractions B8 to 
B12 corresponding to that expected for a VWF monomer. Appreciable quantities of 
contaminating proteins were observed in the later fractions (Figure 4.1 B). In a separate 
experiment, multimer analysis by Western blotting under non-reducing conditions 
showed that VWF multimeric size decreased in relation to fraction number (Figure 
4.1C). For ADAMTS13 assays, fractions B8 to B 10 were pooled since these 
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represented the largest VWF multimers and would be most responsive to ADAMTS13 
proteolysis (Figure 4.1A). 
A specific VWF ELISA was used to quantify the VWF concentration. Reference 
plasma was used to generate a standard curve (the VWF plasma concentration is 
-logg/ml 
106). After plotting the absorbance at 492nm against VWF concentration, the 
standard curve started to plateau at VWF concentrations above 500ng/ml (Figure 
4.1D). However, a standard linear curve was obtained when plotting the absorbance at 
492nm against the Iogio of the VWF concentration (Figure 4.1E). In this way, the 
VWF concentration could be calculated. The yield of the highest molecular weight 
VWF multimers in fractions B8 to B10 obtained from the gel filtered VWF 
preparation depicted was -750µg from 500ml plasma. 
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Figure 4.1. Purification of VWVF from human plasma. 
(: ý) Chromatogram of' \ \\ I purified from human plasma by gel filtration. (B) 5ml fractions \Ncrc 
collected and the \'\\ F purit\ assessed by reducing SDS-P: \GI: on a 7.5°o polyacrylamidc gel, 
followed by silver staining. (C) Multimer analysis of a separate V\\'F purification by Western blotting 
tinder non-reducing conditions. Reference plasma (Ref pis) was used as a standard to show the 
inultimeric composition of \'\\ F. (U and E) \'\\ F as quantified \%ith an ELISA using reference 
plasma to generate a standard curve. 
104 
4.2.2 Influence of thrombin cleavage upon ADAMTS13 proteolysis of 
multimeric VWF 
The VWF-cleaving activity of ADAMTS13, with and without prior incubation with 
thrombin, was assessed using multimeric VWF as a substrate. The assay employs 
urea to unravel VWF so that the ADAMTS13 cleavage site in the A2 domain 
becomes exposed. Initially, proteolysis was analysed by Western blotting using an 
anti-VWF pAb under reducing conditions (section 2.7.1.2). ADAMTS13 pre- 
incubated in the absence of thrombin generated the characteristic -176kDa and 
-. 140kDa VWF cleavage fragments that arise following proteolysis in the A2 domain 
(Figure 4.2A). Moreover, the intensity of the -. 25OkDa full length VWF band 
diminished over the 6 hour time period. In contrast, ADAMTS13 that had been pre- 
treated with thrombin exhibited minimal VWF cleaving activity since the intensity of 
the -250kDa band did not appear to change, and no cleavage products appeared. To 
corroborate this, ADAMTS13 activity was also monitored using a CBA (section 
2.7.1.1). This assay detects the change in VWF multimeric size by measuring its 
collagen binding affinity; larger VWF multimers bind more efficiently to collagen- 
coated wells than do smaller multimers. After 6 hours, the VWF in samples 
containing ADAMTSI3 exhibited -5% original collagen binding activity. In 
contrast, VWF incubated with thrombin-treated ADAMTS13 still exhibited -90% of 
the original collagen binding potential after 6 hours (Figure 4.2B). This suggested 
that once proteolysed by thrombin, ADAMTS 13 can no longer efficiently cleave 
VWF. 
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Figure 4.2. Proteolysis of : \1): \\I'I'S13 by thrombin abolishes acti%ity against multimeric \ \\ F. 
\I)ANITSI ± or thrombin-ticated ADAM IS I, as lire-incubated in 20m\1 Iris-I ICI (1)1I 7.8) Qnd 
imp] I3aCl_ tier 15 minutes at 37 C before adding 3. Sng p1 \'\VF in 1.5\l urea. (A) Sub-samples v. erc 
removed at 0, I. 2 and 6 hours and assessed by Western blotting using an anti-\\V I: pAb. (13) Samples 
ere also analysed using the CB, A (Results shown : SEM, (n 3)). 
4.2.3 Protcolysed AUANITS13 competes ww ith Al)A11"TS13 for multimcric \'WVF 
Although thrombin inactivates A[)AM TS13 function against VWF, v hcthcr this was 
due to disrupted VWF binding or loss of catalytic activity was unclear. To ascertain 
Miether VWF binding was compromised by thrombin proteolysis, competition 
between thrombin-treated A[)AM'I'S 1i and ; A1) AM IS 13 for V\\'I wwas exanmined. For 
this, 60nM thrombin-treated ADAMTS13 (including an excess of Iiirudin to prevent 
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inie Ihur. l 
further thrombin activity) was added to 6nM ADAMTS13 in the presence of low 
VWF concentrations. Assay of VWF function was then performed with samples taken 
over 4 hours for CBA analysis. In the presence of ADAMTS 13, VWF exhibited a 75% 
reduction in collagen binding potential after 4 hours (Figure 4.3). Conversely, 100% 
VWF function remained after 4 hours with 60nM thrombin-treated ADAMTSI3, 
demonstrating that ADAMTS13 activity was abolished. However, the thrombin- 
treated ADAMTS13 and ADAMTS13 mix retained -60% collagen binding potential 
after 4 hours. This suggested that proteolysed material was able to compete with 
ADAMTS13 for VWF, and thus still retained some VWF-binding function. 
100 60nM ADAMTS13/FIIa 
75 
10: 1 Mix 
50- 
25- 
6nM ADAMTS13 
0 
0 50 100 150 200 250 
Time (mins) 
Figure 4.3. Thrombin-treated ADAMTSI3 competes with ADAMTSI3 for VWF 
Multimeric VWF (-8nM) in 15mM BaCI2,1.5M urea and 20mM Tris-HCI (p17.8) was incubated at 
37'C with either 6nM ADAMTSI3,6nM ADAMTS13: 6OnM thrombin-treated ADAMTSI3, or 60nM 
thrombin-treated ADAMTS13. Samples were taken between 0- 240 minutes for analysis by VWF: CBA 
(n=3). 
4.2.4 Proteolysis of ADAMTS13 by thrombin reduces binding against VWF 
Although a 10-fold molar excess of proteolysed material was able to compete with 
ADAMTSI3 for VWF binding, this was incomplete (Figure 4.3). To quantify the 
VWF-binding function of thrombin-treated ADAMTS13, a VWF plate-binding assay 
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was performed (section 2.8.1). When immobilised on microtitre wells, VWF adopts an 
exposed conformation that binds ADAMTS13 with high aftinity173'243. After applying 
1nM to 250nM ADAMTS13 or thrombin-treated ADAMTS13 onto immobilised VWF 
and detecting with an anti-ADAMTS13 pAb, the KD of ADAMTS13 for multimeric 
VWF was -7nM, comparable to previously published data 173. Although thrombin- 
treated ADAMTS13 bound VWF with the same capacity, the KD for VWF was 
-45nM. Consequently, the inability of thrombin-treated ADAMTS13 to proteolyse 
VWF could be due to the reduced KD for its substrate. 
Figure 4.4. Binding of ADAMTS13 to VWF before and after thrombin treatment. 
750ng multimeric VWF was immobilised onto microtiter wells and various concentrations of 
ADAMTS13 or thrombin-treated ADAMTS13 (1nM to 250nM) detected with the anti-ADAMTS13 
pAb. After plotting the absorbance against the ADAMTS 13 concentration and fitting to the one binding 
site model, the KD for ADAMTS13 was -7nM and -45nM for thrombin-treated ADAMTS13 (n =2). 
4.2.5 Bacterial expression and purification of recombinant VWF115 
Another way to assess ADAMTS13 activity is to use short recombinant VWF 
substrates. VWFI15 is an A2 domain fragment spanning residues Glu1554 to 
Arg1668. It contains the Tyr1605-Met1606 scissile bond within its sequence, which 
also has a N-terminal Xpress epitope and a polyhistidine tag187. The advantage of 
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V\1'I I15 OVCF nnultinnrir V\\ F in assessing ADAM ISI., actin itv is that denaturants, 
Iikc urea or guanidine, are not required tier protroIvsis to proceed. I hus, reactions can 
he perlormcd under physiological ionic conditions and protcolvsis can he accurately 
quantified. After inducing V\V 1 I5 expression in transfi0rn cd Rosetta E. co/i cells. 
bacterial cells were harvested, k-scd and the inclusion hod\ I'raction cuntailmW 
VWFI 15 solubiIised in 8M urea. Ihis \\as then purified and refolded using a Ni'' 
ncClatiiig COILunn and an 8M to UM urea linear gradient (section 2.4.2). Aller 
purification. a single --I6.9k1)a hand was clutcd as deterºi1, eLl b SI)S-IA(; I'I and 
C'oomassie Staining (l ioure 4.5). Since a relatively pure sample was obtained, 
V\VF115 vas quantificd using the ßC' 1 assa},. III general. 5OOnºo VWI I 15 was 
obtained from I litre ol'culture. 
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Figure 4.5. Purification and refolding of \ AW'F115 frone inclusion bodies transformed in Rosetta 
E. c oli. 
Inclusion bodies were solubilized'vith 5\I urea and refolded on a Ni", chelating column using an 8\1 to 
OM urea linear gradient. The eluted peak (1) vv as analyzed by SDS-PAG1: and Coomassie staining. 
4.2.6 Thrombin-treated A1)AN'ITSI3 is still active against 15. 
"ho examine the inactivation of ADAM iS 13 by thrombin kinctical IN, the VWVI 115 
substrate was used (section 2.7.2). 8.5nM . A[)AM'I S 13 or thromhin-treated 
A DAMTS 13 was incubated with 6.2µM VWF1 15 and samples taken from 0 to 150 
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minutes for analysis by SDS-PAGE and Coomassie staining. Over 3 hours, 
ADAMTS13 cleaved VWFI15 at the Tyrl605-Met1606 bond and generated two 
cleavage products, lOkDa and 6.9kDa. Interestingly, pre-treating ADAMTS 13 with 
thrombin had no affect upon VWF115 proteolysis. This can be seen by the generation 
of cleavage products at a similar rate as ADAMTS13 (Figure 4.6A). In this 
experiment, high concentrations of VWF115 were required for visualisation of the 
cleavage fragments by Coomassie staining. These conditions were not suitable for 
kinetic analyses. For this, it was necessary to monitor cleavage using VWF115 
concentrations below the Km, such that pseudo-first order kinetic conditions were 
satisfied with initial rates of VWF115 proteolysis being linearly proportional to 
ADAMTS 13 concentration. 
For determination of kinetic constants keat and Km, 8.5nM ADAMTS 13 or thrombin- 
treated ADAMTS13 was incubated with 0.5µM to 20µM VWF115 and reactions 
stopped with 50mM EDTA at 0 to 20 minutes. The products of the reaction were 
analysed by HPLC (sections 2.7.2.1 and 2.7.2.2). At 0 minutes, a single peak 
corresponding to full-length VWFI 15 was observed (Figure 4.6B - top panel). Over 
time, two cleavage product peaks (peak 1 and 2) arising from proteolysis were 
observed (Figure 4.6B - bottom panel). This allowed precise quantification of the 
extent of proteolysis. In each sub-sample, reactions showed less than 15% cleavage, a 
prerequisite for first order kinetics. Initial rates were plotted as a function of VWF115 
concentration, and the data fitted to the Michaelis-Menten equation, allowing 
derivation of the Km and Vmax. The kcat could then also be calculated from the ratio 
Vmax/[E] (enzyme concentration) (Figure 4.6C). The kcat/Km was calculated by taking 
the ratio between the kcat and Km. The catalytic constants for ADAMTS 13 cleavage of 
VWF115 were similar with and without thrombin treatment, but there was a slight 
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difference in KR, between ADAMTS13 (1.61µM) and thrombin-treated ADAMTS13 
(0.86µM) (Table 4.1). This may suggest that after proteolysis by thrombin, 
ADAMTS13 has a slightly higher affinity for VWF115. 
For independent determination of the kcat/Km of VWF115, time course experiments 
were performed as previously mentioned, but using VWF115 concentrations below the 
KR,. Similar kCat/K,, results were obtained using either 0.25µM or 0.5µM VWF115 
suggesting that first order kinetics was achieved (Figure 4.6D). After repeated time 
course experiments using 0.5µM VWF115, ADAMTSI3 gave a mean kcal/K,  value of 
7.37 ± 1.28 x 104 M"s" and thrombin-treated ADAMTS13 gave a mean kC8t/K,, value 
of 11.07 ± 4.39 x 104 M''s'', which was in good agreement with the previous 
determination (Figure 4.6E and Table 4.1). Together, these data demonstrate that 
whereas thrombin proteolysis inhibits the ability of ADAMTS13 to cleave multimeric 
VWF, it has no effect upon its ability to cleave short substrates. Thus, despite the 
presence of a cleavage site within the ADAMTS 13 metalloproteinase domain, it 
appears that this domain remains fully functional against VWFI 15, but not against 
multimeric VWF after proteolysis by thrombin. 
Km (µM) kcal (S) kcat/Km (104M-IS-1) 
Mean :L SEM Mean ± SEM Mean f SEM 
ADAMTS13 (n=4) 1.61±0.47 0.14 ± 0.06 8.70 t 0.90 
Thrombin-treated 0.86 ± 0.35 0.09 ± 0.03 12.60 ± 3.30 
ADAMTS13 n=3 
Table 4.1. Kinetic constants of AUAi 11X1. and thrombin-treated AUANT51J against V WF11S. 
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Figure 4.6. AD; t117'S13 was still active : against N AN F115 after thrombin treatment 
(. ) 8. SnM ADAM1'IS1 3 or thrombin-treated Ali: \M'I'S1 3 as pre-incubated in I50mM NaCl. 5mM 
CaCl' and 20mM Tris-1ICI at 37T for 30 minutes before adding 6 2pM 1 15. Samples were taken 
at 0 to 150 minutes and subjected to SDS-NAGE with Coomassic staining. Cleavage of V\V'IF 1 15 by 
A[). ANITS 13 produced 10kI)a and 6.9k1a cleavage products. (13) These cleavage products could also 
be resolved bN IIPLC in which two cleavage product peaks (1 and 2) were generated, and quantified For 
kinetic analyses. (C) Determination of the k,,,,, h,,, and k,,,,, hkinetic constants was performed by 
calculating the initial rates of V\\'F 1 15 proteolysis at different V\\'FI 15 concentrations (0.5J N1 
201iM). A representative Michealis Menten and Lineweaver-Burke plot is shomn and the results listed 
in Table 4.1. (D) Confirmation that first order kinetics was obtained bN incubating 8. Sn\1 Al)A\ITS1 3 
with 0.25µM or 0.5µ\1 VWFI IS in 150mM NaCl. 5m\1 Ca('I. and 20niM l'ris-ll('I (p117.8) at 37°C. 
Samples were taken at 0 to 3 hours for IIPLC analysis. (F) Similar experiments were then performed 
with 8. SnM ADAMTS13 or thrombin-treated ADAMFSI3 using 0.5µM VWF11S. The k, _'Kof 
AD: \ýTI'SI3 was 7.37 r 1.28 x 10' N1's' and thrombin-treated AI)ANI I S13 was 11.07 1 4.39 x 10' NI 
's' (n- 6). 
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4.2.7 Effect of proteolysis of ADAMTSI3 by thrombin upon its binding to 
VWF115 
ADAMTS13 binding to VWF115 was studied to determine whether this was 
influenced by its proteolysis by thrombin (section 2.8.1). Using a plate-binding assay, 
ADAMTS13 bound VWF115 with a KD of -22nM, similar to previously published 
data' 87 (Figure 4.7). This value differed from that of ADAMTS13 for multimeric 
VWF, -'7nM, suggesting that there are additional sites of interaction with multimeric 
VWF. Thrombin-treated ADAMTS13 bound VWFI 15 with a KD of -14nM, 
suggesting that proteolysis by thrombin marginally enhanced ADAMTS13 binding to 
this A2 domain fragment. This differed from the KD of thrombin"treated ADAMTS13 
for unravelled multimeric VWF (-45nM) (Figure 4.4). Nevertheless, the decrease in 
KD was consistent with the decrease in K,,, after thrombin treatment for VWF115 
(Table 4.1). As VWF115 is much smaller than multimeric VWF, proteolysis of 
ADAMTS13 by thrombin may not affect those domains/regions required for binding 
to VWF115. 
2. 
E 
" 1. 
ß  ADAWS13 
0 0. A ADAMT513 and throrrfiin 
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Figure 4.7. Binding of ADAMTS13 and thrombin-treated ADANITS13 to VWF115. 
250ng VWF115 was immobilised onto microtiter wells and 5nM to 250nM ADAMTSI3 or thrombin- 
treated ADAMTS13 added before detecting with the anti-ADAMTSI3 pAb. Absorbance at 492nm 
against ADAMTS13 concentration was then fitted to the one binding site model. ADAMTS13 bound 
VWF115 with a KD of -22nM and thrombin-treated ADAMTSI3 bound with a KD of -14nM (n = 2). 
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4.2.8 Cleavage of multimeric VWF and VWF115 by ADAMTSI3(R257A) 
Although thrombin cleaved ADAMTS13 in at least 6 sites, proteolysis occurred 
preferentially at R257 in the metalloproteinase domain and RI176 after the TSP8 
domain (Figure 3.5C and Figure 3.12). To assess the affect of proteolysis at R257 
upon ADAMTS 13 function, activity assays were carried out with 
ADAMTS13(R257A) that was resistant to proteolysis at this site. 
ADAMTS 13 and ADAMTS 13(R257A) were pre-treated with or without thrombin and 
incubated with multimeric VWF under denaturing conditions. Sub-samples were taken 
at 0 and 4 hours for multimer gel analysis (section 2.7.1.2). In the presence of 
ADAMTS13, a reduction in high molecular VWF multimers was observed after 4 
hours. This was also observed with ADAMTS13(R257A), demonstrating that the 
R257 mutation did not affect ADAMTSI3 activity. The multimeric composition of 
VWF remained unaltered after 4 hours incubation with thrombin-treated ADAMTS 13, 
confirming that the VWF-cleaving function of ADAMTS13 was inhibited. Although 
ADAMTSI3(R257A) pre-treated with thrombin exhibited reduced proteolytic activity 
by comparison to ADAMTSI3(R257A), it retained some VWF-cleaving function 
(Figure 4.8A). Whilst this demonstrated that proteolysis at the other sites contributes 
to ADAMTS13 inactivation, this also showed that cleavage after R257 is required for 
full inactivation of ADAMTS 13. 
A VWF115 activity assay was also performed using ADAMTS13(R257A) that had 
been preincubated with or without thrombin. Untreated ADAMTSI3(R257A) 
completely cleaved full-length VWFI 15 within 1 hour. Although 
ADAMTS13(R257A) was active after proteolysis by thrombin, activity was reduced 
since full-length VWF115 was still present after 1 hour (Figure 4.8B). Thus, 
disruption of the R257 site demonstrates that proteolysis of this residue in wild type 
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A1)AM'I'S1 i may enhance its activity to counteract the et'Icct oI' Cleavage at the other 
thrombin cleavage sites. 
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Figure 4.8. The R257A ADAMTSI3 variant remained active against \'WW'Fl 15 
(; A) 8nM ADAMTS13 and ADAMTS11 (8257. A) was treated with or vvithout thrombin and pre- 
incubated in BaCI2,1.5M urea and 20mM Iris-I IC! (p117.8) for 15 minutes at 37°C. 1Opgýml multimeric 
V\VF was then added and reactions taken at 0 and 4 hours for multimer geI analysis. A. DA %I 1'S 13 
and EDTA, 13 - ADANITS13, C A1)AM"I'SI3 and thrombin, 1) A1), AMTSI3 (R257A), E 
ADAM"TS13 (R257A) and thrombin. (B) 0nNl ADAMTS13 (R257A) as treated with or without 
thrombin (Ella) and pre-incubated in I50my1 NaC'I, 5m\1 CaCI, and 20niA1 Iris-I I('I (p117.8). 4.8pM 
VWFI15 was then added and samples taken from 0 to 180 minutes for S1)S-P; AGI: and Coomassic 
staining. 
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4.2.9 Influence of plasmin on AI)A\1'I'S13 acti%ity against nºultimeric VW\ I" and 
V\\FI15 
'the effect of plasill in-III ediated I)rotcolv`is on AI )A M-1 IS 13 activity using hot Ii 
multimcric VWI and VW'I I1j was nest examined. I're-trcatºiºent o I' ADAM I'S I .; 
with plasmin had a similar effect as thrombin upon activity against mullinieric V\VF. 
No prOtcolysis of' VW1 by plasmin-treated Al AM I SI 3 was detected by Western 
plotting (Figure 4.9A). This observation was corroborated by V\'1I.: ('I3A analysis 
(Figure 4.913). Similar to thrombin-treated A I)ANI IS 13. Al)AMIS 13 remained active 
against VWF I 15 aller proteolysis by plasmin. I Iow ever. proteolysis of' V\\ I 115 by 
plasmin-treated AUAM'I'S 13 was slower than that of AUAM I'S I1 (Figure 4.9C'). 
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Figure 4.9. Proteolysis of ADAN1'I'S13 bý plasm in abolished actiO) against \'W]" but not against 
\A\'F115. 
(A and B) 8.5n\1 ADAM I'S 13 or pIasmin-ire ated : \U; \\1 IS L', '\as pre-incuhated in 20m\1 Iris-11 (1 
(pll 7.8), 1.5M urea and I5mM 13aCI, for 15 minutes at 37°C. 3.5tig'ml multimcric V\\'F was then 
added and samples taken at 0 to 6 hours for Western blot or C[3: \ analysis. (C) Similarly, 8. SnM 
: \UAMTS13 or plasmin-treated : \DAMTS13 was pre-inruhated in 20mM Iris-I ICI (p117.8), 
I50mM 
NaCl and 5niM CaCT, for 30 minutes at 37°C. 4.81i\1 V'\V'F1 15 as then added and samples taken at 0 
to 4 hours tör SDS-PAGE with ('oomassic staining. 
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4.3 Discussion 
In this chapter, I explored the influence of proteolysis of ADAMTS 13 upon both its 
VWF-cleaving and VWF-binding functions. In the first instance, I employed 
multimeric VWF purified from plasma as a substrate to assess ADAMTS13 activity. 
In these experiments, it was clear that proteolysis of ADAMTS13 by either thrombin 
or plasmin had a profound effect upon its ability to cleave its natural physiological 
substrate VWF. In both cases, very little proteolysis of VWF was detected, 
demonstrating that exposure of ADAMTS 13 to either of these serine protcases caused 
its complete, or near complete inactivation (Figure 4.2 and Figure 4.9). In many ways, 
this finding was perhaps not unexpected given the number of thrombin/plasmin 
cleavage sites (>6) that are located throughout the ADAMTS 13 molecule. However, it 
remained unclear precisely how this inactivation was manifest (i. e. whether 
ADAMTS13 substrate recognition, its proteolytic function, or both, had been 
impaired). Therefore, to define the molecular basis of this inactivation by thrombin, I 
employed a variety of approaches to explore the influence of ADAMTSI3 
fragmentation upon its ability to interact with multimeric VWF, and a recombinant 
VWF A2 domain fragment. In addition, I endeavoured to more closely examine the 
effect upon the enzymatic function of the metalloproteinase domain. 
From the functional competition experiments, it appeared that thrombin-cleaved 
ADAMTS 13 could compete, at least in part, with uncleaved ADAMTS 13 for VWF 
(Figure 4.3). This suggested that proteolysed ADAMTS13 was still able to bind its 
substrate. However, even when thrombin-cleaved ADAMTS 13 was in a 10-fold molar 
excess over its uncleaved counterpart, competition was still incomplete (-. 50%). Thus, 
it seems that whereas proteolysed ADAMTSI3 retains an affinity for VWF, this is 
reduced when compared to that of ADAMTS 13. This contention was confirmed using 
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a plate-binding assay. This revealed that ADAMTS13 bound multimeric VWF with 
high affinity (-7nM), in accordance with previous data 173, but once proteolysed by 
thrombin its affinity was reduced -8-fold (KD -45nM) (Figure 4.4). Given the 
" relatively low concentration of ADAMTS 13 in plasma (-5nM), such an increase in KD 
would likely have an appreciable effect upon the ability of thrombin-cleaved 
ADAMTS13 to interact with VWF, when in a physiological milieu. For this reason, 
the reduced affinity for its substrate could contribute to the inactivation process. 
However, when a 10-fold increased amount of thrombin-cleaved ADAMTS 13 (which 
might be predicted to compensate for its 8-fold reduced affinity) was assayed, no 
proteolysis of VWF was detected (Figure 4.3). Thus, it is clear that an additional 
inactivation mechanism(s) might account for the loss of VWF-cleaving function. 
There are several published ADAMTSI3 activity assays that use both different 
substrates, and reaction conditions. Assays that use multimeric VWF have a major 
advantage because they employ the natural substrate for ADAMTS 13. Consequently, 
it is assumed that, as far as possible, they test the full functionality of ADAMTS13. 
However, it is very difficult to quantify proteolysis in these assays, and as a result, 
they do not allow accurate kinetic analyses to be performed. Furthermore, it is 
unknown whether the presence of non-physiological denaturants, such as urea or 
guanidine, might contribute to ADAMTS13 inactivation after proteolysis by thrombin 
or plasmin. Potentially, the presence of urea may further alter the structural 
conformation of ADAMTSI3 following proteolysis by thrombin or plasmin, which 
might not occur under normal ionic conditions. For example, after proteolysis by 
thrombin at RI 176, I showed that the -4OkDa C-terminal fragment was still ionically 
associated to the rest of the ADAMTSI3 molecule (Figure 3.4), but this may 
dissociate from ADAMTSI3 in the presence of urea. However, thrombin cleavage at 
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R1176 may not influence ADAMTS13 function in vitro since deletion of the CUB 
domains did not impair its activity under denaturing conditions 168.171. Ideally, the 
influence of ADAMTS13 proteolysis would best be investigated under more 
physiological conditions. In principle, this could be assessed using a flow chamber 
assay, which monitors the ability of ADAMTS13 to cleave UL-VWF strings from 
stimulated endothelial cells under flowing conditions in real time'91. This would 
circumvent the need for harsh denaturants by using physiological flow conditions. 
However, determination of kinetic constants is not possible with this assay. 
A major advantage of those ADAMTSI3 activity assays that use short recombinant 
A2 domain substrates is their accurate quantification 168,188,192,193,213,230,244, Fragments 
such as VWF115 can be readily expressed in, and purified from bacteria t87. 
Furthermore, the proteolysis of VWFI 15 can be performed under normal 
physiological ionic conditions (i. e. no denaturants), and its cleavage can be accurately 
quantified (i. e. it is a very sensitive assay). This has allowed kinetic analysis of 
VWF115 proteolysis by ADAMTS13, and the derivation of the kinetic constants for 
this reaction187. For these reasons, I examined the influence of thrombin proteolysis 
upon ADAMTS13 activity using VWF115. Surprisingly though, I found that 
ADAMTSI3 activity was not ablated by thrombin using this approach (Figure 4.6). 
Kinetically, the kcat/Kn, for VWF115 proteolysis was marginally increased following 
pre-incubation with thrombin, due to a slight decrease in the K. for the VWF115 
cleavage reaction (Table 4.1). This suggested that the ADAMTS13 metalloproteinase 
domain remains fully functional after proteolysis by thrombin. Furthermore, this 
demonstrates that the ADAMTS13 inactivation measured in the multimeric VWF 
assay must be attributable to a loss of an aspect of ADAMTS 13 function that is not 
required for proteolysis of VWFI 15. Due to the absence of the other VWF domains 
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and the lack of its multimeric structure, the cleavage of such A2 domain polypeptide 
sequences probably does not depend upon the function of quite as many ADAMTS 13 
domains as those that are required for proteolysis of multimeric VWF. This finding 
highlights a major drawback with assays that use recombinant A2 domain fragment 
substrates because different results may be obtained to the full length VWF substrate 
when analysing ADAMTS 13 activity in plasma samples where appreciable 
ADAMTS13 proteolysis has occurred. 
It has been shown that sequential deletion of the ADAMTSI3 C-terminal domains has 
a limited influence upon cleavage of VWF A2 domain fragments. Indeed, these kinetic 
data suggest that domains C-terminal to the spacer domain contribute little to A2 
domain fragment proteolysis 166. The spacer domain is clearly important for all 
168'171'17Z assays . It seems that this 
domain contains a major binding site for VWF. Very 
recent data confirm this contention, and suggests that the spacer domain directly 
interacts with amino acids contained within the C-terminal part of the A2 domain 
sequence190. In accordance with this, all ADAMTS 13 variants that have been truncated 
before the spacer domain exhibit appreciably reduced activity. Despite this, proteolysis 
of VWF A2 domain fragments still occurs, and specificity for the Tyrl605-Metl606 
bond is typically maintained213. The domain requirements for proteolysis of 
multimeric VWF is slightly more complicated. This is perhaps because there are 
different and more complex interactions that occur, but is likely to involve the spacer 
domain, C-terminal TSP1 domains and CUB domains (section 1.5.3). VWF circulates 
in plasma in a globular conformation, which cannot be cleaved by ADAMTS13. In 
this conformation, VWF does not interact with ADAMTSI3 with high affinity. 
However, the CUB domains may interact with surface exposed A3 domain on VWF 
(or other exposed VWF regions) with low affinity and this may represent the initial 
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tethering mechanism between the two molecules' 85,245. The C-terminal TSPI domains 
may modulate this initial binding interaction to further enhance or prevent the 
colocalisation of ADAMTSI3 and VWF173. In the presence of high shear stress, this 
initial contact may then favour a high-affinity interaction, possibly between the VWF 
A2 domain and ADAMTS13 spacer domain. These multiple interactions and shear 
stress together completely unfold VWF to expose the scissile bond for efficient 
proteolysis of the VWF A2 domain. Whilst deletion of the C-terminal TSP I domains 
and CUB domains has no effect upon the proteolysis of multimeric VWF in the 
presence of urea 168'171, it does have small but significant effects upon its VWF binding 
affinity. ADAMTS13 bound VWF with a KD of -I4nM, ADAMTS13 truncated after 
TSP8 bound VWF with a KD of -45nM and ADAMTS13 truncated after TSP7 bound 
VWF with a KD of -7nM173. This suggests that the distal ADAMTS13 domains (C- 
terminal TSPI and CUB domains) can influence the recognition of substrates by the 
more proximal domains (metalloproteinase to spacer). 
Given the observations that both ADAMTS13 and ADAMTS13 proteolysed by 
thrombin cleaved VWF115 similarly, it was perhaps unsurprising that their binding 
affinities for this recombinant A2 domain fragment were also very similar (Figure 
4.7). This may be the case because the spacer domain is important for this high affinity 
interaction, and yet this domain is not directly influenced by proteolysis by thrombin. 
Noticeably, there was a big difference between the Km and KD of both ADAMTS13 
and thrombin-treated ADAMTSI3 for VWF115 suggesting that a tight binding 
interaction does not influence substrate proteolysis (Figure 4.7 and Table 4.1). The Km 
(15nM) and the KD (14nM) of ADAMTSI3 for multimeric VWF are similar164'173. 
However, enzyme reactions were performed in urea. Also, VWF proteolysis was 
measured qualitatively, rather than quantitatively, using a CBA. Together, the K, n of 
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ADAMTS13 for VWF may not have been accurately determined since the reaction 
conditions do not reflect the physiological ionic environment and analysing proteolysis 
of multimeric VWF quantitatively is difficult with the assays available. 
One of the two favoured sites at which thrombin can cleave ADAMTS 13 is after R257 
in the metalloproteinase domain. Currently, there is no crystal structure for 
ADAMTS13. However, a number of crystal structures exist for metalloproteinase 
domains of snake venom toxins. These share a degree of sequence identity with 
residues around the catalytic site in the metalloproteinase domain of ADAMTSI3. - 
Therefore, modelling the amino acid sequence of the metalloproteinase domain of 
ADAMTS13 based on a known crystal structure of a snake venom toxin may provide 
an indication of the position of the R257 residue in relation to the catalytic site. On a 
molecular model of this domain based upon the crystal structure of Atrolysin C (PDB 
number: latl)246, this residue is predicted to be surface exposed, and to lie adjacent to 
the active site cleft . 
(Figure 4.10). 
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Figure 4.10. Predicted structure of the ADAMTS13 metalloproteinase domain. 
The ADAMTS13 metalloproteinase domain was modeled against the metalloproteinase domain in 
Atrolysin C (PDB number: latl). Alpha helices are shown in blue, beta sheets in orange and loops in 
gray. Key residues in the active sites are highlighted and labelled. The location and position of the three 
histidine side chains are highlighted white and blue and labelled in yellow. The glutamic acid side chain 
residue is highlighted in white and red and labeled in yellow. The Zn'' ion is shown as a yellow ball. 
The position of the Proline-Arginine-Alanine at the R257 thrombin cleavage site is highlighted in red. 
Given the location of this amino acid, it might seem to be a potentially important 
cleavage site with regard to the proteolytic inactivation of ADAMTS 13. To examine 
the role of this proteolytically sensitive site, I tested the activity of ADAMTSI3(R257) 
before and after cleavage by thrombin. Using multimeric VWF as a substrate, 
proteolysed ADAMTS13(R257A) retained some activity after thrombin treatment 
(Figure 4.8A). This suggested that proteolysis after R257 contributes to the 
inactivation process. When using the VWFI15 assay, the activity of 
ADAMTSI3(R257A) was reduced after proteolysis by thrombin (Figure 4.8B). Since 
proteolysis at R257 is predicted to lie on the edge of the active site, proteolysis at this 
site may not interfere with the processing of VWFI 15, unlike multimeric VWF, 
because of the difference in substrate size and accessibility to the active site. This 
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highlights a difference between multimeric VWF and short VWF recombinant 
substrates in assessing ADAMTS 13 function. 
Other thrombin cleavage sites, such as RI 176 preceding the CUB domains, might also 
affect ADAMTS13 function since the CUB domains have been implicated in VWF 
recognition 173,245. Whilst the CUB domains remain ionically associated to the rest of 
the ADAMTS13 molecule after proteolysis by thrombin (Figure 3.4), whether it still 
retains VWF binding potential is unknown. However, the cleavage at RI 176 may not 
be important in vitro since the CUB domains are not essential for activity against 
multimeric VWF under denaturing conditions 168,171. Thus, more studies on the CUB 
domains are required to determine the physiological effects of proteolysis at R1176. 
Taken together, the data presented so far using multimeric VWF as substrate support a 
regulatory mechanism by which ADAMTS 13 could be proteolytically inactivated by 
thrombin (and plasmin) at sites of vascular perturbation. 
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5 PROTEOLYSIS OFADAMTS13 BY THROMBIN IN 
PLASMA 
5.1 Introduction 
In Chapter 3,1 demonstrated that recombinant ADAMTS13 was proteolysed by low 
concentrations of thrombin and plasmin in a purified system. In Chapter 4,1 then 
showed that proteolysed ADAMTS13 was unable to cleave multimeric VWF. In this 
Chapter, I extend these investigations to the plasma environment. 
5.2 Results 
5.2.1 Proteolysis of recombinant ADAMTS13 in plasma 
To first assess proteolysis of ADAMTS13 in a physiological setting, it was necessary 
to optimise its detection in normal human plasma. However, due to the low 
concentration of ADAMTS 13 in plasma (--5nM), the anti -metal Ioproteinase domain 
mAb was found to be ineffective in detecting plasma ADAMTS 13 because of its 
comparatively low affinity (Figure 5.1C, lane 1). Consequently, recombinant 
ADAMTS13 (final concentration 80nM) was added to plasma in order to monitor its 
proteolysis. When this was done, a single -'200kDa band was resolved (Figure 5.113). 
Coagulation was then initiated in ADAMTS13-spiked defibrinated plasma by adding 
relipidated 8pM TF, 4µM phospholipids and 16.6mM CaCl2 and thrombin generation 
quantified in real-time using a fluorogenic substrate and an automated plate reader 
(section 2.8.3). This demonstrated that thrombin was generated in these samples with a 
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characteristic lag-time, followed by a rapid propagation phase (Figure 5. IA). In 
parallel, aliquots were removed between 0 to 30 minutes and the effect of thrombin 
generation upon ADAMTSI3 was examined by Western blotting using the 
ADAMTS13 anti-metalloproteinase domain mAb (Figure 5.113). Over this time 
course, a decrease in the intensity of the -200kDa full-length ADAMTS13 band was 
observed, suggesting a component of the coagulation cascade was responsible for the 
loss of full-length ADAMTS 13 in this system. 
As fibrinogen is a major substrate for thrombin, which was absent from these initial 
experiments, reactions were set up using whole plasma containing 125nM 
ADAMTSI3 and 5mg/ml GPRP-amide. This peptide inhibits polymerisation of fibrin 
and clotting thereby allowing Western blot analysis of samples. Reactions were 
incubated for 30 minutes and subjected to Western blotting using the anti- 
metalloproteinase domain mAb (Figure 5.1C). In the absence of TF, full-length 
ADAMTSI3 was detectable as before (Figure 5.1C, lane 2). However, this band 
disappeared after initiating coagulation (Figure 5.1C, lane 3). The -28kDa cleavage 
fragment previously detected in vitro could not be detected, possibly because other 
plasma proteins impaired resolution/detection of this band. Nonetheless, full-length 
ADAMTS13 remained intact in the presence of the specific thrombin inhibitor, 
hirudin, indicating that the loss of full-length ADAMTS13 from plasma occurred by a 
mechanism involving thrombin (Figure 5.1 C, lane 4). 
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Figure 5.1. Proteolysis of : t1. t' 1'l'S13 following thrombin generation in human plasma. 
Recombinant : 1D: \NI'I-SI i (final concentration 80nNI) ýýas added to defibrinated normal pooled citrated 
human plasma. (A) 'T'hrombin generation was initiated b\ the addition of 8pM IF, 16.6mM ('a- and 
4µN1 phospholipids (PL) (NS: PC: PI. 20: 60: 20). The amount of thrombin generated in defibrinatcd 
A1)ANITS13-spiked plasma was monitored in triplicate in real-time by a I: luoroscan plate reader using 
a fluorogenic thrombin substrate. Readings \\ere quantified %\ith a standard curve generated in parallel. 
(B) Parallel plasma samples \%ere also analysed for ADA\ITS1 3 fragmentation. At 0,10.20 and 30 
minutes, AI)AM1'SI3 degradation as assessed by Western blotting under reducing conditions using an 
anti-A1)AMTS13 metalloproteinase domain mAb. (C) Citrated \N hole human plasma (containing 
5mg ml GPRP-amide) was incubated with either IF IT Ca ' (lane 1). I25n\I A[)ANI I S1 3 (lane 2), 
fF Pl_, Ca`' and 12500 A[)AM I'SI S (lane S) or 'ft Pl. ('a", I25nNl ADAM I'M S and L"3±µ\1 hirudin 
(lane 4) for 30 minutes at 3TC. Samples %\ere analysed b\ \\ etern blottin u. in-, an anti-: \I). \NI I SlS 
metalloproteinase domain mAb. 
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5.2.2 Proteolysis of endogenous ADAMTS13 in plasma 
Although the loss of full-length ADAMTS 13 was shown to occur in plasma after 
initiating thrombin generation, recombinant ADAMTS 13 had to be added to enable its 
detection by Western blotting using the anti-metalloproteinase domain mAb (Figure 
5.1C). In these experiments, the ADAMTS 13 concentration was >16 times greater 
than its normal physiological plasma concentration (-5nM). Consequently, this does 
not accurately monitor the physiological proteolysis of ADAMTS13 by thrombin 
because supraphysiological concentrations of ADAMTS 13 were used. Also, 
ADAMTS13 cleavage fragments could not be resolved in plasma following thrombin 
generation using the anti-metalloproteinase domain mAb due to the comparatively low 
affinity of this mAb. Although the intensity of the full-length ADAMTS 13 band 
diminished after initiating coagulation in whole plasma, generation of cleavage 
fragments would provide direct evidence that the loss of full-length ADAMTS 13 was 
a consequence of proteolysis. 
To assess the proteolysis of endogenous ADAMTS13 following thrombin generation, 
similar experiments were performed in the absence of recombinant ADAMTS 13. To 
increase the sensitivity of the detection of endogenous plasma ADAMTS 13, plasma 
samples were subjected to the Proteoblue albumin depletion kit (section 2.8.4). This 
kit removes abundant proteins in plasma, such as IgG and albumin, which might 
otherwise impair the blotting/detection of plasma ADAMTS13 and the resolution of 
cleavage products. Furthermore, using a pAb rather than a mAb for Western blotting 
appreciably improved the sensitivity of ADAMTS 13 detection. 
Using this approach, the -200kDa band representing endogenous plasma ADAMTS13 
could now be detected (Figure 5.2, lane 4). Recombinant full-length ADAMTS13 was 
detected as an intense -200kDa band using the anti-ADAMTSI3 pAb, which 
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disappeared after complete proteolysis with thrombin in vitro (Figure 5.2, lane 2). Five 
lower molecular weight ADAMTS 13 species were detected after proteolysis by 
thrombin (-120kDa, 97kDa, -66kDa, 50kDa and -. 35kDa) (Figure 5.2, lane 3). When 
added into plasma, these proteolytic fragments were still detected (as well as the 
-200kDa endogenous plasma ADAMTS 13 band) showing that the cleavage fragments 
were not removed or depleted by treatment with the Proteoblue albumin depletion kit 
(Figure 5.2, lane 6). 
Having optimised the detection of ADAMTS 13, coagulation was initiated in normal 
pooled plasma. After 30 minutes, the endogenous ADAMTS 13 band remained intact 
and no proteolytic fragments were observed (Figure 5.2, lane 10). Repeat experiments 
were then performed with 24pM TF to generate increased concentrations of thrombin, 
and at a faster rate. Under these conditions, the -. 200kDa full-length ADAMTS13 
band still remained intact after 30 minutes in both the absence and presence of 5mg/ml 
GPRP-amide (Figure 5.2, lane 8 and 9). Only when 40nM recombinant ADAMTS 13 
was supplemented into plasma and coagulation initiated in the presence of 24pM IF, 
was a small amount of proteolysis was detected - as observed by the generation of the 
-130kDa proteolytic fragment (Figure 5.2, lane 5 and 7). Although the concentration 
of thrombin in these experiments may exceed -180nM (Figure 5. IA), extensive 
proteolysis of recombinant ADAMTS13 appeared not to have occurred after 30 
minutes. However, the -130kDa proteolytic fragment may represent proteolysis at the 
favoured R257 and R1176 sites. Together, these data demonstrate that endogenous 
plasma ADAMTS13 is not readily susceptible to proteolysis during the early stages of 
coagulation. 
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Figure 5.2. Proteolysis of endugencous AD \\I 1513 foIIois ing IIu"umhin generation in Iºwnauº 
plasma. 
; \lter initiating coagulation in w'Itole pl; t, iºia itli Rp\l or 2"lp\1 II . "11º\l phosholipid and 
16.6mM 
(a . albumin and 
Ig(i \k ere remo ed using Proteblue prep albumin depletion kit to enhance detection 
of plasma derived ADAM I'S13. Samples ere analysed b \\'estern blotting under reducing conditions 
using the anti- \I); \\l'I'S 13 pAb. Lane I Biotin laced ladder. 2 40n\l ADAMI 1 3.3 "1011\1 
proteol\sed . \l)A\I'I'SI3.4 - Plasma. 5- 40n\1 ADAM I S13 in plasma. 6 "10n\1 protcoI sed 
ADAM I'S1 3 in plasma. 7 40n\1 AI): \\1 I S13 in plasma \%ith 241\I IF. 8 Plasma with 24p\1 11-. t) 
Plasma with 24pM TF and 5mg ml GPRP amide. 10 Plasma . sich 8pM 1 F. 
5.2.3 Fibrinogen competes iiith AI): v'ITS13 for thrumhin in a purified sNstcm, 
but not in plasma 
To rationalise the lack of proteoIv sis o1' cnd ogenous AUAN1 IS 13 in NOoIe plasma, the 
influence of fibrinogen upon the ability of thrombin to cleave . 
AI): 1M1 I Sl 3 was 
invcstigated. This vas done tör two reasons. First, fibrinogen is an abundant thrombin 
substrate in plasma. fibrinogen is present at a concentration of -7µM1. vvhich is -1400 
times greater than the concentration 01' AI); \ITS 13 in pIasma (-5nM). AIthough the 
K,,, of' thrombin for fibrinogen is cunlparamck \\eak ( 7µM) ", much 01' the 
thrombin : generated will associate with iihrinogen due to its high Plasma 
concentration. Second, a number of thrombin exositc I residues such as: R67.1171, 
R73, Y76. R77 and K8I that are involved in fibrinogen binding-"" are similarl\ 
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important for ADAMTS13 binding (Figure 3.17A). For this reason, fibrinogen may 
compete with ADAMTS13 for thrombin and so prevent its proteolysis. 
To test this hypothesis, ADAMTS 13 was treated with thrombin in vitro in the absence 
or presence of -7µM fibrinogen. Samples were taken between 0 and 2 hours and 
subjected to Western blotting using the anti-ADAMTS 13 pAb under reducing 
conditions. Short exposure of the Western blot showed the loss of the -200kDa full- 
length ADAMTS13 band, the generation of a -160kDa proteolytic fragment and a less 
intense -130kDa degradation fragment within 1 hour in the absence of fibrinogen 
(Figure 5.3A - 1). However, the -200kDa full-length ADAMTS13 band still remained 
after 2 hours in the presence of fibrinogen (Figure 5.3A - 1). Given that the favoured 
sites of proteolysis by thrombin are at R257 and R1176, the -160kDa fragment may 
represent cleavage at either of these sites, whereas the -130kDa band probably 
corresponds to proteolysis at both of these sites. These large molecular weight 
fragments could not be resolved with longer exposure of the Western blot, but this 
allowed the detection of -5OkDa and -35kDa cleavage fragments, which may 
represent fragments arising from cleavage at the less favourable sites. These bands 
were apparent within 30 minutes in the absence of fibrinogen, but only after 1 hour in 
the presence of fibrinogen (Figure 5.3A - II). This suggests that fibrinogen inhibits the 
cleavage of ADAMTS 13 by thrombin. 
To test whether competition by fibrinogen might account for the lack of ADAMTS 13 
proteolysis in plasma, fibrinogen deficient plasma rather than defibrinated plasma was 
employed to avoid the use of Reptilase (Figure 5. IA and Figure 5.3B). Following 
thrombin generation in normal plasma or fibrinogen deficient plasma, the -2OOkDa 
full-length ADAMTS13 band remained intact (Figure 5.3B). Despite the evidence 
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from the in l'ilrO data. it seem cc] that the major cause I 'Or tlic lack of ADAN t1', I. i 
prOtCOI\sis in plasma IlligIIt not be due to Competition \\itu Iihrinººgrn. 
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Figure 5.3. Fibrinogen competes %%ith ADANI TS13 for thrombin. 
(A) 44nN1 . A[); AMlSI3 was incubated NNith 10011\1 thrombin in the presence of' absence of' 7p\l 
fibrinogen in I SOm\1 NaCI, 5m%I CAI, and 20mM '1 ris-l ICI (p117.8) at 37°C. Samples were taken at 0 
to 2 hours and analysed under reducing conditions by Western blotting using, the anti-. AI)-\\I I S1 3 pAb. 
A short (I) and long (II) exposure was taken. Fb fibrinogen. 1. - ladder (B) Detection of I S1 3 
in fibrinogen deficient plasma after thrombin generation \s as perti, rmed as pre\ iousl> described. Lane I 
Ladder, Lane 2- Plasma, Lane 3 Plasma - 24p\l 1'F. Lane -3 I fibrinogen deficient plasma, lane S 
Fibrinogen deficient plasma + 24ptit IF. 
5.2.4 V'WF (foes not protect ADAMITS13 from protcohtic cleavage by thrombin 
Au alternative hypothesis for the lack of' AE); ANI III protcoIvsis in plasma might he 
through protection by VWF. Al)ANi Ts I: and V \\ I circulate in plasma at a 
concentration of -I tg/mI (5nM) and --10µg nil (4OnM)10" respectively. (Furthermore. 
ADAMTS 13 hinds unraveled VwVI: with a Iovw K1) of' - I4nM-1'''. Since V\\' I: is murr 
abundant than ADAMTSl3 in plasma and AIDA\1 I'S I, has a loww KI) for VWI , 
ADA M"I'SI3 may associate with V\V'I and protect AI): 1\1 I sI 3 from proteolysis by 
thrombin at sites of vessel injury. 
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U test this. 44nM ADAM I S13 ý\as incubated \\itli thrombin in hUtli the presence and 
ahsencc of 440nM VWF at 37°('. sample` taken at 0 to .; 
hours and suhjectcdi to 
\b'cstcrn blotting using the anti-ADAM FS I) pAh. In both reactions, the full-length 
--200k1)a nI)/M'I'SI i band disappeared alter I hour and the I60kI)a and 35kI)a 
degradation fragments appeared. This suggested that V \V I in a globular confýºrnýcition 
does not protect ADAM ISI; from protcoly sis by thrombin (IF igure ti. ý ). Similar 
experiments were pal'Or icd in the presence of' urea to aýscss \\Ihcthcr an open 
conformation of VWI might Protect A DAM I SI Z from protcol ' i,, hv thronmhin. 
loý\ever. urea inhibited thrombin activ it\ meaning that this Alert could not he 
dctcrmincd (data not shown). 
All. 11 l S13'ß : AI). 11TS13 
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Figure 5.4. Influence of N'V* F upon proteolysis of F S13 b) thrombin 
44n\1 : \I): \\1 IS 13 was incubated at 37 
C vvith 240n\I thrombin in the pre>rncr or absence of 44OnNI 
\'\\ 1: in I SUmM NaCI, 5mM CaCI_ and 20mM Iris-I I(I O 117.8) ý\ ith or \ý ithout I . 
5\1 urea. Samples 
were taken at 0 to 3 hours and subjected to Western blotting using the anti : AI) \\I I'SI3 p: Ab under 
reducing conditions. 1_ Biotinylated ladder 
5.2.5 Influence of AUAMTS13 concentration its proteol%, sis hN. thruºmhin 
Fhe influence of A1)AM"I'S1 3 concentration On its proteoI sis by thrombin vas next 
examined. For this, various concentrations of Al): 1! NT1 X13 (5.5nM to 176nM) were 
133 
incubated at 37°C with thrombin, samples taken between 0 and 2 hours and subjected 
to Western blotting using the anti-ADAMTS 13 pAb. For each sample, equal amounts 
of ADAMTS 13 were loaded onto the gel. This ensured that the intensity of the bands 
at the different ADAMTSI3 concentrations was comparable so the rate of proteolysis 
could be qualitatively assessed. Using 5.5nM ADAM]'SI3, very little proteolysis 
occurred over 2 hours (Figure 5.5). At II nM ADAMTS I3, a- I60k[a proteolytic 
fragment appeared after I hour and increased in intensity at 2 hours. As the 
concentration of AI)AMTS 13 increased, so did the amount of proteolysis by thrombin. 
Therefore, the appearance of'the -I60kDa proteolytic fragment over time can provide 
a qualitative assessment of the K,,, of thrombin liar AI)AMTS B. Since the rate of 
proteolysis increased with the concentration of' ADAMTS 13. the K,,, of' thrombin Im- 
ADAM'I'S13 is likely to be appreciably higher than the physiological plasma 
concentration of nl)AM"I'S 13 (-5nM). 
ý1) ýtil'I'S13 concentration 
5.5nN1 11 nM 22iiM -44n\1 88n. \ 1 176n\1 'Fülle i 
(hours) I. o! 121212121212 
: zouº: u.: º ** IM "weir lypt a9+; 
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Figure 5.5. Influence of AUA! * I'I'S13 concentration upon proteolysis by thrombin 
VarNini concentrations of ADAh1IS13 (5.5nM to I76nM) was proteolysed with 27nM thrombin in 
I501\1 Na('I, ýinAI ('a('I, and 20mM Tris-11C] (p117.8) for 0 to 2 hours and subjected to Western 
blotting using the anti-ADAM IS 13 pnb. 1, -- 13 iotinylated Ladder (Sigma, UK). 
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5.2.6 Binding affinity of thrombin for ADAMTS13 
As the K,,, for a reaction is often an approximation of the KD between the molecules, I 
explored the affinity of thrombin for ADAMTS13. In the first instance, surface 
plasmon resonance was employed using an SA sensor chip (Biacore, UK) upon which 
biotinylated active site blocked thrombin was immobilised. This was done so that all 
the thrombin molecules were immobilised in the same orientation. However, neither 
orientation specific coupling of thrombin nor direct coupling of ADAMTS13 to a 
CM5 sensor chip provided a robust/reproducible means of measuring this interaction 
(data not shown). Another approach to assess the affinity of the interaction between 
ADAMTS13 and thrombin was to immobilise biotinylated active site blocked 
thrombin onto microtiter wells (section 2.8.1). After incubation with various 
concentrations of ADAMTS13 (5nM to 1µM), binding was detected with the anti- 
ADAMTS13 pAb. These data were fitted to the one binding site model. From this, the 
KD of thrombin for ADAMTS 13 was 81.4nM ± 18.5 (Standard Error) (Figure 5.6), 
which corroborates the possibility that the Km of thrombin for ADAMTS13 is greater 
than the ADAMTSI3 plasma concentration (-5nM). This suggests that appreciable 
Ma not 
interaction between these two molecules 
ýy 
occurX at the plasma concentration 
of ADAMTS 13 and may explain why rapid proteolysis was only observed when 
higher concentrations of ADAMTS13 were used (Figure 3.6, Figure 5.1 and Figure 
5.2). 
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Figure 5.6. Binding of ADAMTS13 to thrombin. 
300ng biotinylated PPACK active site blocked thrombin was immobilised onto microtiter wells and 
varying concentrations of ADAMTS13 (5nM to 1µM) loaded for 2 hours at room temperature. 
ADAMTS13 was then detected with the anti-ADAMTSI3 pAb and the absorbance plotted against 
ADAMTS13 concentration. Fitting the data to the one binding site model then derived the KD. Typical 
graph obtained from five independent experiments. KD = 81.4nM ± 18.5 and B,,,, x = 2.1 ± 0.3. 
5.3 Discussion 
In this chapter, I performed experiments in a plasma milieu to assess the significance 
of the proteolytic degradation of ADAMTS 13 as a physiological mode of regulation. 
When recombinant ADAMTS13 was added into plasma at supraphysiological levels, a 
marked depletion of full-length ADAMTS 13 occurred within 30 minutes of initiating 
coagulation, but remained intact in the presence of hirudin. This suggested that 
thrombin was responsible for the degradation of ADAMTS13 in plasma (Figure 5.1B 
and Q. However, using more sensitive detection techniques revealed that no 
degradation of endogenous ADAMTS 13 occurred following initiation of coagulation 
in plasma (Figure 5.2, lane 8 to 10). To rationalise this, I hypothesised that fibrinogen 
may compete with ADAMTS 13 for thrombin binding due to its abundance in plasma. 
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Despite some competition occurring in vitro, it was clear that this was not the reason 
behind the lack of proteolysis in plasma (Figure 5.3). I then examined the possibility 
that the binding of ADAMTS13 to VWF might protect it from proteolysis. This also 
proved not to influence the rate of proteolysis (Figure 5.4). 
As neither of the two most abundant substrates for ADAMTS 13 or thrombin 
influenced proteolysis, I examined the interaction between ADAMTS 13 and thrombin. 
As the rate of ADAMTS13 proteolysis continued to increase in relation to 
ADAMTS13 concentration up to 176nM, it seemed that the K. for this reaction far 
exceeded the ADAMTS 13 plasma concentration (Figure 5.5). This was further 
confirmed by the estimation of the binding affinity of thrombin for ADAMTS13 
(Figure 5.6). Together, these data would indicate that ADAMTS13 proteolysis is not a 
favoured reaction at the plasma concentration of ADAMTS 13. However, it must be 
remembered that the initiation of coagulation of plasma in vitro does not truly 
represent ( haemostasis in vivo since it involves the interplay between vessel wall 
components, platelets and other plasma proteins. ADAMTS13 might still become 
susceptible to proteolysis in vivo, provided a mechanism exists to bring ADAMTS13 
and thrombin into close proximity to one another, which would overcome the 
moderate binding affinity in vitro. This will be considered in more detail in Chapter 7. 
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6 ONGOING WORK - PROTEOLYSIS OF ADAMTS13 
BY GRANULOCYTE ELASTASE 
6.1 Introduction 
Although ADAMTS13 was susceptible to proteolytic inactivation against multimeric 
VWF by low concentrations of thrombin and plasmin in vitro, ADAMTS13 remained 
intact after initiating thrombin generation in plasma (chapters 3,4 and 5). Therefore, 
thrombin may not physiologically regulate ADAMTS13 activity at sites of vessel 
injury. However, mild to moderate ADAMTS 13 deficiency has been observed in a 
number of pathological states (section 1.6.3). A particular study highlighted the 
presence of proteolytic fragments of ADAMTSI3 in patients suffering from sepsis 
induced DIC220. Sepsis is caused by the presence of pathogenic organisms or their 
toxins in the blood or tissues and can lead to systemic inflammation. DIC is 
characterised by acute widespread activation of coagulation, which can result in both 
thrombotic and hemorrhagic complications caused by systemic thrombin or plasmin 
generation. Therefore, severe secondary ADAMTS 13 deficiency caused through 
cleavage by proteases may occur under pathological scenarios and contribute to the 
severity of DIC. In the above study, it was also demonstrated that granulocyte elastase, 
a serine protease released from the azurophilic granules of polymorphonuclear 
leukocytes, proteolysed ADAMTS 13 in vitro220. However, the consequence of 
proteolysis upon ADAMTS 13 function was not characterised. In what follows, I have 
explored this further. 
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6.2 Results 
6.2.1 Characterisation of proteolysis of ADAMTS13 by granulocyte elastase 
To examine the concentration dependence of granulocyte elastase proteolysis of 
ADAMTS 13 and the various cleavage fragments generated, 250nM ADAMTS 13 was 
incubated with 1 nM to 50nM granulocyte elastase. Samples were taken at 0 to 30 
minutes and analysed by Western blotting using the anti-myc mAb under reducing 
conditions. Granulocyte elastase cleaved ADAMTS13 in a time and concentration 
dependent manner (Figure 6.1A). At 1nM granulocyte elastase, a -160kDa 
degradation fragment (Frag B) began to appear over 30 minutes, but the -200kDa full- 
length ADAMTS13 band (Frag A) remained. At 5nM granulocyte elastase, 
disappearance of the -200kDa full-length ADAMTS 13 band was faster and additional 
faint -100kDa and -70kDa cleavage fragments (Frag C and D) were 
generated/observed along with the -160kDa cleavage fragment. However, full-length 
ADAMTS13 still remained after 30 minutes. Complete loss of the -200kDa full- 
length ADAMTS 13 band was achieved using 25nM and 5OnM granulocyte elastase 
over 30 minutes in which a -4OkDa degradation fragment was generated (Frag E). 
To characterise the other ADAMTS13 degradation fragments, ADAMTS 13 was 
proteolysed with 25nM granulocyte elastase for 30 minutes and subjected to Western 
blotting using the anti-metalloproteinase domain mAb, anti-disintegrin-like domain 
mAb and anti-TSP2-4 pAb under reducing conditions. Using the anti- 
metalloproteinase domain and anti-disintegrin-like domain mAbs, the same -40kDa, 
-90kDa, -100kDa and -160kDa proteolytic fragments were identified (Fragments 1, 
2,3 and 4 respectively) (Figure 6.1 ß). This suggested that these fragments af@6044M 
eleavage at-the same sites, and that all ffagment contained both metalloproteinase and 
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disintegrin-like domains. The -4OkDa and -100kDa cleavage fragments were similar 
to those previously reported using an anti-disintegrin-like domain mAb220. After 
Western blotting and detecting with the anti-TSP2-4 pAb, -70kDa, -400kDa and 
-160kDa proteolytic fragments were generated (Figure 6.1 Q. These may represent the 
same cleavage fragments detected by the anti-metalloproteinase domain mAb or anti- 
myc mAb since the bands generated would have included the TSP2-4 domains based 
on their molecular weight. Based on the molecular weights of the fragments generated 
by each of the antibodies, the fragments generated were mapped onto the domain 
structure of ADAMTS 13 (Figure 6.1 D). 
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Figure 6.1. Proteolysis of ADAMTS13 by granulocyte elastase. 
(A) 250nM ADAMTSI3 was incubated with 1nM to 50nM granulocyte elastase in 150mM NaCl, 5mM 
CaCI2 and 20mM Tris-HCI (pH7.8) at 37°C. Samples were taken from 0 to 30 minutes and subjected to 
Western blotting under reducing conditions using the anti-myc. Similarly, 250nM ADAMTSI3 was 
incubated with 25nM granulocyte elastase and samples taken from 0 to 30 minutes for Western blotting 
using the anti-metalloproteinase domain mAb (B), anti-disintegrin-like domain mAb (B) and anti-TSP2- 
4 pAb (C) under reducing conditions. Each of the fragments generated are either numbered or lettered 
and based on the molecular weights of the fragments, the predicted cleavage sites were mapped (D). 
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6.2.2 Influence of granulocyte elastase on ADAMTSI3 activity against 
multimeric VWF 
Although ADAMTS13 was reported to be susceptible to proteolysis by granulocyte 
elastase, its impact upon activity against multimeric VWF or short recombinant VWF 
substrates was not assessed220. Granulocyte elastase can cleave VWF in vitro247. 
Consequently, to ensure that proteolysis of VWF was ADAMTS13 dependent, and not 
due to granulocyte elastase, ImM MeOSuc-Ala-Ala-Pro-Val chloromethyl ketone 
(CMK) granulocyte elastase inhibitor was added. This irreversibly inhibits activity 
through the covalent bonding of the CMK group to the -OH group of a serine adjacent 
residue, or the -SH group of an adjacent cysteine residue on the target protein248. 
ADAMTSI3 was pre-treated with or without granulocyte elastase, incubated with 
multimeric VWF under denaturing conditions or with VWF 115 and reactions taken for 
analysis by the CBA or SDS-PAGE with Coomassie staining. After proteolysis of 
multimeric VWF by ADAMTS13, a -60% reduction in collagen binding function was 
observed after 3 hours, demonstrating that the loss of VWF function was due to 
proteolysis by ADAMTS 13 (Figure 6.2A). In the presence of granulocyte elastase- 
treated ADAMTSI3, VWF retained -80% collagen binding potential, suggesting that 
the diminished ADAMTS13 activity was due to proteolysis by granulocyte elastase 
(Figure 6.3A). To clarify whether the loss of ADAMTS13 activity was as a result of 
proteolysis by granulocyte elastase or inhibition with CMK, ADAMTS13 was 
incubated with CMK. However, -90% VWF function remained after 3 hours 
suggesting that CMK affected ADAMTS13 activity (Figure 6.2A). With VWF115, 
complete proteolysis occurred in the presence of ADAMTS 13 after 3 hours, but 
ADAMTS 13 activity was greatly reduced after treatment with granulocyte elastase 
(Figure 6.2B). However, ADAMTS13 activity was also dramatically reduced by the 
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presence of' ImM CMK alone (Data not showwn). Together, it is d1itlicult to concIude 
whcthcr A1)AM"I'S 13 was protcolvticalIv inarmated by granulocvtc clastase since 
ADAM I'S 13 activity was also inhihited by ('MK. 
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Figure 6.2. ActiNit) of : \UA%1'I'S13 against \'\\ F after protcoI sis hN granulotNte elast: ºse. 
(A) 44nM ADAM'IS1 i treated with or without ,.: ranulocvte elastase \\as incuhatrd at 37°(' with 
I2pg'ml VWF in 15nlM BaCI2. I. 5M urea and 20m%I Iris-110 (p117.8). Reactions \%cre taten from 0 
to 3 hours and stopped with 50mM FDTA for analysis by CB: A. ImM ('N1K inhibitor vvas also added to 
granulocyte elastase-treated ADAM'I'SI ± to prevent degradation of multinrrric V'\\ I h. -ranulocvte 
elastase. As a control, ImM CMK inhibitor was also added to ADAM I5I (n ý). (It) l-ln\1 
ADAM I'S13 (A1)13) treated with or without granulocyte elastase as incubated at 37(' '%ith 
- 3p M V'WFI 15 
in 150mM NaCl, 5m%I CzWl, and 20mM Iris-II('I (pl[7.8). Im\1 ('MK inhibitor vvas 
also added to the granulocyte elastase-treated : 11): AM TS13 reaction. Samples vscrc taken at 0 to 4 hours 
and analysed by SUS-PAGF with Coomassie staining. 
6.2.3 Granulocyte clastase ablates binding of AI). 1'FS13 to VWF and 
VWF115 
Since it \\as dill[ cuIt to ascertain whether protcol)"iS 01' : 1DAM I'I: ý h\ ; LranuIOOc\IL 
clastasc diminished activity against VWFI 15 or muItimcric V\\ T because ot' the 
confounding inllucnce of the CMK inhibitor, the impact of' ADAM FS1 3 proteolysis 
by granulocyte elastase upon VWF binding was studied. Multimeric V\VF or V\VI: I I5 
was immobilised onto the surface of microtiter vvells and ImM ('MK inhibitor added 
to the granulocyte eIastase-treated ADANITS 11 and ADANTI'S II reactions to preNent 
any degradation of multimeric VWF or VWI 11.5 by jzranulocvte elastase. Alter adding 
I nM to 15OnM ADAMTS 13 in the presence of the CMK inhibitor and detecting %ý ith 
the anti-AUAM'I'S 13 pAb, ADAM1'S 13 bound nmultimeric V W1'1' and \'WF I 15 with 
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high affinity. However, binding of ADAMTS13 to VWF1IS and to multimeric VWF 
was completely abolished after proteolysis by granulocyte elastasc (Figure 6.3A and 
B). This loss of VWF binding would suggest that proteolysis by granulocyte clastase 
completely ablates the VWF-cleaving function of ADAMTS 13. 
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Figure 6.3. Binding of ADANITS13 to VWFNWF115 after proteolysis by granulocyte elastase 
After immobilising multimeric VWF (A) and VWF115 (B) onto microtiter wells, 1nM to lS0nM 
ADAMTS13 or granulocyte elastase-treated ADAMTS13, in the presence of 1mM CMK inhibitor, was 
applied to the wells and detected with the anti-ADAMTS13 pAb (n=4). 
6.3 Discussion 
In this chapter, I have confirmed that granulocyte elastase can cleave and potentially 
inactivate ADAMTSI3. Also, I have shown that granulocyte elastase cleaves 
ADAMTS13 in a time and concentration dependent manner and that proteolysis was 
more rapid than both thrombin and plasmin (Figure 3.5, Figure 3.6, Figure 3.8 and 
Figure 6.1). 
Based on the molecular weight of the degradation fragments specificially identified 
using different antibodies, granulocyte elastase cleaved ADAMTS13 at several sites 
distinct to those proteolysed by thrombin and plasmin (Figure 6.1, Figure 3.5 and 
Figure 3.8). However, based on the molecular weight of the 40kDa C-terminal 
fragment that was also generated by thrombin (Figure 3.3), granulocyte elastase may 
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cleave ADAMTS13 at a site predicted to lie between the TSP8 and CUB domains. 
Although the CUB domains did not remain covalently linked to the rest of the 
ADAMTS13 molecule after proteolysis by thrombin, they still remain ionically 
associated (Figure 3.4). Whether the C-terminal fragment is released after proteolysis 
by granulocyte elastase is uncertain. This could be explored by SDS-PAGE under non- 
reducing conditions and/or by gel filtration of proteolysed material. Although 
granulocyte elastase cleaved ADAMTS13 in the TSP domains, more work is needed 
on its function before the impact of proteolysis can be determined (section 1.5.3). 
After proteolysis by granulocyte elastase, ADAMTS 13 activity against multimeric 
VWF and VWF115 was diminished (Figure 6.2). However, this was confounded by 
the effect of the CMK granulocyte elastase inhibitor upon ADAMTS 13 activity. It was 
predicted that adding an excess of CMK would specifically inhibit granulocyte 
elastase (and not ADAMTS 13) as to date no specific inhibitor of ADAMTS 13 has 
been described. However, the high CMK concentrations present in the reactions 
ei 
appeared to inhibit ADAMTS13 activity, possibly by modifying serine or cystkne 
residues. Therefore, either a lower concentration of CMK might be used or an 
alternative granulocyte elastase inhibitor that does not inhibit ADAMTS 13, such as 
aprotinin, could be used. 
Although it was difficult to measure the inactivation of granulocyte elastase 
proteolysis on ADAMTS13 activity, proteolysis completely abolished the binding of 
ADAMTS13 to both multimeric VWF and VWF115 (Figure 6.3A and B). In contrast, 
thrombin-treated ADAMTS13 was still able to bind multimeric VWF and VWF115 
(Figure 4.4 and Figure 4.7). Given that thrombin has a more specific amino acid 
sequence recognition profile (section 3.2.9) than granulocyte elastase, which cleaves 
after an alanine or a valine at the P1 position of its substrate232, prolonged incubation 
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of ADAMT13 with granulocyte elastase may have allowed proteolysis to occur at 
additional sites in ADAMTS13 that were not observed during short incubations. 
Therefore, incubating ADAMTS13 with granulocyte elastase for shorter periods of 
time might better assess the time dependent effect of proteolysis by granulocyte 
elastase upon VWF binding function. 
Since granulocyte elastase activity is a feature of many pathophysiological processes, 
ADAMTS13 might be susceptible to proteolysis by this serine protease when released 
in an unregulated manner into the plasma and onto the vessel wall from activated 
neutrophils during inflammatory conditions in vivo. Along with thrombin and plasmin, 
this may account for the reduced ADAMTS13 levels/activity and presence of low 
molecular weight fragments in patients suffering from thrombotic complications 
associated with sepsis induced DIC220. Whilst the susceptibility of VWF to proteolysis 
by granulocyte elastase in vitro might suggest that this contributes to haemorrhagic 
complications associated with DIC, VWF levels are known to increase during 
systemic inflammation 
249,250 In fact, granulocyte elastase was shown to cause the 
release of VWF by cultured damaging endothelial cells251. Therefore, it is unknown 
whether proteolysis of VWF by granulocyte elastase occurs under pathophysiological 
conditions in vivo. 
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7 DISCUSSION 
My thesis has been concerned with the affects of ADAMTS 13 proteolysis upon its 
domain structure and function. Since ADAMTS13 is sensitive to proteolysis, I had as 
a working hypothesis that ADAMTS 13 activity could be regulated by scrine protcases 
generated at the site of vessel injury. Using purified proteins, I showed that 
ADAMTS13 was susceptible to proteolysis by thrombin, plasmin and to a lesser 
extent by FXa (Figure 3.3, Figure 3.8 and Figure 3.6). I have shown that proteolysis of 
ADAMTS13 is a complex process with cleavage occurring at several sites in different 
domains. Proteolysis also leads to its inactivation against multimeric VWF (Figure 4.2 
and Figure 4.9). Unlike plasmin, thrombin generation occurs immediately after vessel 
injury and I have considered that it may have a physiological role in regulating 
ADAMTS 13 activity in vivo. To support this hypothesis, experiments with 
recombinant ADAMTS13 added to plasma revealed a marked depletion of full-length 
ADAMTSI3 after initiating coagulation. This was prevented by the addition of 
hirudin, suggesting that the loss of full-length ADAMTS13 was due to thrombin 
(Figure 5.1). Therefore, a novel pro-coagulant function of thrombin was suggested in 
which the local inactivation of ADAMTSI3 allows VWF to promote the necessary 
recruitment of platelets at sites of vascular perturbation. 
However, this plausible model was not supported by further experiments carried out in 
plasma, in which the structure of endogenous ADAMTS13 remained intact and no 
degradation fragments could be detected following initiation of coagulation (Figure 
5.2). The reason for this completely different result appears to be multifactorial, but 
could be largely due to the nature of the interaction between thrombin and 
ADAMTS13. Although this binding interaction is of quite high affinity, -8OnM, this is 
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insufficient to overcome the restriction placed upon the interaction by the low plasma 
concentration of ADAMTS 13 (-5nM) (Figure 5.6). Based on these results, I have had 
to reconsider my hypothesis that proteolysis of ADAMTS13 is a mechanism by which 
serine proteases, generated at the site of vessel injury, physiologically regulate 
ADAMTS13 activity. I believe that ADAMTS13 may become susceptible to 
proteolysis under pathological conditions when the control mechanisms of 
haemostasis, which are normally highly co-ordinated, may become disordered. In what 
follows, I will explore the case for proteolysis of ADAMTSI3 in acute situations of 
thrombus formation and inflammation. Before I can do this, it is necessary to consider 
the inter-relationships between VWF, ADAMTSI3, platelets and other haemostatic 
components in the context of a dynamically forming haemostatic plug or thrombus. 
The first step in the haemostatic response is the interaction of platelets with the 
exposed extracellular matrix at the site of vascular injury. Among the macromolecular 
constituents of the extracellular matrix, collagen is considered to play a major role in 
this process as it supports platelet adhesion through direct and indirect pathways252. At 
shear rates exceeding 1000s"' present in the microcirculation, VWF supports platelet 
adhesion by undergoing conformational changes that exposes the GPIb platelet 
binding sites in the Al domain once immobilised onto extracellular matrix 
components 253.254 This contributes to the initial arrest of platelets through the binding 
of GPIb integrin on platelet surfaces to VWF, which is critical for the continual 
recruitment of platelets and efficient platelet aggregation 
255. At the same time, this 
exposes the ADAMTS13 binding sites in the A2 and A3 domains185,187 and the 
cleavage site in the A2 domain 
139"140, which increases the local concentration of 
ADAMTS13 and makes VWF susceptible to proteolysis at the site of vessel injury. 
Indeed, the presence of VWF subunit fragments and absence of the largest VWF 
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multimers in the plasma of healthy individuals under normal resting conditions 
demonstrates that VWF proteolysis is a physiological process in vivo256. The first 
VWF layer deposited at sites of vessel injury might resist ADAMTSI3 cleavage due 
to its tight association with collagen. ADAMTS13 activity was shown to have no 
affect upon platelet aggregates formed upon the perfusion of whole blood over 
collagen fibrils, but did affect the cohesion between platelets and VWF over 
thrombogenic surfaces at high shear stresses257. This suggests that subsequent VWF- 
platelet layers may be susceptible to removal by ADAMTSI3, but the initial VWF- 
platelet layer would remain bound to provide a surface for platelets to aggregate. 
Collagen exposure also plays an important role in platelet activation during 
haemostasis. This is mediated through a number of specific collagen receptors on the 
platelet surface. FcRy-null mice lacking expression of GPVI failed to generate platelet 
thrombi in vivo following exposure of the subendothelial matrix by ferric chloride in 
contrast to wild type mice258. TF exposure in the extracellular matrix and vessel wall 
can also affect the dynamics of platelet plug growth. The TF-FVIIa complex initiates 
thrombin generation and fibrin formation. Deficiency in any of these proteins within 
this pathway (FIX, FVIII, FX, FV, and prothrombin) decreases thrombin generation 
and thrombus formation259. Also, arterial thrombus formation was found to be 
defective in FXI-/- and FXII-/- mice in vivo 259,260. Whilst patients with FXII deficiency 
have no bleeding phenotype, FXII and FXI may be important in thrombosis but not 
haemostasis259. The initial thrombin generated can then activate PAR molecules on 
inccý6cc. P 
platelet membrane surfaces. This activates platelets and causes the expression of the 
GPIIbIIIa integrin on its surface 253,255, which binds fibrinogen and VWF and leads to 
platelet aggregation. Platelet activation also results in the release of a-granule contents 
that accelerate platelet recruitment and activation. One adhesive protein secreted by 
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the a-granules is UL-VWF. Although UL-VWF preferentially forms strong adhesive 
bonds with its cell receptors261, normal circulating plasma VWF multimers display 
adequate thrombogenic function in ex vivo systems255. Plasma VWF multimers also 
may enhance its adhesive properties by self-aggregating onto thrombogenic 
surfaces262. Together, this may contribute significantly to platelet aggregation at the 
site of vessel injury in vivo. 
However, ADAMTS13 has been shown to be a natural anti-thrombotic agent by 
directly influencing the rates of platelet aggregation and thrombus growth at sites of 
vascular injury under normal arterial (1500s'') and venous (300s'') shear rates in a 
murine model263. This demonstrates that ADAMTS13 might serve a necessary 
function in regulating platelet aggregate size by reducing the VWF multimeric size at 
the site of vessel injury. Furthermore, ADAMTS13 deficiency did not promote 
thrombus growth in the absence of the major platelet integrin GPIIbIIIa under venous 
and arterial shear rates263. Thus, ADAMTS 13 is able to modulate platelet tethering to 
VWF even when platelets express the GPIIbIIIa integrin. 
Nevertheless, platelet plug formation is eventually stabilised even in the presence of 
ADAMTS 13. One explanation is that once thrombin reaches a critical concentration at 
the site of vessel injury, ADAMTS13 may no longer function to destabilise the platelet 
plug in vivo. Thrombin concentrations may reach -850nM in plasma in vitro48. 
However, the amount of thrombin generated at the site of injury in vivo is uncertain. In 
plasma in vivo, local thrombin concentrations may be high and thrombin activity may 
persist for long periods of time. This is because thrombin is continuously being 
generated/recruited to the site of vessel injury due to the presence of procoagulant 
proteins in the flowing blood and protective mechanisms that preserve thrombin 
activity when bound to fibrin. Another protein secreted from the a-granules of 
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activated platelets is the adhesion molecule P-selectin264. When P-sclectin reaches a 
critical density on platelet surfaces, this recruits TF bearing leukocyte microparticlcs 
through the interaction of platelet P-selectin with PSGL-1 on the membrane surface of 
microparticles265. This delivers and concentrates TF in the platelet plug, leading to a 
critical concentration that can initiate blood coagulation. Blood-borne TF may then 
greatly increase the local concentration of thrombin at the site of injury; propagate the 
aggregation and activation of platelets and promote the accumulation of fibrinogen, 
VWF and fibronectin. These adhesive proteins might play roles that consolidate the 
plug and prevent its disruption by ADAMTS 13. 
Proteolysis of ADAMTS13 may still occur when the locally generated thrombin is 
brought into proximity to ADAMTS13 at the site of vessel injury in vivo. One 
mechanism could involve the N-terminal region (amino acids 1-282) of platelet GPIb, 
which can bind thrombin and VWF266.267. At least 3 regions in the N-terminal domain 
of GPIb are involved in VWF binding in the Al domain 
268,269 : the region encompassed 
by the sulphated tyrosine sequence (Asp269-Glu282), the disulphide loop between 
Cys209-Cys248, and the N-terminal flanking/leucine-rich repeat region. The major 
thrombin recognition sequence on GPIb is also located on the sulphated tyrosine 
sequence and binds thrombin residues in exosite II2377270. This would leave exosite I on 
thrombin available for interaction with ADAMTS13 bound to VWF. Since the sites 
for thrombin and VWF binding on GPIb are similar, unoccupied GPIb molecules on 
platelets bound to VWF may provide binding sites for thrombin, which might position 
and enhance the interaction between thrombin and ADAMTSI3. This mechanism 
could limit ADAMTS 13 activity and allow the platelet plug to develop. 
The accumulation of the other adhesive proteins at the site of injury may also play a 
role in consolidating the haemostatic plug and prevent its disruption by ADAMTS13. 
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The role of fibrinogen, VWF and fibronectin in platelet adhesion and aggregation was 
highlighted in studies using mice with targeted deletions. In VWF"' mice, platelet 
adhesion was delayed, but stable thrombi formed. In fibrinogen-/" mice, platelet 
thrombi were unstable and detached from the sub-endothelium occluding downstream 
in the circulation31. Similarly, platelet thrombi were continuously removed in 
fibronectin'/' mice 32,271. Embolisation of the platelet plug in fibrinogen"' and 
fibronectin /" mice may be due to the uninhibited action of ADAMTS 13 activity 
against VWF. This hi hligh the importance of fibrinogen and fibronectin in 
stabilising platelet plug formation by preventing the release of subsequent VWF- 
platelet layers caused by ADAMTSI3. Fibronectin is found in plasma (and in the 
extracellular matrix) at a concentration of -55OnMZn. 
273. Fibronectin mediates cell 
attachment by interacting with cell surface receptors, activated platelets and 
274'277 
extracellular matrix components through its integrin binding RGDS sequence. 
Also, it binds other extracellular macromolecules such as heparan sulphate, 
fibrin(ogen) and collagen, which may be important in the fibronectin-mediated 
adhesion of platelets to the sub-endothelial matrix274'278. With fibrin, the fibrin- 
fibronectin complexes are stabilised by the FXIIIa-catalysed covalent cross-linking of 
fibronectin to the a-chain of fibrin279. 
If the haemostatic plug expands rapidly, it may develop characteristics of a thrombus 
that will grow uncontrollably and may embolise. In vivo imaging in mice has 
demonstrated that tethered platelets were removed from the back of the developing 
thrombus, even when fibrin deposition occurred within 20 seconds after vascular 
injury280. This could have been in part due to the uninhibited action of ADAMTS13 
activity upon VWF-bound platelets where fibrin or fibronectin has not consolidated 
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the expanded thrombus. ADAMTS13 may then serve to regulate the height of the 
haemostatic plug to maintain normal blood flow. 
Therefore, ADAMTS13 deficiency could lead to an enhanced potential for thrombus 
formation. Indeed, reduced ADAMTSI3 antigen levels and activity has been observed 
in a number of thrombotic microangiopathies that present similar clinical symptoms to 
TTP223'281'282 (section 1.6.3). The causes of ADAMTSI3 deficiency are likely to be 
multifactorial. It has been shown that along with reduced ADAMTS13 antigen levels, 
low molecular weight species of ADAMTS13 were also observed in patients with 
sepsis-induced DIC220. DIC arises secondary to a number of other underlying disorders 
such as malignancies, obstetric or vascular disorders and immunological reactions that 
cause systemic activation of coagulation. It is characterised by both acute and 
widespread activation of coagulation, which can result in both thrombotic and 
hemorrhagic complications. Thrombosis results from excessive thrombin generation 
leading to intravascular fibrin formation. Bleeding results from excessive plasmin 
activity leading to fibrinolysis, or the consumption of platelets and coagulation factors 
following extensive thrombosis. The association of low ADAMTS 13 levels with 
severe DIC, together with the dramatic activation of coagulation and fibrinolytic 
systems in this disorder may suggest that proteolysis of ADAMTSI3 by the generated 
serine proteases may have occurred. 
Along with the thrombotic and haemorrhagic complications, the production of 
thrombin can also interact with PAR molecules on cell surfaces to promote further 
activation and additional inflammation15. This upregulates adhesion molecules and 
triggers the production of chemokines that activate neutrophils and monocytes to 
release proteolytic enzymes, such as granulocyte elastase and -cathepsin G283. 
Granulocyte elastase is of particular interest because it was shown to cleave 
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ADAMTS13 in vitro220. The concentration of granulocyte elastase circulating in 
normal plasma is -2nM284. However, the concentration of granulocyte elastase in 
neutrophils exceeds 5mM285 and this pool can be rapidly released from cytoplasmic 
granules into the extracellular space upon neutrophil activation286,287. Granulocyte 
elastase is involved in the degradation of foreign material ingested by neutophils 
during phagocytosis. Upon stimulation by various cytokines and chemokines such as 
tumour necrosis factor-a288, interleukin-8, C5a289 and LPS290, granulocyte elastase may 
facilitate leukocyte infiltration into the vascular bed291,292. This is because it can affect 
the barrier properties of the endothelium by degrading several extracellular matrix 
proteins such as elastin293, cartilage proteoglycans294, collagens 1,11, III and IV295-297, 
fibronectin298 and cadherins299'300. Plasma proteinase inhibitors such as a2- 
macroglobulin301, ai-antitrypsin302, secretory leukoprotease inhibitor303 and eglin 
regulate granulocyte elastase activity, preventing damage to connective tissue. 
Nevertheless, elevated levels of circulating granulocyte elastase and/or decreased 
levels of endogenous inhibitors have been implicated in several inflammatory diseases 
including adult respiratory distress syndrome304 pulmonary emphysema 305 , arthritis 
306 
cyclic neutropenia, myocardial ischemia307, pancreatitis308 and psoriasis309. 
Although the different low molecular weight species of ADAMTS13 detected in 
plasma samples from patients with DIC may be attributable to proteolysis by 
granulocyte elastase and/or other proteolytic enzymes, such as thrombin and plasmin, 
full-length ADAMTS 13 was still present22°. Therefore, cleavage of ADAMTS 13 may 
not proceed completely in vivo since specific inhibitors of the various proteolytic 
enzymes are present at high concentrations in blood; proteolysis may depend on the 
kinetic balance between ADAMTS 13, the proteases, and their inhibitors. 
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DIC and other thrombotic microangiopathies share a common characteristic of 
systemic inflammation. Since an underlying pathological condition may be required 
for ADAMTS13 to become susceptible to proteolysis, reduced ADAMTS13 
function/levels is perhaps likely to be an effect, rather than a cause for the 
pathophysiology of various inflammatory diseases. Moreover, severe ADAMTS13 
deficiency would be needed to aggravate a predisposing inflammatory condition since 
only -5% ADAMTS 13 function is required for effective cleavage of VWF224. 
Deficient VWF proteolysis can also be caused by other factors under these 
pathological conditions such as consumptive deficiency of ADAMTS 13. This 
possibility was supported by the finding that ADAMTS13 activity becomes transiently 
deficient even in healthy subjects infused with either LPS or demopressin310-313, which 
induces significant release of UL-VWF from vascular endothelial cells 104,314. Also, 
ADAMTS13 activity may be directly inhibited by molecules associated with systemic 
inflammation such as haemoglobin 226, Interleukin-6225, TSP-134'315, soluble P- 
selectin182 and VWF311. Therefore, systemic inflammation can result from a 
combination of increased consumption, reduced synthesis, proteolysis and the 
presence of ADAMTS 13 inhibitors, which would all contribute to the pathology of 
different inflammatory conditions. 
The normal plasma concentration of VWF is -1Ogg/ml (-4OnM)316, but this rapidly 
increases 2-3 fold upon systemic activation of the endothelium and further enhances 
platelet tethering due to the acute release of UL-VWF249,250. The physiological resting 
plasma concentration of ADAMTS13 is -5nM and is at an 8: 1 molar ratio to VWF160. 
However, the rate of ADAMTS13 synthesis in the liver does not appear to be 
increased by proinflammatory cytokines159. Therefore, the molar ratio imbalance 
between ADAMTS13 and VWF during systemic inflammation may prevent the 
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efficient proteolysis of VWF. This may not be critical when proteolysis is measured 
after long incubation periods under denaturing conditions, but could potentially affect 
the kinetics of multimeric VWF cleavage in constant and rapid blood flow. Consistent 
with this possibility, cleavage of UL-VWF strings under flow conditions requires 
higher ADAMTS 13 activity as compared to that under non-flow conditions 317. 
Along with the elevated levels of VWF found during inflammation, high levels of 
VWF are associated with an increased risk of myocardial infarction or ischemic heart 
disease 318.323. A study implicated moderate ADAMTS13 deficiency in the 
pathogenesis of myocardial infarction324. However, two studies demonstrated that 
there was no link between ADAMTSI3 and VWF levels in causing myocardial 
2Z7 infarction or ischemic heart disease'325. Additional studies are required to ascertain 
whether ADAMTS 13 contributes to the pathology of these conditions. 
Together, reduced ADAMTS 13 antigen and activity may promote the development of 
microthrombi in the circulation and contribute to the coagulopathy, causing ischemia 
and damage to a variety of organs through enhanced fibrin generation and deposition 
to vascular endothelial cells, often associated with systemic inflammation such as 
sepsis 326-328. One possibility is that fibrin deposits onto un- or partially cleaved UL- 
VWF adhered to endothelial cells191'263, an interaction previously demonstrated329'330. 
This highlights the importance of UL-VWF proteolysis in the pathophysiology of 
severe systemic inflammation and provides a direct link between inflammation and 
thrombosis. It has been suggested that the addition of recombinant ADAMTS13 could 
be used therapeutically as an anti-thrombotic agent for complications associated with 
systemic inflammation, such as those patients suffering from septic shock220. 
The influence of ADAMTS 13 activity upon the pathogenesis of various inflammatory 
disease states is relatively unexplored. Although severe ADAMTSI3 deficiency is 
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found in patients with TTP, moderate deficiency has been demonstrated in patients 
with systemic inflammation. Given the elevated levels of VWF released during 
pathological states, moderate ADAMTS 13 deficiency may be sufficient to impair 
VWF proteolysis and potentially lead to thrombotic microangiopathy causing ischemic 
tissue injury and organ failure. Elevated levels of thrombin, plasmin and granulocyte 
elastase (released from activated neutrophils) are present in plasma during systemic 
inflammation. Since ADAMTS13 is susceptible to proteolytic inactivation by these 
serine proteases that are secreted abundantly during systemic inflammation, this might 
suggest a role for its contribution to the pathophysiology of various inflammatory 
disease states in vivo. Therefore, future work might investigate the impact of systemic 
inflammation upon ADAMTS13 function using murine models. It must be 
remembered though that ADAMTS13 appears to have a less important role in murine 
models than in human systems (section 1.6.1), which may not represent the influence 
of inflammation upon ADAMTS13 function in vivo. Nevertheless, murine models still 
provide preliminary evidence for the effect of inflammation upon ADAMTSI3 
activity in vivo since data can be obtained relatively quickly in comparison to other 
animal models. This would be done by inducing inflammation using bacterial LPS, 
taking samples over time and analysing various parameters. 
ADAMTS 13 and VWF antigen levels would be quantified to assess the changes that 
occurred during the course of LPS treatment. VWF multimeric composition would 
also be measured to assess the changes in VWF function that occur over time. 
Together, this would determine whether a relationship exists between antigen levels of 
ADAMTS13 and VWF, ADAMTS13 and VWF multimeric composition and VWF 
antigen levels and its multimeric composition throughout the course of LPS treatment. 
If ADAMTS13 levels decrease after LPS treatment, replacement therapy with 
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recombinant ADAMTS 13 would be used to restore ADAMTS 13 levels and may 
improve the survival of mice with inflammation induced by LPS. 
I have shown that thrombin, plasmin and granulocyte elastase cleaved ADAMTS 13 at 
unique sites. These could act as molecular signatures for cleavage of ADAMTS 13 by a 
particular proteolytic enzyme during inflammatory states. Although the proteolytic 
fragments generated by individual serine proteases have been characterised, these 
proteolytic enzymes are active in plasma at the same time. Therefore, digestion of 
ADAMTS13 by a combination of different proteolytic enzyme(s) might further 
characterise the potential proteolytic fragments generated in vivo. Before identifying 
the serine protease(s) responsible for the proteolysis of ADAMTS 13 in LPS-treated 
mice, proteolysis of murine ADAMTS13 by each of the different serine proteases 
would be carried out first in vitro to characterise the cleavage fragments generated, 
since murine ADAMTS13 may be cleaved differently to human ADAMTSI3. If 
cleavage of ADAMTS 13 does occur, specific serine protease inhibitor(s) could then be 
added to assess whether this may prevent the proteolysis of ADAMTS13 and reduce 
the pathology associated with LPS treatment. 
ADAMTS13 function could be assessed using VWF115 and multimeric VWF. Since 
differences in ADAMTSI3 activity against multimeric VWF and VWFI15 were 
observed following proteolysis by thrombin and plasmin, this may lead to conflicting 
results when analysing ADAMTS13 activity in which appreciable ADAMTS 13 
proteolysis has occurred. Therefore, ADAMTS13 activity against VWF115 and 
multimeric VWF would be assessed after proteolysis by both of these enzymes. This 
would not only confirm the use of VWF115 for analysis of ADAMTS13 activity, but 
also provide important data on the suitability of short VWF substrates for analysing 
ADAMTS13 function in which thrombotic complications had occurred. Thereafter, 
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ADAMTS13 activity in LPS-treated mice would be assessed against VWF115 and 
correlated with its activity against multimeric VWF. 
Together, this would define the impact of ADAMTS13 deficiency caused through 
proteolysis by serine proteases and its subsequent contribution to the pathology during 
systemic inflammation. Should aberrant ADAMTS13 and/or VWF function be 
associated with systemic inflammation, these may be identified as potential 
therapeutic targets for the treatment of systemic inflammation. 
Based on my results, proteolytic inactivation of ADAMTS 13 by thrombin may not be 
a normal physiological mechanism to prevent the release of tethered platelets at the 
site of vessel damage. Although this would suggest tethered platelets immobilised on 
VWF would initially be removed during platelet plug development, exposure of sub- 
endothelial collagen and TF would cause the early generation of thrombin and 
deposition of fibrin. Subsequently, platelet aggregation and activation and the 
accumulation of VWF, fibrinogen and fibronectin would propagate pro-coagulant 
responses and stabilise the platelet plug. ADAMTS13 would then be unable to remove 
the platelets in the core of the developing platelet plug because of the tight association 
between the adhesive proteins and activated platelet surfaces. However, ADAMTS13 
may serve an important function in regulating the height of the growing platelet plug 
at the site of vessel injury to maintain normal blood flow. Nevertheless, proteolysis of 
ADAMTS13 may occur in the presence of elevated levels of thrombin, plasmin, 
granulocyte elastase and other serine proteases and may contribute to the pathology of 
various disease states. 
159 
8 REFERENCES 
1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002; 8: 1227-1234 
2. Ruggeri ZM. Structure of von Willebrand factor and its function in platelet 
adhesion and thrombus formation. Best Pract Res Clin Haematol. 2001; 14: 257-279 
3. Massberg S, Gawaz M, Gruner S, Schulte V, Konrad 1, Zohlnhofer D, 
Heinzmann U, Nieswandt B. A crucial role of glycoprotein VI for platelet recruitment 
to the injured arterial wall in vivo. J Exp Med. 2003; 197: 41-49 
4. Inoue 0, Suzuki-Inoue K, Dean WL, Frampton J, Watson SP. Integrin 
alpha2betal mediates outside-in regulation of platelet spreading on collagen through 
activation of Src kinases and PLCgamma2. J Cell Biol. 2003; 160: 769-780 
5. Miura Y, Ohnuma M, Jung SM, Moroi M. Cloning and expression of the 
platelet-specific collagen receptor glycoprotein VI. Thromb Res. 2000; 98: 301-309 
6. Miura Y, Takahashi T, Jung SM, Moroi M. Analysis of the interaction of 
platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of 
GPVI, but not the monomeric form, shows affinity to fibrous collagen. J Biol Chem. 
2002; 277: 46197-46204 
7. Knight CG, Morton LF, Onley DJ, Peachey AR, Messent AJ, Smethurst 
PA, Tuckwell DS, Farndale RW, Barnes MJ. Identification in collagen type I of an 
integrin alpha2 betat-binding site containing an essential GER sequence. J Biol Chem. 
1998; 273: 33287-33294 
8. Verkleij MW, MJ IJ, Heijnen-Snyder GJ, Huizinga EG, Morton LF, Knight 
CG, Sixma JJ, de Groot PG, Barnes MJ. Adhesive domains in the collagen III 
fragment alphal(III)CB4 that support alpha2betal- and von Willebrand factor- 
mediated platelet adhesion under flow conditions. Thromb Haemost. 1999; 82: 1137- 
1144 
9. Kuijpers MJ, Schulte V, Bergmeier W, Lindhout T, Brakebusch C, 
Offermanns S, Fassler R, Heemskerk JW, Nieswandt B. Complementary roles of 
glycoprotein VI and alpha2betal integrin in collagen-induced thrombus formation in 
flowing whole blood ex vivo. Faseb J. 2003; 17: 685-687 
10. Sarratt KL, Chen H, Zutter MM, Santoro SA, Hammer DA, Kahn ML. 
GPVI and alpha2betal play independent critical roles during platelet adhesion and 
aggregate formation to collagen under flow. Blood. 2005; 106: 1268-1277 
11. Tangelder GJ, Slaaf DW, Arts T, Reneman RS. Wall shear rate in 
arterioles in vivo: least estimates from platelet velocity profiles. Am J Physiol. 
1988; 254: H 1059-1064 
12. Wu YP, Vink T, Schiphorst M, van Zanten GH, MJ IJ, de Groot PG, 
Sixma JJ. Platelet thrombus formation on collagen at high shear rates is mediated by 
von Willebrand factor-glycoprotein lb interaction and inhibited by von Willebrand 
factor-glycoprotein IIb/IIIa interaction. Arterioscler Thromb Vase Biol. 2000; 20: 1661- 
1667 
13. Bergmeier W, Rackebrandt K, Schroder W, Zirngibl H, Nieswandt B. 
Structural and functional characterization of the mouse von Willebrand factor receptor 
GPIb-IX with novel monoclonal antibodies. Blood. 2000; 95: 886-893 
14. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet 
activation in G alpha(q)-deficient mice. Nature. 1997; 389: 183-186 
15. Coughlin SR. Thrombin signalling and protease-activated receptors. 
Nature. 2000; 407: 258-264 
160 
16. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a 
functional thrombin receptor reveals a novel proteolytic mechanism of receptor 
activation. Cell. 1991; 64: 1057-1068 
17. Chen J, Ishii M, Wang L, Ishii K, Coughlin SR. Thrombin receptor 
activation. Confirmation of the intramolecular tethered liganding hypothesis and 
discovery of an alternative intermolecular liganding mode. J Biol Chem. 
1994; 269: 16041-16045 
18. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. 
Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct 
ADP receptors on human platelets. J Biol Chem. 1998; 273: 2024-2029 
19. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, 
Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet 
ADP receptor targeted by antithrombotic drugs. Nature. 2001; 409: 202-207 
20. Jantzen HM, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds EE, 
Conley PB. Evidence for two distinct G-protein-coupled ADP receptors mediating 
platelet activation. Thromb Haemost. 1999; 81: 111-117 
21. Leon C, Ravanat C, Freund M, Cazenave JP, Gachet C. Differential 
involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. 
Arterioscler Thromb Vasc Biol. 2003; 23: 1941-1947 
22. Jin J, Kunapuli SP.. Coactivation of two different G protein-coupled 
receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sei USA. 
1998; 95: 8070-8074 
23. Dorsam RT, Kim S, Murugappan S, Rachoor S, Shankar H, Jin J, 
Kunapuli SP. Differential requirements for calcium and Src family kinases in platelet 
GPIIb/IIIa activation and thromboxane generation downstream of different G-protein 
pathways. Blood. 2005; 105: 2749-2756 
24. Dangelmaier C, Jin J, Smith JB, Kunapuli SP. Potentiation of 
thromboxane A2-induced platelet secretion by Gi signaling through the 
phosphoinositide-3 kinase pathway. Thromb Haemost. 2001; 85: 341-348 
25. Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 
family are activated via thromboxane A2 and thrombin receptors in human platelets. 
Proc Natl Acad Sei USA. 1994; 91: 504-508 
26. Paul BZ, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A(2)- 
induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol 
Chem. 1999; 274: 29108-29114 
27. Ohkubo S, Nakahata N, Ohizumi Y. Thromboxane A2-mediated shape 
change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets. Br J 
Pharmacol. 1996; 117: 1095-1104 
28. Yang J, Wu J, Kowalska MA, Dalvi A, Prevost N, O'Brien PJ, Manning D, 
Poncz M, Lucki I, Blendy JA, Brass LF. Loss of signaling through the G protein, Gz, 
results in abnormal platelet activation and altered responses to psychoactive drugs. 
Proc Natl Acad Sei USA. 2000; 97: 9984-9989 
29. Bevers EM, Tilly RH, Senden JM, Comfurius P, Zwaal RF. Exposure of 
endogenous phosphatidylserine at the outer surface of stimulated platelets is reversed 
by restoration of aminophospholipid translocase activity. Biochemistry. 1989; 28: 2382- 
2387 
30. Zwaal RF, Comfurius P, Bevers EM. Lipid-protein interactions in blood 
coagulation. Biochim Biophys Acta. 1998; 1376: 433-453 
161 
31. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. 
Persistence of platelet thrombus formation in arterioles of mice lacking both von 
Willebrand factor and fibrinogen. J Clin Invest. 2000; 106: 385-392 
32. Ni H, Yuen PS, Papalia JM, Trevithick JE, Sakai T, Fassler R, Hynes RO, 
Wagner DD. Plasma fibronectin promotes thrombus growth and stability in injured 
arterioles. Proc Natl Acad Sci USA. 2003; 100: 2415-2419 
33. Dixit VM, Haverstick DM, O'Rourke K, Hennessy SW, Broekelmann TJ, 
McDonald JA, Grant GA, Santoro SA, Frazier WA. Inhibition of platelet aggregation 
by a monoclonal antibody against human fibronectin. Proc Natl Acad Sci USA. 
1985; 82: 3844-3848 
34. Bonnefoy A, Daenens K, Feys HB, De Vos R, Vandervoort P, Vermylen J, 
Lawler J, Hoylaerts MF. Thrombospondin-1 controls vascular platelet recruitment and 
thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by 
ADAMTS 13. Blood. 2006; 107: 955-964 
35. Dixit VM, Haverstick DM, O'Rourke KM, Hennessy SW, Grant GA, 
Santoro SA, Frazier WA. A monoclonal antibody against human thrombospondin 
inhibits platelet aggregation. Proc Natl Acad Sei USA. 1985; 82: 3472-3476 
36. Chung J, Gao AG, Frazier WA. Thrombspondin acts via integrin- 
associated protein to activate the platelet integrin alphallbbeta3. J Biol Chem. 
1997; 272: 14740-14746 
37. Chung J, Wang XQ, Lindberg FP, Frazier WA. Thrombospondin-1 acts 
via IAP/CD47 to synergize with collagen in alpha2beta1-mediated platelet activation. 
Blood. 1999; 94: 642-648 
38. Trumel C, Plantavid M, Levy-Toledano S, Ragab A, Caen JP, Aguado E, 
Malissen B, Payrastre B. Platelet aggregation induced by the C-terminal peptide of 
thrombospondin-1 requires the docking protein LAT but is largely independent of 
alphaIIb/beta3. J Thromb Haemost. 2003; 1: 320-329 
39. Reheman A, Gross P, Yang H, Chen P, Allen D, Leytin V, Freedman J, Ni 
H. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet 
aggregation. J Thromb Haemost. 2005; 3: 875-883 
40. Asch E, Podack E. Vitronectin binds to activated human platelets and 
plays a role in platelet aggregation. J Clin Invest. 1990; 85: 1372-1378 ' 
41. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. 
Vitronectin is not essential for normal mammalian development and fertility. Proc Natl 
Acad Sei USA. 1995; 92: 12426-12430 
42. Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin 
inhibits the thrombotic response to arterial injury in mice. Blood. 1999; 93: 1825-1830 
43. Marguerie GA, Thomas-Maison N, Ginsberg MH, Plow EF. The platelet- 
fibrinogen interaction. Evidence for proximity of the A alpha chain of fibrinogen to 
platelet membrane glycoproteins IIb/III. Eur J Biochem. 1984; 139: 5-11 
44. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. 
Involvement of large plasma von Willebrand factor (vWF) multimers and unusually 
large vWF forms derived from endothelial cells in shear stress-induced platelet 
aggregation. J Clin Invest. 1986; 78: 1456-1461 
45. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet 
aggregation as a consequence of different shearing flow conditions. J Clin Invest. 
1998; 101: 479-486 
46. Nemerson Y. Tissue factor and hemostasis. Blood. 1988; 71: 1-8 
162 
47. Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Hoffmann T. 
Evidence for the presence of tissue factor activity on subendothelium. Blood. 
1989; 73: 968-975 
48. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions 
during tissue factor-induced blood coagulation. Blood. 2002; 100: 148-152 
49. Davie EW, Ratnoff OD. Waterfall Sequence for Intrinsic Blood Clotting. 
Science. 1964; 145: 1310-1312 
50. Macfarlane RG. An Enzyme Cascade in the Blood Clotting Mechanism, 
and Its Function as a Biochemical Amplifier. Nature. 1964; 202: 498-499 
51. Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding 
site on human platelets. J Biol Chem. 1978; 253: 6908-6916 
52. Tracy PB, Eide LL, Bowie EJ, Mann KG. Radioimmunoassay of factor V 
in human plasma and platelets. Blood. 1982; 60: 59-63 
53. Chesney CM, Pifer D, Colman RW. Subcellular localization and secretion 
of factor V from human platelets. Proc Natl Acad Sei USA. 1981; 78: 5180-5184 
54. Lorand L. Factor XIII: structure, activation, and interactions with 
fibrinogen and fibrin. Ann NY Acad Sei. 2001; 936: 291-311 
55. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, 
Broze GJ, Jr. Functional significance of the Kunitz-type inhibitory domains of 
lipoprotein-associated coagulation inhibitor. Nature. 1989; 338: 518-520 
56. Broze GJ, Jr., Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich 
JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue 
factor complex also inhibits factor Xa: insight into its possible mechanism of action. 
Blood. 1988; 71: 335-343 
57. Rosenberg RD, Rosenberg JS. Natural anticoagulant mechanisms. J Clin 
Invest. 1984; 74: 1-6 
58. Olson ST, Chuang YJ. Heparin activates antithrombin anticoagulant 
function by generating new interaction sites (exosites) for blood clotting proteinases. 
Trends Cardiovasc Med. 2002; 12: 331-338 
59. Esmon CT. Molecular events that control the protein C anticoagulant 
pathway. Thromb Haemost. 1993; 70: 29-35 
60. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for 
thrombin-catalyzed activation of protein C. Proc Natl Acad. Sei USA. 1981; 78: 2249- 
2252 
61. Walker FJ. Regulation of activated protein C by protein S. The role of 
phospholipid in factor Va inactivation. J Biol Chem. 1981; 256: 11128-11131 
62. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition 
of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sei US 
A. 2006; 103: 3106-3111 
63. Taylor FB, Jr., Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial 
cell protein C receptor plays an important role in protein C activation in vivo. Blood. 
2001; 97: 1685-1688 
64. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, 
Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, 
Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A 
metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. 
Nature. 1997; 385: 729-733 
65. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix 
metalloproteinase-3 releases active heparin-binding EGF-like growth factor by 
cleavage at a specific juxtamembrane site. J Biol Chem. 1997; 272: 31730-31737 
163 
66. Pohl G, Kallstrom M, Bergsdorf N, Wallen P, Jornvall 11. Tissue 
plasminogen activator: peptide analyses confirm an indirectly derived amino acid 
sequence, identify the active site serine residue, establish glycosylation sites, and 
localize variant differences. Biochemistry. 1984; 23: 3701-3707 
67. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the 
mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis 
inhibitor. J Biol Chem. 1998; 273: 27176-27181 
68. Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GA, Latt SA, 
Orkin SH. Human von Willebrand factor (vWF): isolation of complementary DNA 
(cDNA) clones and chromosomal localization. Science. 1985; 228: 1401-1406 
69. Bonthron D, Orkin SH. The human von Willebrand factor gene. Structure 
of the 5' region. Eur J Biochem. 1988; 171: 51-57 
70. Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, 
Sorace JM, Alevy YG, Sadler JE. Structure of the gene for human von Willebrand 
factor. J Biol Chem. 1989; 264: 19514-19527 
71. Katsumi A, Tuley EA, Bodo I, Sadler JE. Localization of disulfide bonds 
in the cystine knot domain of human von Willebrand factor. J Biol Chem. 
2000; 275: 25585-25594 
72. Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh 
KA, Chopek MW, Sadler JE, Fujikawa K. Amino acid sequence of human von 
Willebrand factor. Biochemistry. 1986; 25: 3171-3184 
73. Marti T, Rosselet SJ, Titani K, Walsh KA. Identification of disulfide- 
bridged substructures within human von Willebrand factor. Biochemistry. 
1987; 26: 8099-8109 
74. Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol. 2003; 10: 142- 
149 
75. Pietu G, Ribba AS, Meulien P, Meyer D. Localization within the 106 N- 
terminal amino acids of von Willebrand factor (vWF) of the epitope corresponding to 
a monoclonal antibody which inhibits vWF binding to factor VIII. Biochem Biophys 
Res Commun. 1989; 163: 618-626 
76. Sobel M, Soler DF, Kermode JC, Harris RB. Localization and 
characterization of a heparin binding domain peptide of human von Willebrand factor. 
J Biol Chem. 1992; 267: 8857-8862 
77. Colombatti A, Bonaldo P. The superfamily of proteins with von 
Willebrand factor type A-like domains: one theme common to components of 
extracellular matrix, hemostasis, cellular adhesion, and defense mechanisms. Blood. 
1991; 77: 2305-2315 
78. Celikel R, Varughese KI, Madhusudan, Yoshioka A, Ware J, Ruggeri ZM. 
Crystal structure of the von Willebrand factor Al domain in complex with the function 
blocking NMC-4 Fab. Nat Struct Biol. 1998; 5: 189-194 
79. Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von 
Willebrand Factor Al domain and implications for the binding of platelet glycoprotein 
lb. J Biol Chem. 1998; 273: 10396-10401 
80. Sutherland JJ, O'Brien LA, Lillicrap D, Weaver DF. Molecular modeling 
of the von Willebrand factor A2 Domain and the effects of associated type 2A von 
Willebrand disease mutations. J Mol Model (Online). 2004; 10: 259-270 
81. Huizinga EG, Martijn van der Plas R, Kroon J, Sixma JJ, Gros P. Crystal 
structure of the A3 domain of human von Willebrand factor: implications for collagen 
binding. Structure. 1997; 5: 1147-1156 
164 
82. Beacham DA, Wise RJ, Turci SM, Handin RI. Selective inactivation of the 
Arg-Gly-Asp-Ser (RCDS) binding site in von Willebrand factor by site-directed 
mutagenesis. J Biol Chem. 1992; 267: 3409-3415 
83. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-I inked 
oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, 
B, and H(O) structures. J Biol Chem. 1992; 267: 8723-8731 
84. Matsui T, Fujimura Y, Nishida S, Titani K. Human plasma alpha 2- 
macroglobulin and von Willebrand factor possess covalently linked ABO(H) blood 
group antigens in subjects with corresponding ABO phenotype. Blood. 1993; 82: 663- 
668 
85. Shima M, Fujimura Y, Nishiyama T, Tsujiuchi T, Narita N, Matsui T, 
Titani K, Katayama M, Yamamoto F, Yoshioka A. ABO blood group genotype and 
plasma von Willebrand factor in normal individuals. Vox Sang. 1995; 68: 236-240 
86. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of 
von Willebrand factor by ADAMTS 13. J Thromb Haemost. 2003; 1: 33-40 
87. Mohlke KL, Purkayastha AA, Westrick RJ, Smith PL, Petryniak B, Lowe 
JB, Ginsburg D. Mvwf, a dominant modifier of murine von Willebrand factor, results 
from altered lineage-specific expression of a glycosyltransferase. Cell. 1999; 96: 111- 
120 
88. O'Donnell J S, McKinnon TA, Crawley JT, Lane DA, Laffan MA. 
Bombay phenotype is associated with reduced plasma-VWF levels and an increased 
susceptibility to ADAMTSI3 proteolysis. Blood. 2005; 106: 1988-1991 
89. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by 
cultured human endothelial cells. Proc Natl Acad Sei USA. 1974; 71: 1906-1909 
90. Purvis AR, Sadler JE. A covalent oxidoreductase intermediate in 
propeptide-dependent von Willebrand factor multimerization. J Biol Chem. 
2004; 279: 49982-49988 
91. Voorberg J, Fontijn R, van Mourik JA, Pannekoek H. Domains involved in 
multimer assembly of von willebrand factor (vWF): multimerization is independent of 
dimerization. Embo J. 1990; 9: 797-803 
92. Dong Z, Thoma RS, Crimmins DL, McCourt DW, Tuley EA, Sadler JE. 
Disulfide bonds required to assemble functional von Willebrand factor multimers. J 
Biol Chem. 1994; 269: 6753-6758 
93. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a 
role in von Willebrand factor multimer assembly. Proc Natl Acad Sei USA. 
1992; 89: 3531-3535 
94. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing 
and multimerization precede the formation of Weibel-Palade bodies. Blood. 
1994; 83: 3536-3544 
95. Verweij CL, Hart M, Pannekoek H. Proteolytic cleavage of the precursor 
of von Willebrand factor is not essential for multimer formation. J Biol Chem. 
1988; 263: 7921-7924 
96. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev 
Biochem. 1998; 67: 395-424 
97. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by 
human endothelial cells: processing steps and their intracellular localization. J Cell 
Biol. 1984; 99: 2123-2130 
98. Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von 
Willebrand protein by human megakaryocytes. J Clin Invest. 1985; 76: 1102-1106 
165 
99. Cramer EM, Meyer D, le Menn R, Breton-Gorius J. Eccentric localization 
of von Willebrand factor in an internal structure of platelet alpha-granule resembling 
that of Weibel-Palade bodies. Blood. 1985; 66: 710-713 
100. Wagner DD, Saffaripour S, Bonfanti R, Sadler JE, Cramer EM, Chapman 
B, Mayadas TN. Induction of specific storage organelles by von Willebrand factor 
propolypeptide. Cell. 1991; 64: 403-413 
101. Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek 
H. Biogenesis of von Willebrand factor-containing organelles in heterologous 
transfected CV-1 cells. Embo J. 1993; 12: 749-758 
102. Haberichter SL, Fahs SA, Montgomery RR. von Willebrand factor 
storage and multimerization: 2 independent intracellular processes. Blood. 
2000; 96: 1808-1815 
103. Hop C, Fontijn R, van Mourik JA, Pannekoek H. Polarity of constitutive 
and regulated von Willebrand factor secretion by transfected MDCK-II cells. Exp Cell 
Res. 1997; 230: 352-361 
104. Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, 
Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial 
cells involves V2 receptors and cAMP. J Clin Invest. 2000; 106: 107-116 
105. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, 
biologically potent von Willebrand factor multimers. Cell. 1986; 46: 185-190 
106. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, 
Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. 
Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of 
experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin 
in humans. Blood. 1996; 88: 2951-2958 
107. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. 
Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand 
antigen II) after secretion from endothelial cells. Proc Natl Acad Sci USA. 
1987; 84: 1955-1959 
108. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, 
de Groot PG, Denis CV. An experimental model to study the in vivo survival of von 
Willebrand factor. Basic aspects and application to the R120511 mutation. J Biol 
Chem. 2004; 279: 12102-12109 
109. Tsai HM. Deficiency of ADAMTS-13 in thrombotic and 
thrombocytopenic purpura. J Thromb Haemost. 2003; 1: 2038-2040 
110. Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ. The 
affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. 
Blood. 1995; 85: 3150-3157 
111. Rand JH, Patel ND, Schwartz E, Zhou SL, Potter BJ. 150-kD von 
Willebrand factor binding protein extracted from human vascular subendothelium is 
type VI collagen. J Clin Invest. 1991; 88: 253-259 
112. Federici AB, Bader R, Pagani S, Colibretti ML, De Marco L, Mannucci 
PM. Binding of von Willebrand factor to glycoproteins lb and IIb/IIla complex: 
affinity is related to multimeric size. Br J Haematol. 1989; 73: 93-99 
113. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, 
Marchant RE. Shear-dependent changes in the three-dimensional structure of human 
von Willebrand factor. Blood. 1996; 88: 2939-2950 
114. Vlot AJ, Koppelman SJ, Meijers JC, Dama C, van den Berg HM, Bouma 
BN, Sixma JJ, Willems GM. Kinetics of factor VIII-von Willebrand factor association. 
Blood. 1996; 87: 1809-1816 
166 
115. Bahou WF, Ginsburg D, Sikkink R, Litwiller R, Fass DN. A monoclonal 
antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of 
its antigenic determinant to a nonadecapeptide at the amino terminus of the mature 
vWF polypeptide. J Clin Invest. 1989; 84: 56-61 
116. Ginsburg D, Bockenstedt PL, Allen EA, Fox DA, Foster PA, Ruggeri 
ZM, Zimmerman TS, Montgomery RR, Bahou WF, Johnson TA, et al. Fine mapping 
of monoclonal antibody epitopes on human von Willebrand factor using a recombinant 
peptide library. Thromb Haemost. 1992; 67: 166-171 
117. Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major 
factor VIII binding domain resides within the amino-terminal 272 amino acid residues 
of von Willebrand factor. J Biol Chem. 1987; 262: 8443-8446 
118. Saenko EL, Scandella D. The acidic region of the factor VIII light chain 
and the C2 domain together form the high affinity binding site for von willebrand 
factor. J Biol Chem. 1997; 272: 18007-18014 
119. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 
domain of factor VIII in binding to von Willebrand factor. J Biol Chem. 
1994; 269: 11601-11605 
120. Shima M, Yoshioka A, Nakajima M, Nakai H, Fukui H. A monoclonal 
antibody (NMC-VIII/10) to factor VIII light chain recognizing G1u1675-Glu1684 
inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical 
vein endothelial cells. Br J Haematol. 1992; 81: 533-538 
121. Nogami K, Shima M, Giddings JC, Hosokawa K, Nagata M, Kamisue S, 
Suzuki H, Shibata M, Saenko EL, Tanaka I, Yoshioka A. Circulating factor VIII 
immune complexes in patients with type 2 acquired hemophilia A and protection from 
activated protein C-mediated proteolysis. Blood. 2001; 97: 669-677 
122. Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface 
heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low 
density lipoprotein receptor-related protein. J Biol Chem. 2001; 276: 11970-11979 
123. Hill-Eubanks DC, Parker CG, Lollar P. Differential proteolytic activation 
of factor VIII-von Willebrand factor complex by thrombin. Proc Natl Acad Sei USA. 
1989; 86: 6508-6512 
124. Myles T, Yun TH, Leung LL. Structural requirements for the activation 
of human factor VIII by thrombin. Blood. 2002; 100: 2820-2826 
125. Precup JW, Kline BC, Fass DN. A monoclonal antibody to factor VIII 
inhibits von Willebrand factor binding and thrombin cleavage. Blood. 1991; 77: 1929- 
1936 
126. Nyman D. Interaction of collagen with the factor VIII antigen-activity - 
von Willebrand factor complex. Thromb Res. 1977; 11: 433-438 
127. Santoro SA, Cowan JF. Adsorption of von Willebrand factor by fibrillar 
collagen--implications concerning the adhesion of platelets to collagen. Coll Relat 
Res. 1982; 2: 31-43 
128. Bockenstedt P, McDonagh J, Handin RI. Binding and covalent cross- 
linking of purified von Willebrand factor to native monomeric collagen. J Clin Invest. 
1986; 78: 551-556 
129. Roth GJ, Titani K, Hoyer LW, Hickey MJ. Localization of binding sites 
within human von Willebrand factor for monomeric type III collagen. Biochemistry. 
1986; 25: 8357-8361 
130. Pareti Fl, Niiya K, McPherson JM, Ruggeri ZM. Isolation and 
characterization of two domains of human von Willebrand factor that interact with 
fibrillar collagen types I and III. J Biol Chem. 1987; 262: 13835-13841 
167 
131. Romijn RA, Westein E, Bouma B, Schiphorst ME, Sixma JJ, Lenting PJ, 
Huizinga EG. Mapping the collagen-binding site in the von Willebrand factor-A3 
domain. J Biol Chem. 2003; 278: 15035-15039 
132. Hoylaerts MF, Yamamoto H, Nuyts K, Vreys I, Deckmyn 11, Vermylen J. 
von Willebrand factor binds to native collagen VI primarily via its Al domain. 
Biochem J. 1997; 324 (Pt 1): 185-191 
133. Mazzucato M, Spessotto P, Masotti A, De Appollonia L, Cozzi MR, 
Yoshioka A, Perris R, Colombatti A, Dc Marco L. Identification of domains 
responsible for von Willebrand factor type VI collagen interaction mediating platelet 
adhesion under high flow. J Biol Chem. 1999; 274: 3033-3041 
134. Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von 
Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and 
collagen and characterization of its three distinct functional sites. J Biol Chem. 
1989; 264: 17361-17367 
135. Maita N, Nishio K, Nishimoto E, Matsui T, Shikamoto Y, Morita T, 
Sadler JE, Mizuno H. Crystal structure of von Willebrand factor Al domain 
complexed with snake venom, bitiscetin: insight into glycoprotein Ibalpha binding 
mechanism induced by snake venom proteins. J Biol Chem. 2003; 278: 37777-37781 
136. Ulrichts H, Udvardy M, Lenting PJ, Pareyn I, Vandeputte N, 
Vanhoorelbeke K, Deckmyn H. Shielding of the Al-domain by the D'D3 domains of 
von willebrand factor modulates its interaction with platelet glycoprotein IB-IX-V. J 
B iol Chem. 2005 2006 ; 2851: a 09 -1oß 
137. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by 
arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996; 84: 289- 
297 
138. Fressinaud E, Baruch D, Girma JP, Sakariassen KS, Baumgartner HR, 
Meyer D. von Willebrand factor-mediated platelet adhesion to collagen involves 
platelet membrane glycoprotein IIb-IIIa as well as glycoprotein lb. J Lab Clin Med. 
1988; 112: 58-67 
139. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma 
protease is dependent on its conformation and requires calcium ion. Blood. 
1996; 87: 4235-4244 
140. Furlan M, Robles R, Lamie B. Partial purification and characterization of 
a protease from human plasma cleaving von Willebrand factor to fragments produced 
by in vivo proteolysis. Blood. 1996; 87: 4223-4234 
141. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human 
von Willebrand factor-cleaving protease and its identification as a new member of the 
metal loproteinase family. Blood. 2001; 98: 1662-1666 
142. Plaimauer B, Zimmermann K, Volkel D, Antoine G, Kerschbaumer R, 
Jenab P, Furlan M, Gerritsen H, Lammle B, Schwarz HP, Scheiflinger F. Cloning, 
expression, and functional characterization of the von Willebrand factor-cleaving 
protease (ADAMTS 13). Blood. 2002; 100: 3626-3632 
143. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, 
Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, 
Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Jr., Ginsburg D, 
Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic 
thrombocytopenic purpura. Nature. 2001; 413: 488-494 
144. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid 
sequence of purified von Willebrand factor-cleaving protease. Blood. 2001; 98: 1654- 
1661 
168 
145. Kaushal GP, Shah SV. The new kids on the block: ADAMTSs, 
potentially multifunctional metalloproteinases of the ADAM family. J Clin Invest. 
2000; 105: 1335-1337 
146. Stocker W, Grams F, Baumann U, Reinemer P, Gomis-Ruth FX, McKay 
DB, Bode W. The metzincins--topological and sequential relations between the 
astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily 
of zinc-peptidases. Protein Sei. 1995; 4: 823-840 
147. Tang BL. ADAMTS: a novel family of extracellular matrix proteases. Int 
J Biochem Cell Biol. 2001; 33: 33-44 
148. Kuno K, Matsushima K. ADAMTS-1 protein anchors at the extracellular 
matrix through the thrombospondin type I motifs and its spacing region. J Biol Chem. 
1998; 273: 13912-13917 
149. Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, Lopez-Otin C. 
Cloning, expression analysis, and structural characterization of seven novel human 
ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 
domains. Gene. 2002; 283: 49-62 
150. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 
2005; 106: 11-17 
151. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, 
Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y. Mutations and 
common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor- 
cleaving protease activity. Proc Natl Acad Sci USA. 2002; 99: 11902-11907 
152. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. 
Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease 
involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001; 276: 41059- 
41063 
153. Zhou W, Inada M, Lee TP, Benten D, Lyubsky S, Bouhassira EE, Gupta 
S, Tsai HM. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest. 
2005; 85: 780-788 
154. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, 
Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H, Fujimura Y. Localization of 
ADAMTS 13 to the stellate cells of human liver. Blood. 2005; 106: 922-924 
155. Suzuki M, Murata M, Matsubara Y, Uchida T, Ishihara H, Shibano T, 
Ashida S, Soejima K, Okada Y, Ikeda Y. Detection of von Willebrand factor-cleaving 
protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun. 
2004; 313: 212-216 
156. Liu L, Choi H, Bernardo A, Bergeron AL, Nolasco L, Ruan C, Moake 
JL, Dong JF. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb 
Haemost. 2005; 3: 2536-2544 
157. Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells 
synthesize and release ADAMTS-13. J Thromb Haemost. 2006; 4: 1396-1404 
158. Shang D, Zheng XW, Niiya M, Zheng XL. Apical sorting of 
ADAMTS13 in vascular endothelial. cells and Madin-Darby canine kidney cells 
depends on the CUB domains and their association with lipid rafts. Blood. 
2006; 108: 2207-2215 
159. Claus RA, Bockmeyer CL, Kentouche K, Sieber MW, Oberle V, 
Kaufmann R, Deigner HP, Losche W. Transcriptional regulation of ADAMTS 13. 
Thromb Haemost. 2005; 94: 41-45 
169 
160. Furlan M, Robles R, Morselli B, Sandoz P, Lammte B. Recovery and 
half-life of von Willebrand factor-cleaving protease after plasma therapy in patients 
with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999; 81: 8-13 
161. Van Wart HE, Birkedal-Hansen H. The cysteinc switch: a principle of 
regulation of metalloproteinase activity with potential applicability to the entire matrix 
metal loproteinase gene family. Proc Natl Acad Sci USA. 1990; 87: 5578-5582 
162. Majerus EM, Zheng X, Tuley EA, Sadler JE. Cleavage of the 
ADAMTS13 propeptide is not required for protease activity. J Biol Chem. 2003; 2.7?. * W'3 -Ss 
163. Yiallouros I, Grosse Berkhoff E, Stocker W. The roles of G1u93 and 
Tyr149 in astacin-like zinc peptidases. FEBS Lett. 2000; 484: 224-228 
164. Anderson PJ, Kokame K, Sadler JE. Zinc and calcium ions cooperatively 
modulate ADAMTS13 activity. J Biol Chem. 2006; 281: 850-857 
165. Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drcwke 
E, Hassenpflug W, Haberle J, Kentouche K, Kohne E, Kurnik K, Mueller-Wiefel D, 
Obser T, Santer R, Sykora K-W. von Willebrand factor cleaving protease and 
ADAMTS13 mutations in childhood TTP. Blood. 2003; 101: 1845-1850 
166. Ai J, Smith P, Wang S, Zhang P, Zheng XL. The proximal carboxyl- 
terminal domains of ADAMTS13 determine substrate specificity and are all required 
for cleavage of von Willebrand factor. J Biol Chem. 2005; 280: 29428-29434 
167. Soejima K, Nakamura H, Hirashima M, Morikawa W, Nozaki C, 
Nakagaki T. Analysis on the Molecular Species and Concentration of Circulating 
ADAMTS13 in Blood. J Biochem (Tokyo). 2006; 139: 147-154 
168. Soejima K, Matsumoto M, Kokame K, Yagi H, Ishizashi H, Maeda H, 
Nozaki C, Miyata T, Fujimura Y, Nakagaki T. ADAMTS-13 cysteine-rich/spacer 
domains are functionally essential for von Willebrand factor cleavage. Blood. 
2003; 102: 3232-3237 
169. Hashimoto G, Shimoda M, Okada Y. ADAMTS4 (aggrecanase-1) 
interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan. 
J Biol Chem. 2004; 279: 32483-32491 
170. Rodriguez-Manzaneque JC, Milchanowski AB, Dufour EK, Leduc R, 
Iruela-Arispe ML. Characterization of METH-1/ADAMTSI processing reveals two 
distinct active forms. J Biol Chem. 2000; 275: 33471-33479 
171. Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand 
factor requires the spacer domain of the metalloprotease ADAMTSI3. J Biol Chem. 
2003; 278: 30136-30141 
172. Tao Z, Wang Y, Choi H, Bernardo A, Nishio K, Sadler JE, Lopez JA, 
Dong JF. Cleavage of ultralarge multimers of von Willebrand factor by C-terminal- 
truncated mutants of ADAMTS-13 under flow. Blood. 2005; 106: 141-143 
173. Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTSI3 to von 
Willebrand factor. J Biol Chem. 2005; 280: 21773-21778 
174. Assink K, Schiphorst R, Allford S, Karpman D, Etzioni A, Brichard B, 
van de Kar N, Monnens L, van den Heuvel L. Mutation analysis and clinical 
implications of von Willebrand factor-cleaving protease deficiency. Kidney Int. 
2003; 63: 1995-1999 
175. Klaus C, Plaimauer B, Studt JD, Dorner F, Lammle B, Mannucci PM, 
Scheiflinger F. Epitope mapping of ADAMTS13 autoantibodies in acquired 
thrombotic thrombocytopenic purpura. Blood. 2004) 103 : 4Skº -9 
176. Bork P, Beckmann G. The CUB domain. A widespread module in 
developmentally regulated proteins. J Mol Biol. 1993; 231: 539-545 
170 
177. Banno F, Kaminaka K, Soejima K, Kokame K, Miyata T. Identification 
of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor- 
cleaving protease. J Biol Chem. 2004; 2.79.30&96.903 
178. Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ. 
Congenital thrombotic thrombocytopenic purpura in association with a mutation in the 
second CUB domain of ADAMTS 13. Blood. 26A3 2oYt; 103. '627-9 
179. Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TO, Dong JF, 
Moake JL. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial- 
cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand 
factor multimers. Blood. 2005; 106: 4199-4209 
180. Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, McKee PA. 
Substructure of human von Willebrand factor. J Clin Invest. 1985; 76: 1491-1500 
181. Fretto LJ, Fowler WE, McCaslin DR, Erickson HP, McKee PA. 
Substructure of human von Willebrand factor. Proteolysis by V8 and characterization 
of two functional domains. J Biol Chem. 1986; 261: 15679-15689 
182. Padilla A, Moake JL, Bernardo A, Ball C, Wang Y, Arya M, Nolasco L, 
Turner N, Berndt MC, Anvari B, Lopez JA, Dong JF. P-selectin anchors newly 
released ultralarge von Willebrand factor multimers to the endothelial cell surface. 
Blood. 2004; 103: 2150-2156 
183. Michaux G, Pullen TJ, Haberichter SL, Cutler DF. P-selectin binds to the 
D'-D3 domains of von Willebrand factor in Weibel-Palade bodies. Blood. 
2006; 107: 3922-3924 
184. Chauhan AK, Goerge T, Schneider SW, Wagner AD. Formation of 
platelet strings and microthrombi in the presence of ADAMTS13 inhibitor does not 
require P-selectin or beta3 integrin. J Thromb Haemost. 2006 
185. Dong JF, Moake JL, Bernardo A, Fujikawa K, Ball C, Nolasco L, Lopez 
JA, Cruz MA. ADAMTS-13 metalloprotease interacts with the endothelial cell- 
derived ultra-large von Willebrand factor. J Biol Chem. 2003; 278: 29633-29639 
186. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet 
glycoprotein Ib{alpha} to von Willebrand factor domain Al stimulates the cleavage of 
the adjacent domain A2 by ADAMTSI3. Proc Natl Acad Sei USA. 2004; 0: IOS'7fs-83 
187. Zanardelli S, Crawley JT, Chion CK, Lam JK, Preston RJ, Lane DA. 
ADAMTSI3 substrate recognition of von Willebrand factor A2 domain. J Biol Chem. 
2006; 281: 1555-1563 
188. Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from 
D1596 to R1668 of von Willebrand factor, provides a minimal substrate for 
ADAMTS-13. Blood. 2004; 103: 607-612 
189. Wu JJ, Fujikawa K, McMullen BA, Chung DW. Characterization of a 
core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc 
Natl Acad Sci USA. 2006; 103: 18470-18474 
190. Gao W, Anderson PJ, Majerus EM, Tuley EA, Sadler JE. Exosite 
interactions contribute to tension-induced cleavage of von Willebrand factor by the 
antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci USA. 
2006; 103: 19099-19104 
191. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton 
CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA. ADAMTS-13 rapidly cleaves 
newly secreted ultralarge von Willebrand factor multimers on the endothelial surface 
under flowing conditions. Blood. 2002; 100: 4033-4039 
171 
192. Whitelock JL, Nolasco L, Bernardo A, Moake J, Dong JF, Cruz MA. 
ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that 
uses recombinant VWF-A2 domain as substrate. J Thromb Haemost. 2004; 2: 485-491 
193. Cruz MA, Whitelock J, Dong JF. Evaluation of ADAMTS-13 activity in 
plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate. 
Thromb Haemost. 2003; 90: 1204-1209 
194. De Cristofaro R, Peyvandi F, Palla R, Lavoretano S, Lombardi R, Merati 
G, Romitelli F, Di Stasio E, Mannucci PM. Role of chloride ions in modulation of the 
interaction between von Willebrand factor and ADAMTS-13. J Biol Chem. 
2005; 280: 23295-23302 
195. De Cristofaro R, Peyvandi F, Baronciani L, Palla R, Lavoretano S, 
Lombardi R, Di Stasio E, Federici AB, Mannucci PM. Molecular Mapping of the 
Chloride-binding Site in von Willebrand Factor (VWF): ENERGETICS AND 
CONFORMATIONAL EFFECTS ON THE VWF/ADAMTS-13 INTERACTION. J 
Biol Chem. 2006; 281: 30400-30411 
196. George JN, Sadler JE, Lammte B. Platelets: thrombotic 
thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program). 2002: 315- 
334 
197. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, 
Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIIl: von Willebrand 
factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J 
Med. 1982; 307: 1432-1435 
198. Furlan M, Lammle B. von Willebrand factor in thrombotic 
thrombocytopenic purpura. Thromb Haemost. 1999; 82: 592-600 
199. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair 
RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the 
treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. 
N EngI J Med. 1991; 325: 393-397 
200. Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt JD, 
Lammte B, Scheiflinger F. ADAMTS13 gene defects in two brothers with 
constitutional thrombotic thrombocytopenic purpura and normalization of von 
Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J 
Haematol. 2003; 120: 821-824 
201. Uchida T, Wada H, Mizutani M, Iwashita M, Ishihara H, Shibano T, 
Suzuki M, Matsubara Y, Soejima K, Matsumoto M, Fujimura Y, Ikeda Y, Murata M. 
Identification of novel mutations in ADAMTS13 in an adult patient with congenital 
thrombotic thrombocytopenic purpura. Blood. 2004; loft: 20: i-3 
202. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic 
thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von 
Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001; 14: 437-454 
203. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, 
Zhang W, Tsai HM, Wagner DD, Ginsburg D. Shigatoxin triggers thrombotic 
thrombocytopenic purpura in genetically susceptible ADAMTS 13-deficient mice. J 
Clin Invest. 2005; 115: 2752-2761 
204. Banno F, Kokame K, Okuda T, Honda S, Miyata S, Kato H, Tomiyama 
Y, Miyata T. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not 
sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006; 107: 3161-3166 
205. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo 
SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai H-M. 
172 
Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel. N. Engl. J. Med. 
2000; 342: 1773-1777 
206. Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to 
von Willebrand factor metalloproteinase and increased binding of von Willebrand 
factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann 
Intern Med. 2000; 132: 794-799 
207. Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, 
Dorner F, Rieger M. Nonneutralizing IgM and IgG antibodies to von Willebrand 
factor-cleaving protease (ADAMTS-13) in a patient with thrombotic 
thrombocytopenic purpura. Blood. 2003; 102: 3241-3243 
208. Luken BM, Kaijen PH, Turenhout EA, Hovinga JA, van Mourik JA, 
Fijnheer R, Voorberg J. Multiple B-cell clones producing antibodies directed to the 
spacer and disintegrin/thrombospondin type-I repeat I (TSPI) of ADAMTSI3 in a 
patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006; 4: 235'5-6y 
209. Luken BM, Turenhout EA, Kaijen PH, Greuter MJ, Pos W, van Mourik 
JA, Fijnheer R, Voorberg J. Amino acid regions 572-579 and 657-666 of the spacer 
domain of ADAMTS13 provide a common antigenic core required for binding of 
antibodies in patients with acquired TTP. Thromb Haemost. 2006; 96: 295-301 
210. Studt JD, Hovinga JA, Radonic R, Gasparovic V, Ivanovic D, Merkler 
M, Wirthmueller U, Dahinden C, Furlan M, Lammte B. Familial acquired thrombotic 
thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. 
Blood. 2004; 103: 4195-4197 
211. Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia 
caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003; 70: 183-185 
212. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. 
Remission of chronic thrombotic thrombocytopenic purpura after treatment with 
cyclophosphamide and rituximab. Ann Intern Med. 2003; 138: 105-108 
213. Zhou W, Dong L, Ginsburg D, Bouhassira EE, Tsai HM. Enzymatically 
active ADAMTS 13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a 
novel therapeutic strategy? J Biol Chem. 2005; 280: 39934-39941 
214. Rarick MU, Espina B, Mocharnuk R, Trilling Y, Levine AM. Thrombotic 
thrombocytopenic purpura in patients with human immunodeficiency virus infection: a 
report of three cases and review of the literature. Am J Hematol. 1992; 40: 103-109 
215. Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic 
purpura-like syndromes following bone marrow transplantation: an analysis of 
associated conditions and clinical outcomes. Bone Marrow Transplant. 2001; 27: 641- 
646 
216. Moake JL, Byrnes JJ. Thrombotic microangiopathies associated with 
drugs and bone marrow transplantation. Hematol Oncol Clin North Am. 1996; 10: 485- 
497 
217. Tsai HM, Sarode R, Downes KA. Ultralarge von Willebrand factor 
multimers and normal ADAMTSI3 activity in the umbilical cord blood. Thromb Res. 
2002; 108: 121-125 
-218. Caramaschi P, Riccetti MM, Pasini AF, Savarin T, Biasi D, Todeschini 
G. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura. Report 
of three cases and review of the literature. Lupus. 1998; 7: 37-41 
219. Hulstein JJ, van Runnard Heimel PJ, Franx A, Lenting PJ, Bruinse HW, 
Silence K, de Groot PG, Fijnheer R. Acute activation of the endothelium results in 
increased levels of active Von Willebrand Factor in HELLP syndrome. J Thromb 
Haemost. 2006; 4 : '1T69-)S 
173 
220. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, 
Takano K, Ohmori T, Sakata Y. Severe secondary deficiency of von Willebrand 
factor-cleaving protease (ADAMTSI3) in patients with sepsis-induced disseminated 
intravascular coagulation: its correlation with development of renal failure. Blood. 
2006; 107: 528-534 
221. Bohm M, Betz C, Miesbach W, Krause M, von Auer C, Geiger H, 
Scharrer I. The course of ADAMTS-13 activity and inhibitor titre in the treatment of 
thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J 
Haematol. 2005; 129: 644-652 
222. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. 
Changes in health and disease of the metalloprotease that cleaves von Willebrand 
factor. Blood. 2001; 98: 2730-2735 
223. Moore JC, Hayward CP, Warkentin TE, Kelton JG. Decreased von 
Willebrand factor protease activity associated with thrombocytopenic disorders. 
Blood. 2001; 98: 1842-1846 
224. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand 
factor-cleaving protease (ADAMTSI3) in thrombocytopenic disorders: a severely 
deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 
2002; 100: 710-713 
225. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of 
inflammatory cytokines on the release and cleavage of the endothelial cell-derived 
ultralarge von Willebrand factor multimers under flow. Blood. 2004; 104: 100-106 
226. Studt JD, Hovinga JA, Antoine G, Hermann M, Rieger M, Scheiflinger F, 
Lammle B. Fatal congenital thrombotic thrombocytopenic purpura with apparent 
ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. 
Blood. 2005; 105: 542-544 
227. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. 
ADAMTS13 and von Willebrand Factor and the risk of myocardial infarction in men. 
Blood. 2006 
228. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H 
antigen expressed on circulating von Willebrand factor is modified by ABO blood 
group genotype and is a major determinant of plasma von Willebrand factor antigen 
levels. Arterioscler Thromb Vase Biol. 2002; 22: 335-341 
229. Siekmann J, Turecek PL, Schwarz HP. The determination of von 
Willebrand factor activity by collagen binding assay. Haemophilia. 1998; 4 Suppl 3: 15- 
24 
230. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, 
a first fluorogenic substrate for ADAMTS 13 assay. Br J Haematol. 2005; 129: 93-100 
231. Tortorella M, Pratta M, Liu RQ, Abbaszade I, Ross H, Burn T, Amer E. 
The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan 
substrate recognition and cleavage. J Biol Chem. 2000; 275: 25791-25797 
232. Harris JL, Backes BJ, Leonetti F, Mahrus S, Ellman JA, Craik CS. Rapid 
and general profiling of protease specificity by using combinatorial fluorogenic 
substrate libraries. Proc Natl Acad Sei USA. 2000; 97: 7754-7759 
233. Higgins DL, Lewis SD, Shafer JA. Steady state kinetic parameters for the 
thrombin-catalyzed conversion of human fibrinogen to fibrin. J Biol Chem. 
1983; 258: 9276-9282 
234. Chang JY. Thrombin specificity. Requirement for apolar amino acids 
adjacent to the thrombin cleavage site of polypeptide substrate. Eur J Biochem. 
1985; 151: 217-224 
174 
235. Di Cera E. Thrombin interactions. Chest. 2003; 124: 1 IS-17S 
236. Narayanan S. Multifunctional roles of thrombin. Ann Clin Lab Sei. 
1999; 29: 275-280 
237. Philippou H, Rance J, Myles T, Hall SW, Ariens RA, Grant PJ, Leung L, 
Lane DA. Roles of low specificity and cofactor interaction sites on thrombin during 
factor XIII activation. Competition for cofactor sites on thrombin determines its fate. J 
Biol Chem. 2003; 278: 32020-32026 
238. Sadler JE. Thrombomodulin structure and function. Thromb Haemost. 
1997; 78: 392-395 
239. Ye J, Liu LW, Esmon CT, Johnson AE. The fifth and sixth growth factor- 
like domains of thrombomodulin bind to the anion-binding exosite of thrombin and 
alter its specificity. J Biol Chem. 1992; 267: 11023-11028 
240. Tsiang M, Jain AK, Dunn KE, Rojas ME, Leung LL, Gibbs CS. 
Functional mapping of the surface residues of human thrombin. J Biol Chem. 
1995; 270: 16854-16863 
241. Hall SW, Gibbs CS, Leung LL. Identification of critical residues on 
thrombin mediating its interaction with fibrin. Thromb Haemost. 2001; 86: 1466-1474 
242. Yuri TH, Baglia FA, Myles T, Navaneetham D, Lopez JA, Walsh PN, 
Leung LL. Thrombin activation of factor XI on activated platelets requires the 
interaction of factor XI and platelet glycoprotein lb alpha with thrombin anion-binding 
exosites I and II, respectively. J Biol Chem. 2003; 278: 48112-48119 
243. Raghavachari M, Tsai H, Kottke-Marchant K, Marchant RE. Surface 
dependent structures of von Willebrand factor observed by AFM under aqueous 
conditions. Colloids Surf B Biointerfaces. 2000; 19: 315-324 
244. Remuzzi G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin E, 
Contaretti S, Caprioli J, Gamba S, Ruggenenti P, Perico N, Mannucci PM. von 
Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and 
familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. 
Blood. 2002; 100: 778-785 
245. Tao Z, Peng Y, Nolasco L, Cal S, Lopez-Otin C, Li R, Moake JL, Lopez 
JA, Dong JF. Recombinant CUB-1 domain polypeptide inhibits the cleavage of 
ULVWF strings by ADAMTS13 under flow conditions. Blood. 2005; 106: 4139-4145 
246. Zhang D, Botos I, Gomis-Ruth FX, Doll R, Blood C, Njoroge FG, Fox 
JW, Bode W, Meyer EF. Structural interaction of natural and synthetic inhibitors with 
the venom metalloproteinase, atrolysin C (form d). Proc Natl Acad Sei USA. 
1994; 91: 8447-8451 
247. Bonnefoy A, Legrand C. Proteolysis of subendothelial adhesive 
glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, 
leukocyte cathepsin G, and elastase. Thromb Res. 2000; 98: 323-332 
248. Segal DM, Powers JC, Cohen GH, Davies DR, Wilcox PE. Substrate 
binding site in bovine chymotrypsin A-gamma. A crystallographic study using peptide 
chloromethyl ketones as site-specific inhibitors. Biochemistry. 1971; 10: 3728-3738 
249. Bajaj MS, Tricomi SM. Plasma levels of the three endothelial-specific 
proteins von Willebrand factor, tissue factor pathway inhibitor, and thrombomodulin 
do not predict the development of acute respiratory distress syndrome. Intensive Care 
Med. 1999; 25: 1259-1266 
250. Lopez-Aguirre Y, Paramo JA. Endothelial cell and hemostatic activation 
in relation to cytokines in patients with sepsis. Thromb Res. 1999; 94: 95-101 
251. Chignard M, Balloy V, Renesto P. Leucocyte elastase-mediated release 
of von Willebrand factor from cultured endothelial cells. Eur Respir J. 1993; 6: 791-796 
175 
252. Baumgartner HR. Platelet interaction with collagen fibrils in flowing 
blood. I. Reaction of human platelets with alpha chymotrypsin-digested 
subendothelium. Thromb Haemost. 1977; 37: 1-16 
253. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple 
substrate-receptor interactions in platelet thrombus formation under flow. Cell. 
1998; 94: 657-666 
254. Moroi M, Jung SM, Nomura S, Sekiguchi S, Ordinas A, Diaz-Ricart M. 
Analysis of the involvement of the von Willebrand factor-glycoprotein lb interaction 
in platelet adhesion to a collagen-coated surface under flow conditions. Blood. 
1997; 90: 4413-4424 
255. Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive 
interactions to platelet aggregation in flowing blood. Blood. 1999; 94: 172-178 
256. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit 
composition of plasma von Willebrand factor. Cleavage is present in normal 
individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants 
with aberrant structure of individual oligomers (types IIC, IID, and lIE). J Clin Invest. 
1986; 77: 947-951 
257. Donadelli R, Orje JN, Capoferri C, Remuzzi G, Ruggeri ZM. Size 
regulation of von Willebrand factor-mediated platelet thrombi by ADAMTSI3 in 
flowing blood. Blood. 2006; 107: 1943-1950 
258. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC. 
Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. 
Blood. 2006; 107: 3902-3906 
259. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, Seiffert 
DA, Schumacher WA, Ogletree ML, Gailani D. Effects of factor IX or factor XI 
deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb 
Haemost. 2005; 3: 695-702 
260. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, 
Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation 
factor XII. J Fxp Med. 2005; 202: 271-281 
261. Arya M, Anvari B, Romo GM, Cruz MA, Dong JF, McIntire LV, Moake 
JL, Lopez JA. Ultralarge multimers of von Willebrand factor form spontaneous high- 
strength bonds with the platelet glycoprotein lb-IX complex: studies using optical 
tweezers. Blood. 2002; 99: 3971-3977 
262. Savage B, Sixma JJ, Ruggeri ZM. Functional self-association of von 
Willebrand factor during platelet adhesion under flow. Proc Natl Acad Sci USA. 
2002; 99: 425-430 
263. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer 
B, Scheiflinger F, Ginsburg D, Wagner DD. Systemic antithrombotic effects of 
ADAMTS 13. J Exp Med. 2006; 203: 767-776 
264. Larsen E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R, Wagner 
DD, Furie B. PADGEM protein: a receptor that mediates the interaction of activated 
platelets with neutrophils and monocytes. Cell. 1989; 59: 305-312 
265. Satta N, Toti F, Feugeas 0, Bohbot A, Dachary-Prigent J, Eschwege V, 
Hedman H, Freyssinet JM. Monocyte vesiculation is a possible mechanism for 
dissemination of membrane-associated procoagulant activities and adhesion molecules 
after stimulation by lipopolysaccharide. J Immunol. 1994; 153: 3245-3255 
266. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a 
murine monoclonal antibody that abolishes ristocetin-induced binding of von 
176 
Willebrand factor to platelets: additional evidence in support of GPlb as a platelet 
receptor for von Willebrand factor. Blood. 1983; 61: 99-110 
267. Yamamoto N, Kitagawa H, Tanoue K, Yamazaki H. Monoclonal 
antibody to glycoprotein Ib inhibits both thrombin- and ristocetin-induced platelet 
aggregations. Thromb Res. 1985; 39: 751-759 
268. Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, dc Groot PG, Sixma 
JJ, Gros P. Structures of glycoprotein Ibalpha and its complex with von Willebrand 
factor Al domain. Science. 2002; 297: 1176-1179 
269. Cauwenberghs N, Vanhoorelbeke K, Vauterin S, Deckmyn H. Structural 
determinants within platelet glycoprotein Ibalpha involved in its binding to von 
Willebrand factor. Platelets. 2000; 11: 373-378 
270. Ward CM, Andrews RK, Smith Al, Berndt MC. Mocarhagin, a novel 
cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor 
glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276- 
Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha- 
thrombin. Biochemistry. 1996; 35: 4929-4938 
271. Matuskova J, Chauhan AK, Cambien B, Astrof S, Dole VS, Piffath CL, 
Hynes RO, Wagner DD. Decreased plasma fibronectin leads to delayed thrombus 
growth in injured arterioles. Arterioscler Thromb Vase Biol. 2006; 26: 1391-1396 
272. Mosesson MW, Umfleet RA. The cold-insoluble globulin of human 
plasma. I. Purification, primary characterization, and relationship to fibrinogen and 
other cold-insoluble fraction components. J Biol Chem. 1970; 245: 5728-5736 
273. Stenman S, Vaheri A. Distribution of a major connective tissue protein, 
fibronectin, in normal human tissues. J Exp Med. 1978; 147: 1054-1064 
274. Mosher DF. Physiology of fibronectin. Annu Rev Med. 1984; 35: 561-575 
275. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell 
recognition signal. Cell. 1986; 44: 517-518 
276. Plow EF, Ginsberg MH. Specific and saturable binding of plasma 
fibronectin to thrombin-stimulated human platelets. J Biol Chem. 1981; 256: 9477-9482 
277. Ginsberg M, Pierschbacher MD, Ruoslahti E, Marguerie G, Plow E. 
Inhibition of fibronectin binding to platelets by proteolytic fragments and synthetic 
peptides which support fibroblast adhesion. J Biol Chem. 1985; 260: 3931-3936 
278. Houdijk WP, de Groot PG, Nievelstein PF, Sakariassen KS, Sixma JJ. 
Subendothelial proteins and platelet adhesion. von Willebrand factor and fibronectin, 
not thrombospondin, are involved in platelet adhesion to extracellular matrix of human 
vascular endothelial cells. Arteriosclerosis. 1986; 6: 24-33 
279. Mosher DF. Cross-linking of cold-insoluble globulin by fibrin-stabilizing 
factor. J Biol Chem. 1975; 250: 6614-6621 
280. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo 
imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the 
mouse. Nat Med. 2002; 8: 1175-1181 
281. Raife T, Atkinson B, Montgomery R, Vesely S, Friedman K. Severe 
deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct 
population of thrombotic microangiopathy patients. Transfusion. 2004; 44: 146-150 
282. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von 
Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of l1l 
cases. Blood. 2001; 98: 1765-1772 
283. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, 
Tipping PG. Protease-activated receptor I mediates thrombin-dependent, cell- 
177 
mediated renal inflammation in crescentic glomerulonephritis. J Exp Med. 
2000; 191: 455-462 
284. Samarkos M, Aessopos A, Fragodimitri C, Karagiorga M, Kalotychou V, 
Voskaridou E, Kavouklis E, Loukopoulos D. Neutrophil elastase in patients with 
homozygous beta-thalassemia and pseudoxanthoma elasticum-like syndrome. Am J 
Hematol. 2000; 63: 63-67 
285. Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN, 
Shapiro SD. Mice lacking neutrophil elastase reveal impaired host defense against 
gram negative bacterial sepsis. Nat Med. 1998; 4: 615-618 
286. Owen CA, Campbell MA, Sannes PL, Boukedes SS, Campbell EJ. Cell 
surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative 
mechanism by which neutrophils focus and preserve catalytic activity of serine 
proteinases. J Cell Biol. 1995; 131: 775-789 
287. Owen CA, Campbell EJ. Neutrophil proteinases and matrix degradation. 
The cell biology of pericellular proteolysis. Semin Cell Biol. 1995; 6: 367-376 
288. Topham MK, Carveth HJ, McIntyre TM, Prescott SM, Zimmerman GA. 
Human endothelial cells regulate polymorphonuclear leukocyte degranulation. Faseb 
J. 1998; 12: 733-746 
289. Rainger GE, Rowley AF, Nash GB. Adhesion-dependent release of 
elastase from human neutrophils in a novel, flow-based model: specificity of different 
chemotactic agents. Blood. 1998; 92: 4819-4827 
290. Houston DS, Carson CW, Esmon CT. Endothelial cells and extracellular 
calmodulin inhibit monocyte tumor necrosis factor release and augment neutrophil 
elastase release. J Biol Chem. 1997; 272: 11778-11785 
291. Harlan JM, Schwartz BR, Reidy MA, Schwartz SM, Ochs HD, Harker 
LA. Activated neutrophils disrupt endothelial monolayer integrity by an oxygen 
radical-independent mechanism. Lab Invest. 1985; 52: 141-150 
292. Westlin WF, Gimbrone MA, Jr. Neutrophil-mediated damage to human 
vascular endothelium. Role of cytokine activation. Am J Pathol. 1993; 142: 117-128 
293. Senior RM, Bielefeld DR, Starcher BC. Comparison of the elastolytic 
effects of human leukocyte elastase and porcine pancreatic elastase. Biochem Biophys 
Res Commun. 1976; 72: 1327-1334 
294. Roughley PJ, Mason RM. The electrophoretic heterogeneity of bovine 
nasal cartilage proteoglycans. Biochem J. 1976; 157: 357-367 
295. Starkey PM, Barrett AJ, Burleigh MC. The degradation of articular 
collagen by neutrophil proteinases. Biochim Biophys Acta. 1977; 483: 386-397 
296. Gadek JE, Fells GA, Wright DG, Crystal RG. Human neutrophil elastase 
functions as a type III collagen "collagenase". Biochem Biophys Res Commun. 
1980; 95: 1815-1822 
297. Davies M, Barrett AJ, Travis J, Sanders E, Coles GA. The degradation of 
human glomerular basement membrane with purified lysosomal proteinases: evidence 
for the pathogenic role of the polymorphonuclear leucocyte in glomerulonephritis. 
Clin Sci Mol Med. 1978; 54: 233-240 
298. McDonald JA, Kelley DG. Degradation of fibronectin by human 
leukocyte elastase. Release of biologically active fragments. J Biol Chem. 
1980; 255: 8848-8858 
299. Carden D, Xiao F, Moak C, Willis BH, Robinson-Jackson S, Alexander 
S. Neutrophil elastase promotes lung microvascular injury and proteolysis of 
endothelial cadherins. Am J Physiol. 1998; 275: H385-392 
178 
300. Ginzberg HH, Cherapanov V, Dong Q, Cantin A, McCulloch CA, 
Shannon PT, Downey GP. Neutrophil-mediated epithelial injury during 
transmigration: role of elastase. Am J Physiol Gastrointest Liver Physiol. 
2001; 281: G705-717 
301. Wewers MD, Herzyk DJ, Gadek JE. Alveolar fluid neutrophil clastase 
activity in the adult respiratory distress syndrome is complexed to alpha-2- 
macroglobulin. J Clin Invest. 1988; 82: 1260-1267 
302. Galbusera M, Ruggenenti P, Noris M, Burnouf-Radosevich M, Benigni 
A, Mannucci PM, Remuzzi G. alpha 1-Antitrypsin therapy in a case of thrombotic 
thrombocytopenic purpura. Lancet. 1995; 345: 224-225 
303. Sallenave JM, Donnelly SC, Grant IS, Robertson C, Gauldie J, Haslett C. 
Secretory leukocyte proteinase inhibitor is preferentially increased in patients with 
acute respiratory distress syndrome. Eur Respir J. 1999; 13: 1029-1036 
304. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Eng) 
J Med. 2000; 342: 1334-1349 
305. Kuraki T, Ishibashi M, Takayama M, Shiraishi M, Yoshida M. A novel 
oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase- 
induced emphysema in rats. Am J Respir Crit Care Med. 2002; 166: 496-500 
306. Feltelius N, Hallgren R. Circulating inhibitor bound elastase in patients 
with ankylosing spondylitis and rheumatoid arthritis and the influence of 
sulphasalazine treatment. Ann Rheum Dis. 1988; 47: 10-14 
307. Ceriana P. Effect of myocardial ischaemia-reperfusion on granulocyte 
elastase release. Anaesth Intensive Care. 1992; 20: 187-190 
308. Uehara S, Gotoh K, Handa H, Honjo K, Hirayama A, Sakamoto W. 
Changes in polymorphonuclear neutrophil-elastase in pancreatitis. Agents Actions 
Suppl. 1992; 38: 405-412 
309. Glinski W, Pierozynska-Dubowska M, Glinska-Ferenz M, Jablonska S. 
Decreased specific anti-elastase activity in the uninvolved skin of patients with 
psoriasis. Arch Dermatol Res. 1991; 283: 224-229 
310. Reiter RA, Knobl P, Varadi K, Turecek PL. Changes in von Willebrand 
factor-cleaving protease (ADAMTS 13) activity after infusion of desmopressin. Blood. 
2003; 101: 946-948 
311. Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von 
Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol. 
2004; 126: 213-218 
312. Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous 
administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and 
reproducibility. Thromb Haemost. 1987; 58: 1033-1036 
313. Reiter RA, Varadi K, Turecek PL, Jilma B, Knobl P. Changes in 
ADAMTSI3 (von-Willebrand-factor-cleaving protease) activity after induced release 
of von Willebrand factor during acute systemic inflammation. Thromb Haemost. 
2005; 93: 554-558 
314. Schorer AE, Moldow CF, Rick ME. Interleukin 1 or endotoxin increases 
the release of von Willebrand factor from human endothelial cells. Br J Haematol. 
1987; 67: 193-197 
315. Pimanda JE, Ganderton T, Maekawa A, Yap CL, Lawler J, Kershaw G, 
Chesterman CN, Hogg PJ. Role of thrombospondin-1 in control of von Willebrand 
factor multimer size in mice. J Biol Chem. 2004; 279: 21439-21448 
316. Counts RB. Solid-phase immunoradiometric assay of factor-VIII protein. 
Br J Haematol. 1975; 31: 429-436 
179 
317. Dong JF, Whitelock J, Bernardo A, Ball C, Cruz MA. Variations among 
normal individuals in the cleavage of endothelial-derived ultra-large von Willebrand 
factor under flow. J Thromb Haemost. 2004; 2: 1460-1466 
318. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, 
Rumley A, Lowe GD. von Willebrand factor and coronary heart disease: prospective 
study and meta-analysis. Eur Heart J. 2002; 23: 1764-1770 
319. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, 
Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue 
plasminogen activator levels in plasma precede a first acute myocardial infarction in 
both men and women: evidence for the fibrinolytic system as an independent primary 
risk factor. Circulation. 1998; 98: 2241-2247 
320. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. 
Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh 
Artery Study. ArteriosclerThromb Vasc Biol. 1997; 17: 3321-3325 
321. Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP. Factor VIII, 
von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly 
Heart Study. BrJ Haematol. 1999; 105: 110-116 
322. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. 
Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J 
Haematol. 1994; 88: 601-607 
323. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. 
Prospective study of hemostatic factors and incidence of coronary heart disease: the 
Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997; 96: 1102-1108 
324. Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced 
von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial 
infarction. J Thromb Haemost. 2006; It : 2490 -3 
325. Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, 
Gomez Garcia EB, Dippel DW, Leebeek FW. High von Willebrand factor levels 
increase the risk of first ischemic stroke: influence of ADAMTS 13, inflammation, and 
genetic variability. Stroke. 2006; 37: 2672-2677 
326. Gando S, Nanzaki S, Morimoto Y, Kobayashi S, Kemmotsu O. Systemic 
activation of tissue-factor dependent coagulation pathway in evolving acute respiratory 
distress syndrome in patients with trauma and sepsis. J Trauma. 1999; 47: 719-723 
327. Erlich J, Fearns C, Mathison J, Ulevitch RJ, Mackman N. 
Lipopolysaccharide induction of tissue factor expression in rabbits. Infect Immun. 
1999; 67: 2540-2546 
328. Voves C, Wuillemin WA, Zeerleder S. International Society on 
Thrombosis and Haemostasis score for overt disseminated intravascular coagulation 
predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis. 
2006; 17: 445-451 
329. Endenburg SC, Hantgan RR, Lindeboom-Blokzijl L, Lankhof H, Jerome 
WG, Lewis JC, Sixma JJ, de Groot PG. On the role of von Willebrand factor in 
promoting platelet adhesion to fibrin in flowing blood. Blood. 1995; 86: 4158-4165 
330. Keuren JF, Baruch D, Legendre P, Denis CV, Lenting PJ, Girma JP, 
Lindhout T. von Willebrand factor C1C2 domain is involved in platelet adhesion to 
polymerized fibrin at high shear rate. Blood. 2004; 103: 1741-1746 
180 
9 APPENDIX 
Amino acid Direction Primer Sequence (5' to 3') Annealing 
mutation temperature 
'C 
R257A Forward GCGCCGCGCCCGCCGCCGGCCTC 67 
G 
R257A Reverse CGAGGCCGGCGGCGGGCGCGGC 67 
GC 
R287G Forward CGTGTGGGACCCGCCGGGGCCTC 50 
AACCCGGG 
R287G Reverse CCCGGGTTGAGGCCCCGGCGGG 50 
TCCCACACG 
R393H Forward GGTCTAGCTGGGGTCCCCACAGT 55 
CCTTGCTCCCGC 
R393H Reverse GCGGGAGCAAGGACTGTGGGGA 55 
CCCCAGCTAGACC 
R415H Forward GCAGTGCAACAACCCCCATCCTG 45 
CCTTTGGGGGGCG 
R415H Reverse CGCCCCCCAAAGGCAGGATCGG 45 
GGTTGTTGCACTGC 
R91OG Forward GCTCCGTCTCCTGCGGGGGAGGT 60 
CTGATGGAGCTCC 
R91OG Reverse GGAGCTCCATCAGACCTCCCCCG 60 
CAGGAGACGGAGC 
R968G Forward CGTGAGCTGTGGGGGAGGGGTC 55 
GTGCGGAGG 
R968G Reverse CCTCCGCACGACCCCTCCCCCAC 55 
AGCTCACG 
R1176H Forward CCGGCTCCCCAGCCTCATCGGCT 60 
CCTGCCCG 
R1176H Reverse CGGGCAGGAGCCGATGAGGCTG 60 
GGGAGCCGG 
Table 9.1. Site directed mutagenesis primers for generating AUAi 11S1J mutant vector 
constructs. 
Mutations introduced are highlighted in red, bold and underlined. 
Seq uencing primer Primer sequence (5' to 3' 
Seqeunce primer 1 (CMV promoter) AAAATGTCGTAACAACTCCGC 
Se quence p rimer 2 TCCTTGCCTGTGGCTTTC 
Se quence p rimer 3 GGTGCACCTGGTGAAGATGG 
Se quence p rimer 4 CACCATTGCCCATGAGATTG 
Se quence p rimer 5 AGGGAGCACCTGGATATGTG 
Se quence p rimer 6 ATGTGTTGGTGCTGACCTCC 
Se quence p rimer 7 CTGCAGGACATTTGGCTGTG 
Se quence p rimer 8 TCGAGTACAGAGTGGCCCTC 
Se quence p rimer 9 GAGACTGTCCAGTGCCAAGG 
181 
Seq uence primer 10 GAACGAGACCTGTGTGCCAG 
Seq uence primer 11 GTCCAGGAAGAGCTGTGTGG 
Seq uence primer 12 ATGTCCCTTGGCCCATGTTC 
Seq uence primer 13 CTGTGCCAGCTGATTTCTGC 
Seq uence primer 14 CGCGTCCTTGAGAGTTCTCT 
Seq uence primer 15 TCATTAATGTGGCTCCGCA 
Table 9.2. ADAMTS13 sequencing primers 
Anti en Domain Specificity Concentration Source 
ADAMTS 13 Metalloproteinase I mg/ml Scheiflinger, 
Fritz 
ADAMTS 13 Myc e ito e 1.4 mg/ml Invitro en, UK 
ADAMTS13 CUB domain 1.4 mg/ml Scheiflinger, 
Fritz 
ADAMTS 13 Disintegrin-like I mg/ml Motto, David 
ADAMTS 13 Ab 5 mg/ml Generated in Lab 
ADAMTSI3 TSP2-4 0.5 mg/ml Generated in Lab 
ADAMTS4 metal lo roteinase 1 mg/ml Na gase, Hediaki 
Table 9.3. ADAMTS13 antibodies used for Nestern blotting and ELISA 
Composition of growth medium 
LB broth 
lOg tryptone, 5g yeast extract, lOg NaCl and with/without 15g agar. Fill to 1 litre 
ddH2O and autoclave for 15 minutes 
2YT 
16g bacto tryptone, l Og bacto yeast extract and 5g NaCl. Fill to 1 litre with ddH20 and 
autoclave. 
182 
ADDENDA AND CORRIGENDA 
183 
COPY OF PUBLICATIONS ARISING FROM THIS 
THESIS 
184 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY 
Proteolytic inactivation of ADAMTS 13 by thrombin and plasmin 
James T. B. Crawley, Jonathan K. Lam, James B. Rance, Lulgina R. Mollica, James S. O'Donnell, and David A. Lane 
The muitimerlc size and the function of 
circulating von Willebrand factor are 
modulated via Its proteolytic cleavage by 
the plasma metal loproteinase, AD- 
AMTS13. It is unclear how ADAMTS13 
activity Is regulated within the vascular 
system. In the absence of a regulatory 
mechanism, ADAMTS13 activity might 
compromise platelet adhesion at sites of 
vascular Injury. We hypothesized that at 
sites of vascular Injury, ADAMTS13 activ- 
ity could be regulated locally by coagula- 
tion proteinases. Initiation of coagulation 
In human plasma resulted In the disap" 
pearance of added full-length recombi- 
nant ADAMTS13. This loss was Inhibited 
by hirudin. Using purified proteins, we 
showed that ADAMTSI3 Is proteolyzed at 
several cleavage sites by thrombin In a 
time- and concentration-dependent man- 
ner. Furthermore, this proteolysis ablated 
ADAMTS13 activity against purified von 
Willebrand factor. Preincubation of throm- 
bin with soluble thrombomodulin, but not 
heparin, Inhibited the proteolysis of AD- 
AMTS13, suggesting the Involvement of 
thrombin exosite I (and not exosite II) In 
ADAMTS13 recognition. Plasmin also 
cleaved ADAMTS13 Into similar frag- 
ments, resulting In the loss of ADAMTS1 3 
activity. This study demonstrates the sus- 
ceptibility of ADAMTS13 to proteolytlc 
Inactivation and suggests possible roles 
for thrombin and plasmin at sites of vas- 
cular Injury. (Blood. 2005; 105: 1085.1093) 
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Introduction 
Von Willcbrand factor (VWF) is a large (2050 amino acid/-250 
kDa) multidomain glycoprotein whose functions are critical for 
normal hemostasis. t VWF has 2 principal roles that influence the 
hemostatic process: (1) it acts as a carrier protein for coagulation 
factor VII12 and (2) it mediates rapid adhesion of platelets to sites of 
vascular perturbation. The latter is one of the first hemostatic events 
following endothelial disruption and occurs through the specific 
binding of VWF to exposed subendothelial matrix proteins (princi- 
pally collagen).; Once immobilized, VWF affinity for the glycopro- 
tein (GP) lb-IX-V receptor complex on the surface of circulating 
platelets is significantly enhanced! This results 
in the tethering of 
platelets at sites of vascular damage and in the 
formation of a 
primary platelet plug. Tethered platelets are subsequently activated 
and expose phosphatidylserine-rich surfaces that are critical 
for 
efficient thrombin generation to occurs 
VWF is constitutively secreted into the blood by endothelial 
cells as multimers of varying size that 
differ predominantly in the 
number of component VWF units. A significant proportion 
is also 
stored within Weibel-Palade 
bodies, predominantly as "ultra-large" 
multimers (UL-VWF)6 that may exceed 
2X 104 kDa. ' This pool is 
released on demand 
in response to endothelial cell activation? 
The properties of circulating VWF are, in part, dependent on its 
molecular size. Larger VWF multimers not only 
bind circulating 
platelets more readily than smaller 
forms, but also undergo marked 
conformational changes 
in response to the rheologic forces exerted 
by the circulating bloods Under normal flowing conditions, VWF 
ntultimers circulate 
in a globular form. However, when VWF is 
exposed to increased shear 
forces, these molecules unravel into a 
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"stringlike" conformation. This increases the number of exposed 
platelet/matrix binding sites and thus enhances the platelet tether- 
ing potential of the VWF molecule. 
Thrombotic thrombocytopenic purpura (TTP) is a rare, life- 
threatening condition, linked to UL-VWF function .9 Patients with 
TTP develop platelet-rich thrombi in their microvasculature, 10 
which may lead to renal failure, neurologic dysfunction, and 
ultimately, death. Such clinical sequelae are, at least in part, related 
to the elevated plasma UL-VWF levels detected in affected 
individuals. " These increased UL-VWF levels may promote 
platelet-rich thrombus formation by more readily tethering/ 
aggregating circulating platelets. 12 However, the precise stimulus 
that precipitates an episode of TIP remains unclear. The cause of 
increased UL-VWF levels in most patients with TTP has been 
attributed to deficiency in ADAMTS13.13 This enzyme cleaves 
VWF in the A2 domain at the Y1605-M1606 bond' and so 
converts UL-VWF into smaller forms that demonstrate a reduced 
adhesive/prothrombotic potential. Consequently, TTP sufferers 
with congenital defects in ADAMTS 13, or those with autoantibody 
inhibitors that compromise ADAMTS 13 function, are unable to 
process UL-VWF normally. 
ADAMTSI3 is secreted into the blood as an active enzyme's 
with a plasma concentration of approximately I µg/mL. 16 It is a 
stable enzyme with a plasma half-life of approximately 2 to 3 
days. 17 Plasma ADAMTSI3 is a 1349 residue protein with a 
molecular mass of 180 kDa to 200 kDa. 18 The metalloprotcinase 
domain contains a highly conserved active site that includes 3 
histidine residues that coordinate a Zn2+ ion. The disintegrin-like 
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domain and the first thrombospondin type-I repeat (TSPI) domain 
precede the cysteine-rich domain and spacer domain, followed by 7 
consecutive TSPI and 2 C-terminal CUB domains. 
It is uncertain how ADAMTSI3 activity is both regulated and 
localized. ADAMTS13 cleaves VWF inefficiently in the absence of 
shear forces, or a denaturant (eg, urea), that "unravels" VWF and 
permits access of ADAMTSI3 to the scissile bond. 19 Although 
VWF is normally protected from proteolysis by its tertiary 
structure, it seems unlikely that ADAMTSI3 activity in blood is 
not specifically regulated. In this study, we describe the protcolytic 
cleavage/inactivation of ADAMTS 13 by thrombin and FXa. More- 
over, we also demonstrate the proteolytic inactivation of AD- 
AMTS13 by plasmin, another protease generated specifically at 
sites of vessel damage, following thrombin-dependent fibrin 
deposition. 
Materials and methods 
Expression and purification of recombinant ADAMTS13 
full-length ADAMTS 13 cDNA (a gift from Dr R Scheiflinger, Baxter, 
Austria) was cloned in-frame into the mammalian expression vector, 
pcDNA3. I myc/His, which fused a myc epitope and polyhistidinc tag to the 
C-terminus of ADAMTSI3. Stably transfectcd HEK293 cells were gener- 
ated by standard techniques, using G418 for selection. Cleared serum-free 
conditioned medium was desalted and thereafter, ADAMTS 13 was purified 
with a Nie*-HiTrap Column (AmershamPharmacia, Buckinghamshire. 
United Kingdom), according to the manufacturer's instructions. Purified 
fractions were dialyzed into 20 mM Tris-HCI (pH 7.8) and analyzed by 
Western blotting using either anti-ADAMTSI3 protease domain (a gift 
from Dr F. Scheiflinger") or anti-myc epitope monoclonal antibodies 
(invitrogen, Paisley, United Kingdom). Recombinant ADAMTS13 purity 
was assessed by nonreducing sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Coomassie staining. 
ADAMTS 13 concen- 
tration was determined with a BCA total protein assay kit (Perbio, 
Tattenhall, United Kingdom). 
proteolysis of ADAMTS13 In human plasma 
To 800 p. L citrated normal human plasma, or plasma defibrinated with 
Reptilase Reagent (Pentapharm, Basel, Switzerland), recombinant AD- 
AMTS 13 (80 nM) was added to increase the ADAMTS 13 concentration. To 
3 100-µL samples of ADAMTSI3-spiked plasma, 8 pM lipidated human 
tissue factor (TF; Baxter, Vienna, Austria) and phosholipids 
(phosphatidyl- 
scrine/phosphatidylcholine/phosphatidylethanolamine 
(PS/PC/PE], 20: 60: 
20) (Avanti. Alabaster, AL) were added. Thereafter, 0.4 mM fluorogenic 
thrombin substrate, Z-Gly-Gly-Arg-AMC-HCI (Sachem, 
Merseyside, United 
Kingdom), was added and samples were recalcified to initiate thrombin 
generation. Thrombin generation was monitored 
in real-time using a 
Fluoroscan plate reader (Thermo, Bassingstoke, United Kingdom) and 
quantified by comparison to a standard curve generated at the same time. 
From parallel samples lacking the thrombin substrate, subsamples (25 
. 
L) were removed and analyzed by Western blotting using the 
anti-ADAMTSI3 protease 
domain antibody. In some experiments, 5 
Rtg/mL Gly-Pro-Arg-Pro-amide 
(Sigma, Poole, United Kindom) was 
added to whole plasma samples to prevent polymerization and cross- 
linking of fibrin. Hirudin (100 U/mL) was added to one sample to 
specifically inhibit thrombin. 
Enzymatic proteolysis of ADAMTSI 3 by thrombin, FXa, 
and plasmin 
ADAMTSI3 (250 nM) was incubated with 
0.9 nM to 90 nM human 
, -thrombin 
(Sigma), FXa (Calbiochem, Nottingham, United Kingdom) or 
Plasmin (Calbiochem) 
in 20 mM Tris-HCI (pH 7.8), 5 mM CaCI2,150 mM 
N3CI at 37°C. At specific time points 
(0-6 hours), ADAMTS 13 fragmenta- 
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Lion was analyzed by Coomassie staining and Western blotting (with 
anti-protease domain or anti-myc monoclonal antibody (mAb]). Experi- 
ments using heparin or thrombomodulin (TM) were similarly performed 
except that thrombin (50 nM) was preincubated for 5 minutes with 
equimolar or a 10-fold molar excess of unfractionated heparin (CP 
Pharmaceuticals, Wrexham, United Kingdom) or soluble rabbit TM (Cam- 
bridge Bioscience, Cambridge, United Kingdom), respectively. To assess 
the relative specificity of thrombin for ADAMTS 13 over other ADAMTS 
family members, parallel experiments in which ADAMTS4=° (a kind gift of 
Dr H. Nagasc, Imperial College London, United Kingdom) was treated with 
9 nM thrombin for 0 to 6 hours were analyzed by Western blotting using 
ADAMTS4 protease domain-specific polyclonal antibodies"0 (also a gift of 
Dr H. Nagasc). 
Purification of VWF from human plasma 
VWF was purified from normal human plasma as described by Bowen. =1 
Briefly, 600 mL fresh frozen plasma was cryoprecipitated. The pellet was 
dissolved in 10 mL 20 mM Tris-HCI (pH 8). Samples were cleared before 
purification by gel filtration using a Sepharose CL-2ß HiPrep 26/60 column 
(AmershamPharmacia). VWF concentration in each fraction was deter- 
mined using a specific VWFenzyme-linked immunosorbent assay (ELISA), 
as previously described. 22 The purity of VWF was assessed by reducing 
SDS-PAGE and silver staining. 
ADAMTS13 activity assays 
To assess the effect of protcolysis on ADAMTSI3 activity, I mM 
ADAMTS 13 was incubated with and without 9 nM thrombin or plasmin for 
16 hours at 37°C. ADAMTSI3 activity assays were performed essentially 
as describedt" and using a VWF collagen-binding assay (VWF-CBA. 
Technoclone, Surrey. United Kingdom). Briefly, 5µg of each ADAMTS 13 
sample (with and without proteinuse treatment) was preincubated with 10 
mM BaC12 for 10 minutes at 37°C. Thereafter, samples were incubated at 
37°C with 8 nM purified human VWF in reaction conditions containing 1.5 
M urea, 10 mM BaCl2,5 mM NaCI, 0.5 mM CaCl2, and 15 mM Tris-HCI 
(pH 8.0). At 0.1,2.4. and 6 hours, subsamples were removed for analysis 
of VWF proteolysis. Samples were mixed with 2X reducing SDS loading 
buffer and heated for 20 minutes at 95°C. Samples were separated on 5% 
polyacrylamide gels and electroblotted onto a polyvinylidene difluoride 
(PVDF) membrane. Proteolysis of VWF was examined by Western blotting 
using a polyclonal anti-VWF antibody (Dako, Cambridge, United King- 
dom). Parallel samples were also analyzed in triplicate with a VWF-CBA, 
according to the manufacturer's instructions. ADAMTS 13 activity was thus 
assessed indirectly by examining its effect on VWF collagen-binding 
function. VWF-CBA results were normalized by parallel sampling in the 
absence of recombinant ADAMTS 13. 
Results 
Purification of recombinant ADAMTSI3 
Recombinant myc/6xHis-taggcd ADAMTS13 was expressed into 
conditioned medium from HEK293 cells that had been stably 
transfected with the vector, pcDNA3.1/ADAMTSI3/myc/His. AD- 
AMTS 13 (-200 kDa) was purified and concentrated by affinity 
chromatography; see result of SDS-PAGE (Figure 1, lane 1). 
Western blot analysis using an anti-ADAMTSI3 protease domain 
antibody highlighted the presence of the same prominent band at 
approximately 190 kDa to 210 kDa (Figure 1, lane 2), in 
accordance with a previous report. 11 However, analysis of this 
same sample using an anti-myc epitope antibody revealed the 
presence of an additional but lower intensity band at approximately 
40 kDa (Figure 1, lane 3). This minor species was believed to be a 
C-terminal ADAMTS13 degradation fragment (containing the 
myc/His tag) that was copurifed with the full-length enzyme. 
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Figure 1. Purification of recombinant human ADAMTS13. ADAMTS13 was 
expressed by HEK293 cells stably lianstected with the expression vector, pcDNA3 1, 
ADAMTS 13, myc. 'His ADAMTS 13 was purified from conditioned medium Ni'' -HiT rap 
columns Purified material was electrophoresed on a 7.5% polyacrylamide gel under 
nonreducing conditions and stained with Coomassie (lane 1) Lanes 2 and 3 Western 
blot analysis under reducing conditions with the anti-ADAMTS13 protease domain 
art body and anti-myc epitope antibody, respectively Lad marker ladder 
ADAMTS13 is proteolyzed following activation of coagulation 
in human plasma 
Western blotting tu drtCCt enrlugcnrws ADA NI-I S 13 in human 
plasma was ineffective due to its low concentration. Addition of 
recombinant A DAM IS 13 to delihrinated plasma allowed detection 
of a single appmsiul: uely 200-kDa ADANITS13 hand. Ad line. 
relipidated TF. phospholipids. and Ca'' initiated thrombin encr, r 
lion that was quantified in real-time using a luorogenic suhstr, ii 
and an automated plate reader. This demonstrated that thrombin 
was generated in ADAklTSI3-spiked plastna samples ssith u 
characteristic lag-time followed by a rapid propagation pha, c 
(Figure 2A). In parallel samples lacking the thrombin substrate, 
aliquots were removed at different tonte points (0-30 minule, ). and 
the effect of coagulation on ADAMMTS 13 ,N as examined by Western 
blotting using the anti-ADAMTS 13 protease domain monoclonal 
antibody. In sample, 
in Which thrombin was generated (Figure 213). 
a decrease in the 
intensity of the full-length ADAM'US 13 hand ss as 
observed. This dcnum, uated that activation of the coagulation 
th ADAM1-L'S 13. In the cascade caused the rapid loss of full-leng11 
absence of a procuagulant stimulus (ie, 
in samples lacking I F. 
phospholipids. and 
Ca' ), no such depletion in full-length Al) 
AMTSI3 over the 30-minute time course (not shown). To further 
asses, this loss of 
ADANITS 13, whole human plasma (containing, 
hbrinrýcen) Was supplemented with ADANITS 13 and also 5 mg/mL 
Gly-PrO-Arg-Pro-amide. to prevent fibrin polymerization and 
%uhsequent cross-linking. 
Analysis of these samples hý Western 
blotting using the anti - protease domain mAh (Figure 2C) revealed 
that wthout supplemented ADAM'l'S13, no AD: A\1TS13 vv: r, 
detected in plasma (Figure 2C. lame 1). In the absence tof 
pruCOagular, t stimulus, recd mhinanI 
ADAM I'S 13 was defected as a 
tingle hand of approximately 
200 kDa (Figure 2C, ], tile 2). 
Felllos ing a 30-111inute incubation at 37 C \k ith TF, Ca' , and 
phoSphOlipicl5. the 
intentiity of the full-length ADANITS13 hand 
was markedly reduced (Figure 
2C, lane 3). hut this was completely 
inhibited by hirudin (Figure 2C, lane 4). This implied that the loss 
of ADAMTS 
13 from plasma was mediated in part via a mechanism 
in<<rlving thrombin. 
Thrombin cleaves ADAMTS13 at several sites 
pcerulation of ADA NITS 13 by thrombin and/or FXa was consid- 
ered a possible mechanism 
fur the removal of full-length AD- 
, \til'pS13 
from plasma. Tu circum\ent the technical difficulties 
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fr; lcmcnts, \%ith the c\ce ptiun of the -10 kl); t C Icrntinul species. 
rrni; tin ct v ulcntly ; tsstuciatctl h}' tlisullitlc htmtl linkage.. 
1-0 
u It) al W . cu Iii 40 I nne 
v vr v (mills) 
B +rrr. r1. +( A 
C 
\I1\ý1111i +++ 
Ilrrudrn - 
Figure 2. ADAMTS13 is proteolyzed following thrombin generation in human 
plasma. Recombinant ADAMTS13 (final concentration 80 nM) was added to 
defibnnated normal pooled citrated human plasma (A) Thrombin generation was 
initiated by the addition of 8 pM TF, Ca, ', and phospholipids (PLs, PS/PC/PE, 
20.60.20). The amount of thrombin generated in defibnnated ADAMTS13-spiked 
plasma was monitored in triplicate in real-time by a Fluoroscan plate reader using a 
fluorogenic thrombin substrate. Readings were quantified with a standard curve 
generated in parallel. (B) Parallel plasma samples were also analyzed for AD- 
AMTS13 fragmentation. At 0.10,20. and 30 minutes. ADAMTS13 degradation was 
assessed by Western blotting under reducing conditions using an anti-ADAMTS13 
protease domain antibody. (C) Citrated whole human plasma (containing 5 mg/mL 
GPRP-amide) was incubated with either TF/PLs/Cal' (lane 1), 125 nM ADAMTS13 
(lane 2), TF/PLs/Cal' and 125 nM ADAMTS13 (lane 3), or TF/PLsJCa, ', 125 nM 
ADAMTS13, and 100 U/mL hirudin (lane 4) for 30 minutes at 37"C Samples were 
analyzed by Western blotting using an anti-ADAMTS13 protease domain antibody. 
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Western Not analysis of these Same . an)ples u. in_ the anu- 
AD: \NI TS 13 protease domain antihods revealed that under reduc- 
ing Conditions. the piotea. c domain was present within an appro- i- 
malely 28-k Da band (Figure 3C). Under nonredueing conditions 
and after treatment with thrombin, the protease domain was present 
in the approximately I50-kDa hand (Figure 3C). 
Anal}-, k of these . ample,, u>i IC the anti-msc antthods res Baled 
that an approximately 40-kDa C-terminal fragment of : \D, \\1 IS 13 
was generated after thrombin treatment under both reducing 111d 
nonreducing condition', (Figure 3D). i hi. implies that at the most 
C'-terminal cleavage Site. thrombin proteoi>ies AU: 1N1TS13 be- 
Unpaired cvsteine residue., and that the C-terminal fragment 
(containing all or most of the 2 CUH domains) i..,, no longer 
cos alently associated ss ith the rest of the ADAM TS 13 molecule. 
Time- and concentration-dependent cleavage of 
ADAMTS13 by thrombin 
InLuhaUom of ADAM I S1; %kith \aning concentration, of hum an 
thrumhin ((l. `) nA1-9(1 nNI or 0.1 IUmL - I(l U/WL. ) for 011 o6 hours, 
followed h) Western hli trine with the anti-AI)AN1TS13 pr trac 
domain antibody. revealed That AI)AMTS13 was clea\cdl hN 
thrombin in a time- and concrntrui on-dependent fashion (Figure 
3(ß) 
. 
In the presence of ü» nNI thrombin. no cleavage of the 
appruximatel)' 200-kDa 
full-length AI)ASTl'S 13 band N: u uh- 
sersed aller a I-hour 
incubation. At _' 
hours. an additional fain) 
hand of ahhroximuteI) 150 Ma became es drat and hý h hours. 
lhi. hand and a band at aphro\imcnrlr 28 k[)a sore also obtirnrd. 
lil OOD, 1 1-EL3HUAHY 7006 " VOLUME 106, NUMBEH 3 
Figure 3. Purified ADAMTS13 is cleaved by thrombin and 
FXa in a concentration- and lime-dependent fashion. 
1 'unhod ADAM I ti I'. i I"Inn oM i was incubated with and without 
9 nM thrombin tl Ii; il in 7Ii mM iris-HCI (pH 7 (1) containing 
150 mM NaCl and 5 mM Ca' at 37C for 1(3 hours Samples 
wire eleclrophoresod on a 4' to 15' polyacrylamirln qel 
undor both reducing (A) and nonreducrng ((3) condilimu, 
Inllowed by Coomassie staining I hrombin was detected as ,i 
bind of approximately 36 kDa (white arrowhead), full-length 
ADAMTS13 and its proleolytic fragments are iduntihod by 
arrows (C) Western blot analysis of ADAMFS13 with and 
without complete thrombin proteolysis (under reducing and 
nonreducing conditions) using the anti-ADAM IS 13 protease 
domain antibody. (D) Western blot analysis of ADAM I S13 
with and without complete thrombin proteolysis (under reduc- 
ing and nonreducing conditions) using the antrmyc oprtope 
antibody (E) Varying concentrations of thrombin (0 nM-90 
nM) were incubated with 250 nM ADAMTSI3 at 37"C for 0 to 
i, hours in 20 mM Tris-HCI (pH 78) containing 150 mM NaCl 
, rI 'i mM Ca"Samples were analyzed under reducing 
dilions by Western blotting using the anti-ADAM TS 13 
oloase domain antibody (F) FXa (50 nM) was incubated 
. ut" '50 nM ADAMTS13 at 37"C for 0 to 6 hours in 20 mM 
HCI (pH ; f(5 rorlowmq 1 S0 mM NaCl ant', mM C. r 
V, mg 1) nil thrombin, the rate tit AI)A\l lS13 prolculi\sis Was 
aphrceiahl\ cnhunred. Alter rml) ;O minutes. little full erteilt 
Al)AM"fSII remained. Nloieoser. the 3 major Iragmem; ruun 
hands ( 150 kl)a. Oll kl)a, and 28 kDa, respcclivels ) were 
prominent. Over lime. the high Mr hand disappeared, whereas the 
hand of appro\im: ucls 28 kIa became stronger. With 9(1 nM 
thrombin. there was complete loss of full-length AI)A11'ISI i 
"ithin 30 minutes. Interestingly. the gain in the intensil\ of the 28 
kDa hand did not necc,, sarilý reflect the boss of intensity of the 
higher Str hands. One possible cause of this might be the presence 
of . rn additional nonspecific or less fa\ oral cleavage site vc ithill file 
protease domain that with time, generated it fragment that was only 
marginally smaller than the '_$-kI)a hand. 
Gzperi H uts were also performed using I-X t. These cicmon- 
stratccl that IFNa caused AI)ANITS13 fragmentation similarly to 
that caused h\ thrombin. Iltmc\er. the rate of AI)ANII'S11 
Ix xeo I sk hk 1: \a was less titan that of thrombin (Figure IF). 
Fell at SU nil i-\a, proteoI si, of AI)A\1IS13 ssas marke llt 
ý10\kc"r than nhen') 11\1 Ihriuhin ssa. used Il kure 3111. 
Characterization of ADAMTS13 proteolysis by thrombin 
Toi further an: I\/L" : I). \\1ISI3 li; i, _mrlllaliun. 1)tItLtII Prutru 
l) led ADAMS S 13 specie. wrC %i, ualiird by \ Wen hi ttin_. As 
hetum. "c &Ieiecied either N-tcrnunus-containing (rainirnls'0lh 
[tic anti . \I)AMTS13 protease domain : ultihtul) (I i, turr "I; 11 Or 
('-ICrminus-runt; iiIli ng liacmrnl. ýýilh Ihr anti m)r unuhý, l) II: lg 
tire 4B1. In these cshrrimenls, short iniuhali0nts using limited 
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Figure 4. Identification of ADAMTS13 fragments generated by thrombin. 
Recombinant ADAMIS13 (250 nM) was incubated wilh 9 nM human thrombin at 
37 C for 30 minutes in 20 mM ins-HCI (pH 7 8) containing 150 mM NaCl and 5 mM 
Ca"', causing partial proteolysis of ADAM TS13 Samples were analyzed by Western 
blotting (A) ADAMTS13 was detected using the anli-ADAMTSI3 protease domain 
antibody ADAMTS13 (lane 1) was incubated with thrombin (lane 2) Increased 
quantities of ADAMTS13 (400 nM) were incubated with thrombin and extended 
development of blots (lane 3) (B) Probing of samples from panel A using the anti-myc 
antibody ADAMTS13 (lane 1): ADAMTS13 treated with thrombin (lanes 2.3, and 4) 
Lanes 3 and 4 represent the same sample, lane 3 contains 251. of the volume loaded 
in lane 4 (C) The predicted identities of the cleavage fragments in panel A (Frags 1-6) 
and panel B (Frags A-D) are represented The locations of the predicted cleavage 
sites are approximate Fragment boundaries and sizes were estimated from the 
molecular weights calculated from panel A and panel B The fragments generated by 
cleavage at the favored cleavage sites are shown in bold 
quantities of thrombin were emplused to Iacilitate visualitatiun of 
pro(eolytic intermediates of ADANITS 13 (Figure 41 B. lane 2). In 
addition. increased quantities of ADANITSII sere treated vsith 
thrombin and blots developed (ur extended periods to better 
identify transient proteulytic intermediates that. over time. would 
be further cleaved into smaller species (Figure 4A. lane 3: Figure 
4B. lane 4). 
Limited treatment of ADAMMTS 13 with thrombin revealed at 
least 3 protease domain-containing fragments (Figure 4A, lane 2) 
of apprOvimately 150 kDa. -10 kDa, and _'S kDa (ciesi,, nated 
Frag I. 
Fra_ 5. and Frag 6. rc; pecti\cl) ). Frag I and Frag G sere the major 
. Pccies. Ho\wevver, proteolysis urine increased quantities of AI)- 
VA1'F'S13 (Figure 4A, lane 3) indicated that at least an additional 3 
Intermediate species were generated by thrombin treatment (Fra' -'s 
2.3. and 4): the faintness of these bands. visible on the original 
blot, is suggestive of additional. yet less favvored, thrombin 
vleaval-, e sites. In Figure -4C. the approximate locations of Frogs I 
to 6 arc predicted based on their mobilities and identilieation bN the 
detecting antibodies. 
Similar analysis of C'-terminal. myc cpitope-containing liag- 
tttents (Figure 4B) reg Baled a fragmentation pattern that corrobo- 
rated and complemented the data obtained using the anti- 
ADANII'S13 protease domain antibody. The major species 
generated by thrombin were Frag A (-160 kDa) and Frag D 
(- 40 kDa). again highlighting the potential preference fr 
proteolysis at the most C-terminal and 
N-termin; tl si(es. Intere. t- 
ingi), the approximately 40-kDa ('-lernfinal Fragment that was 
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ul, urilied \v ithA I)A \i'I SII (Iurin)t it 4) I IItI1) 11 I IrI); u; IIi I1 
, null 1I he rrwlved Irntn ha", I). Ihiti nrielrt Iul1dv 11; 11 1)4)111 
Tt'k. 'r, Iit L ; IriScn yin rlrav; rgr dl HIC ýcrnrr I)IOICOk Ilk . 111v 
'vI1 I1iye silr. 
1)uc (4) (heir I, re1ictcrl 1111111 MOIrcul; u \NC (((Ii 1)(11 
n"s4)lcc Ihr 170 kl); i. I(1) LUu. and 15(1 I, Ihr Irrunrrrtls Ih; rt \cuulrl 
uncslwnrl 14 4 the (-trnninal ; (spcets ul I'rrg, -1.5. ; ill () II i); urr 
1("I. These spe irs Irh; rhly (' rip a teil is hail A. ()[It(- aj! alll. 
pIotr, IVsis of inrrr: rsril (I u; rntilirs rit ; \I)A\FlSI3 ill lir; rlrl 
4)l liti IL11 intrrmr(lialr sI)lCirs 5' !( ernrrute l Il r, iis It ; 14)d ('1. 
"'. 1) p ssihiI rcl, rrtirnling Ihr (' Irrinin; 11 purlinn 01 I lap , 
nit I'r; IC 3. : \, e; iin. (lit, location of' Ihrs( It; rerucnk I. prcJirlcd 
nI Ictnr l(' 
Proteolysis by thrombin ablates ADAMTS13 activity 
C letnlln, il Iru11, Alloll oI \I): \\1 ISI; It: ni Ihr . )); irrt cluin: un 
h: l. III C%10usis hrrn rrlu1rtCd ( AIt IIIsh Al )A\1'ISI I : IrlitI 
t). ' =' It \l oul l seem that tiler hrntrl, k sis hs Ihntnlhin, the 
hrcllrasr (10111ctin lu '1 SP S remains COVAentIN lnlarl thn uuh 
disulhhidc hllntl linkages Although : In al, pnt\inlalclt -111 kl)a 
('-terminal Ir: lt; nlcnt of AI)ANf'ISI3. C011Ilining Ihr ("1113 
I1011IM11S. 1, hroteoivlicalls ICIUO%r l [IN Ihn lnhiu. the loss 0I 
these Jtlnlains dots lilt appe ur to significantly ailed ihr 
\'\V[ clc: n inl : Irtk il} of \I)AM1'I S 13 ill slulic : 1>sa\ s.: -" 
Thus, to ascertain wilelhrr thrtllnhin cleavage iuight simull; l- 
nrl, usly abrogate . \I); \\1 IS Ii Qctiv itv, t\c clnnharrtl the ability 
ill full-length and thmmhin hruteuulý ieui Ai)AM IS 13 tut ritte 
purified human \'\\'I . 
Human \ Wl- Iva,, purled (hull lI: I, I is h\ 
crýuhrrdiplt: luun ( Iluuccrl h\ gel liltratiun (Iii'ure 5: \). Ihr 
11tH I1ritel11 Iranians elutckl 131 ('(, I dutlIt umtut The purity 
ul \'\\'F\tas assessedhý SI)5-1'A(iI:: IIIl>il\rr, IaInin (Figure 
5131. FI': tctic, ns BS to 1310 \%e1e fire of (Major eu lltaminaling 
beineins and teere Out,, used as an AI); \N1'I S13 substrate 
AI)A\ITS13 hreincuh, ited in the absence tut thrtnnhin ts: l. lull'\ 
active and generated characteristic 17(-kl): I and 1.3(I LI): I \'WI. 
hand, (Figure SC). Moreover. the intrnsity of the -15(t-kl)a 
\'\\'t: 
hand diminished user the h-hour time course. Al)A\1'I'S1 3 that 
had been pretreated s%ith thnlmhin exhibited little or no 
VWF-clea\'Itlg ailisllv'. As the V\1'I' Western blot detection 
method i, qualitative, we also r\aminc l AI)A\t P S13 cleavage 
01 b'\\'1- in a quantitative manner h\ numuluti nt Iuu of VWF 
Iunctirm with u V\\'F-C13: \ (Figure 51)) These data corroho- 
rated the \ WF fragnuntatuun result,. At h hours, the VWFF in 
sanlllles ýunlainitt AI)ANI FS 13 preincuhated tw itlioui thrombin 
c\hihited allhrn\iiuatcl 5', ' original collagen-hin ling Nell its 
clue to loss of V'\\ 1- ('unction arising from AI); A\1'1-513- 
depenclent hrutrl)s1>. In contrast, \'\\'F inruhmed with thn, m- 
hin-treated Al)ANITS13 still exhibited approximately 911'; 01 
the original i lllatirn-binding potential. 'Laken together, these 
data confirm that once hrotrnlti iecl by thrombin. ADAM IS I3 is 
to l meet able to etticirntlý cleaxe \'\\'l and so inhibit Is 
ph\ siuloi, tc I unction. 
Effect of thrombin cofactors on ADAMTS13 proteolysis 
fu Iurthcr : n. r. Ihr nature Of the interaction of thnomhin %k ith 
: \DAN1"hSI ; anal also tu exanunr the ti:; in "huch lhruinhtn- 
dcpendent , \f); \\t'I'SI3 inurti\: ition might itself he regulated or 
Ior; tliicd to the SlIC" of \: ucular injun, we ill- r, tig: ttC I the ehiect Of 
thrombin cohact(Irs t'ITl and hclruFin) on the rate of ; AI); A\t IS 
hrutr lvsis. For thee e\perinuntti, VVc hreinruhatcd 50 IN thmm 
hin Rar 5 minutes With either rcluimolar l50 nAli 0i 1h Old neolau 
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Figure 5. Proteolysis of ADAMTS13 by thrombin abolishes ADAMTS13 enzy- 
matic activity toward purified human VWF. Human VWF was purified from human 
plasma by gel filtration. After gel filtration (A), the purity of VWF in each fraction was 
assessed by reducing SDS-PAGE on a 7.5°ßo polyacrylamide gel, followed by sdve 
staining (B) Fractions B8-B12 contained VWF. visualized as a band of approximately 
250 kDa (arrow), and were free of major contaminating proteins. Only the highest 
purity VWF from fractions B8-B10 were used as a substrate for ADAMTS1 
ADAMTS13 that had been pretreated with and without 9 nM thrombin in 20 rnP9 
Tns-HCI (pH 7.8) containing 150 mM NaCl and 5 mM Ca-* for 16 hours at 37C was 
assayed for activity. Subsamples were removed at 0,1.2, and 6 hours and assessed 
by Western blotting using an anti-VWF polyclonal antibody (C). ADAMTS13 gene - 
ated characteristic VWF proteolytic fragments of 176 kDa and 140 kDa Samples 
studied in panel C were also analyzed using a functional assay based on collagen 
binding (VWF-CBA) as outlined in "Materials and methods" (D). Results shown 
SEM. in 3) 
cxcc%, ti (500 nN1) ofeither soluble rabbit TM or heparin. Thereafter. 
we examined the extent of ADANITSI3 tracmrntation over it 
hnur incubation period. 
77trumhamudulin. Preincubation of thrombin %kilh soluble 
rabbi) 1', \l markedly inhibited the ability of thrombin to proteolv /c 
ADANI1'S13 (Figure 6A). In the absence ofTý1, ýr lccrlýtiiti ýýcut 
lo near completion attel one hour of' incubation ww ith Ihrumhin. At 
III,, lime, only trace amounts of' lull-length ADAMTS 1, could he 
detected Howwevcr, \ý ith preincuhation of'thrnmhin with equine olar 
quantities of T. M. the rate of full-Iareth ADAM I'S 13 band deple- 
tion wit-, reduced. The rate at %%hich the smallest Iragmenlatiun 
build (Frag 6) was generated was also similarly impaired. As 
expeclcLl. the erect of it 
IU-fold molar c\cc» of TAI was etwa 
pronounced 
Indeed, alter it U-minute incubation \ýilh thrombin, 
HI1k)l). 1111 i10 JAIh :. nm. "VUIUMI lo,., NIIMIII fii 
rl lilllr \I ): \\I ISI I' iIlk, ni. iu, m \. i, ri ii il ui 
n I Illy lit) I \I , anti il. ; \Ii i unr II(III. r, linialr l IlwI Hiob 
IlI III >Ih . ut Ihr rrln: uning AI ): \\1 IS I 11%. i. Gill IIII Ik I. 
/1eparili. Ii (1 IiLII. tl in of Il11 mlhi11 Nk1III ryuInlnl, ii II ,I Iu 
fold 11101ar cxrr. sS of hClruin, h, (l no inllihilulY i'Iit t n Al) 
\\11'tiI fragnlrntation, by cm paiiu n I) ýittti Ir' Iarkinp 
Ilrlr, nIII l hurl (I t. III (Iced, II :I 111 lot(] r\<<',. Ihr laic ul 
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Figure 6. Cofactors of thrombin and ADAMTS13 proteolysis. Recombinant 
ADAMTS 13 1250 nM1 %as treated with 50 nM thiomb n that had been preincubated at 
37 C with either egwmolar or a 10-fold molar excess of either soluble rabbit IM (A) or 
hepann (B) in 20 mM Tns-HCI (pH 7 8) containing 150 mM NaCl and 5 mM Ca". 
ADAMTS13 Iragmentation was monitored under reducing conditions using the 
anti-protease domain antibody (A) Thrombin was preincubated with either 50 nM or 
500 nM soluble rabbit TM for 5 minutes Thereafter, the ability of each thrombin/TM 
mix to cleave ADAMTS13 was monitored at 0 minutes, 30 minutes, and t hour t me 
points. and was compared with that of thrombin alone. (B) Thrombin was preincu- 
bated with either 50 nM or 500 nM heparin and analyzed as in panel A. (C) The 
specificity of thrombin for ADAMTS 13 relative to other ADAMTS-family members was 
gauged by incubating 250 nM ADAMTS4 in 20 mM Tris-HCI (pH 7.8) containing 150 
mM NaCI and 5 mM Ca-" with 9 nM thrombin for 0 to 6 hours. Samples were 
analyzed by Western blotting using a polyclonal anti-ADAMTS4 protease domain 
antibody. 
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Specificity of thrombin for ADAMTS13 
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ADAMTS13 is rapidly proteolyzed and inactivated by plasmin 
"(hnnnhin and I \: r : rrr crncr: ued rapidl\ at Ihr >itr of %: scular 
injure, Ilowcvcr. other protrases are also, locally activated lo11ow- 
ing initiation of cc :r elation that might also influence AI). \\I IS 13 
function. Wr rvrniinrd the susceptibility of AI)AMI'SII to 
rlraý: r! c and inrrliVuti0m by rla. min. I ulluww ing limited I)mteoly- 
sis of ADAM IS 13 (`) uM plasmin for 30 minutes: Fiume 7A), 
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Figure 7. Proteolytic inactivation of ADAMTS13 by plasmin. Recombinant 
ADAMTS 13 (250 nM) was incubated with 9 nM human plasmin in 20 mM Tris-HCI (pH 
7.8) containing 150 mM NaCl and 5 mM Ca2' at 37'C for 30 minutes, causing partial 
proteolysis of ADAMTS13 (A) 
Samples were analyzed by Western blotting using 
either anti-ADAMTS 13 protease 
domain (lane 1) or anti-myc epitope antibodies (lane 
2) The rate of plasmin-dependent ADAMTS13 proteolysis was assessed by 
incubating varying concentrations of plasmin 
(0 nM-90 nM) with 250 nM ADAMTS13 
at 37`C for 30 minutes to 6 hours (B) 
Samples were analyzed under reducing 
conditions by Western blotting using the anti-ADAMTSI3 protease domain antibody. 
To assess the effect of plasm in proteolysis on ADAMTS13 function. ADAMTS13 was 
pretreated with or without 
9 nM plasmin for 16 hours at 37"C and thereafter assayed 
for activity by 2 methods, as outlined in "Materials and methods. " Subsamples were 
removed from each assay at 
0.1,2,4, and 6 hours and assessed by Western blotting 
using an anti-VWF polyclonal antibody 
(C). ADAMTS13 generated characteristic 
VWF proteolytic fragments of 176 kDa and 140 kDa that were visualized after 1 hour 
and increased 
in intensity over the 6-hour time course. There was also a concomitant 
decrease in the intensity of the 250-kDa 
VWF band. Analysis of VWF function as in 
Figure 60 using a VWF-CBA (D). Results shown " 
SEM. in - 3). 
AI)AMI!; 1.1IF (1)1 Al N IY IIIHOM13IN 101) 1 
\l): \\1'IS Ii to IIiit t, h. rnr(I Io I I)i 11c )I\ v' I)\ IhnmIhin (I ipIII r 
l: \ 131. inn'itl ill \\ilh i(' 1111111M '11W6111.11 \ Fiu rlcan; I)'t" ; illri 
trrl; iin ; uuillinc rrýi lur.. IIti c 'cr. hl; itimin ; ilsn LIL' i (' , iltrr 
I) inr. %%hiL11 hulrnti; ill\ r\l)lain" (lit- I)rr, (-ncc ul aIII, In; ili\I, 
\1): \N1TSI3 Iratnirn(v. OI Itvtiiuly inICIC. l %kuti Ihr . ibhliuun; il 
rlr; l\ igc "ur in ihr IbntirdSC t10111,611 (hill (. rnrrur(I I: r; ig It7 I'hiN 
Iricinrnl \k. i. 1101 irnrrurtl h\ Ihmnihill. P1,001111) rlr; nr I : \I 
AM IS13 mitrr rapidlý Ih; in Ihn nihin lit inl, vr I iguic 711 and 
I: iCurr 3. rrtiItrclicrl, ). IIHICCil. ;u (1. ') IINI Itln VIII, hull length 
: \U: \NlIS13 \ýa,, rpidlý (IcIletedl/poleolvied 'Flic ellcrl ul 
hl; tsmill IirulrulY,, i,, on ; \l)AN1'FSI3 activity 'Ail" as r' eh using 
pur cd hum. ul V WF. it,, hrlrr. I'rrlrcalmrnl of r\I)ANTFS 13 \% ich 
hla'niin had the . mine Alec( oll V\1'I' cleaving aOOI\it\ as ill(] 
thrombin. No hmlcolvsii of VW1 hr I I; nnlin hicated Al): \M1Iti 13 
%%, a,, detected hý Western blotting 11"iiurr 7('). I ur(hcrnlurc. (uil, \a 
, mull reduction in VWI -('11A \+a,, in hlatimin ur; ilcd 
sample,. whereas untreated Al). \\il'ti13 generated Lhiirictrristic 
\'\VI clr; i\ IIC Products and rihidll abolished the VWl- collagen- 
binding acli%ity (Figure 71)(. 
Discussion 
III this , tu h. sý: addressed ho%% : \I): \\FFSI3 mil-hl lx' Icgulaie I Fu 
(late, no specific protease inhlhitor ha, Ix"rn Rtrntifirdl IItat nti911111 x"; rlIC 
and restrict Ihr known role of AUA\fI S 13 activ'hs in the prc\ canon it 
unwanted \'WI adherence and platelet aggregation t the m(act 
endothelium. The absence of a specific itthihiloa V. as considered 
, urhri, inv m sieis of the crucial role pla)cd by inhibitors in regtilatmt 
pr teases that participate in nunnal hero stasis. A single rclx, lt has 
implicated interletikin ( a, a Ixoihle regular r ýýI ; \I): \\FI S I?: him 
cwt-. the rnechanl, nt for this : out its , ienilicanrr in nrmn: rl ; \I ): \\FI S I? 
regulation remain unrrrtain. 'r Accordingly. ise have inscsiu ; tied rnHc- 
olý, u IN a reguLUUr\ mechanism. 
We have , pus+n the rapid disappearance of full-length recumhi 
n; uu ADAM IS1i from delihrinatedI human planar in is hielt 
thrumhin generation had been initiated (Figure 2). One explanation 
for this \s a, the proteol) tic depletion of : \DANITS 13 by it 
component of the coagulation cascade. Further e idence tier this 
was pro i ed1 using \N hole plasma. in which the depletion of' 
full-length Al). \\1I'S13 tit, inhibited h\ hirudin. Thereafter. we 
confirmed that in vitro lo%% concentrations (it' IhnmiMn cleave 
huritied ADAM'I'S 13 art several site. I Figure, z and l I, but Jac. riot 
eirare : \D: \\1FS4 (Figure 6). Interestingly. I: Xa cleaved AD- 
AMTS 13 ssitI Ia \cry similar Irapnentation pattern Io that of 
thrombin. Ilossever, F\a hmteolviccl Al)\\1FS13 appreciahlý 
slower. As thrombin is more active against AI)ANI ISI; and given 
that the local ýunccntratiun, of thmntbin that are generated in \i\o 
inv'ariahlý exceed those o F\a. the prolrolv, i, of AI), \\lTS 13 hý 
thrombin is more liked} to he ref hh\, iol rgic importance. 
It %%a, apparent that the proteoli, is of AI), \\ITS 13 by thrombin 
occur, prclcrrntiall) at 2 sites (Figure 3). The lira appear, to he 
located close to the engt (, I the protease domain ant the second. near 
to the start of the first ('113 domain. : \I): \\1'I'S13 fragments 
generated by cleavage at these , irr, %\rrr rapidly generated. With 
the exception of the most (" terminal site. thrombin clea\rd at site, 
located b tween paired c ste ne residue,. Thu, after proteolysis. 
the resulting AU: \\1IS13 cleavage tragmrni, retrial', covalrntlý 
associated. %\ith the exception of the approxtlnalely 40 1, Ua 
C-terrninal ('l'ki domain-containing region (Figure 3). 
The physiologic relesaitce of hroteol* Oc Irmo sal of (lie CUB 
domains. located at the ('-temtintu of ADAM'S 13, i-, uncertain. These 
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domains are not required for VWF-cleaving activity measured under 
static conditions. 23,24 Moreover, certain strains of mice have been 
identified that express an ADAMTS13 variant that lacks the CUB 
domains (and also TSPI-7 and TSPI-8), 27 further suggesting that the 
functions of these domains are not critical in vivo. Although auto- 
antibodies against the CUB domains have been found in patients with 
acquired TTP, 28 it is unclear whether these compromise ADAMTS 13 
function. The recent study reporting that CUB domain-derived peptides 
inhibit VWF-cleaving activity under flowing, but not static, conditions 
might, however, imply a potentially important functional role to these 
domains. 29 This latter finding suggests that removal of the CUB 
domains by thrombin might further contribute to ADAMTSI 3 inactiva- 
tion in vivo. Further studies are now required to determine the precise 
cleavage site and physiologic effect of the protcolytic removal of the 
CUB domains. 
ADAMTS 13 is secreted into plasma, where it circulates as an 
active enzyme. At sites of endothelial disruption, VWF binds 
collagen and unfolds in response to shear forces. This in turn 
facilitates platelet tethering-critical for efficient platelet plug 
formation. If ADAMTS13 were to have no specific inhibitor, its 
VWF-cleaving activity would be predicted to oppose the essential 
tethering of platelets once the scissile bond in VWF is exposed by 
rheologic forces. The data presented here suggest an effective 
regulatory mechanism in which ADAMTSI3 could be proteolyti- 
cally inactivated by thrombin at sites of vascular perturbation, even 
at the low thrombin concentrations observed during the 
initial lag 
phase of coagulation. During initial platelet plug 
formation, 
platelets adhere to VWF and then exposed collagen. 
However, 
although this first platelet layer might resist ADAMTS 
13-mediated 
VWF cleavage/platelet release due to its tight association with 
collagen, subsequent layers of platelets will be more remote 
from 
collagen. In vivo imaging of thrombus development 
in mice has 
demonstrated that thrombin activity/fibrin deposition are generated 
very rapidly (within 20 seconds) after vascular 
injury. 30 Interest- 
ingly, this study also reveals the "blebbing-off' of tethered platelets 
from the back of the developing thrombus prior to thrombin 
generation/fibrin deposition. This observation might 
be explained 
by or correspond to the action of uninhibited ADAMTS 13 on 
VWF-bound platelets and highlight a need for local ADAMTSI3 
inactivation at the site of injury. 
Thrombin has multiple physiologic substrates and roles 31.2 
Following the initiation of coagulation, thrombin confers its 
prothrombotic activity by cleaving fibrinogen, 
feedback activation 
of up-stream clotting factors, and the activation of tethered 
platelets. 33 Together, these functions promote rapid thrombus 
formation. We now propose a model describing a novel procoagu- 
lant function for thrombin. Uniquely, this involves the inactivation 
of an enzyme (ADAMTS 13) to promote thrombus growth, as 
opposed to its well-characterized roles in activation of protease- 
activated receptor (PAR) molecules and clotting factors V, VIII, 
X, 
, XI, and 
XIII. 32 Recently, several studies have attempted to impli- 
cate moderate ADAMTSI3 deficiency in the pathogenesis of 
certain thrombotic disorders 
34.36 Our data suggest that reductions 
in ADAMTSI3 activity might arise as a result of increased 
thrombin-dependent inactivation during the course of a thrombotic 
event. Therefore, additional studies are now required to ascertain 
BLOOD, I FEBRUARY 2005 " VOLUME 105, NUMBER 3 
whether partial deficiency of ADAMTSI3 is a primary cause, or 
merely a consequence, of thrombosis. 
Physiologically, the activity and specificity of thrombin is modu- 
lated, in part, by cofactors. Competition between cofactors for exosite 
binding have been proposed as a mechanism for directing the activities 
of thrombin. » In binding TM, the specificity of thrombin toward 
fibrinogen, protein C. and PAR molecules is dramatically altered. -18 This 
serves to restrict its pmcoagulant activities to the site of vascular injury. 
This effect is partly due to the occupancy of exosite Ion thrombin with 
TM 39 We found that if thrombin was preincubatcd with TM. its ability 
to protcolyze ADAMTS13 was appreciably compromised (Figure 6). 
This might therefore implicate exosite I as a possible site of interaction 
with ADAMTS13. As preincubation of thrombin with heparin had no 
effect on the rate of ADAMTS 13 cleavage, it seems unlikely that exosite 
III on thrombin plays a significant role in its interaction with AD- 
ANITS13. Interestingly. there seemed to be a slight enhancement of 
ADAMTTS 13 proteolysis by thrombin in the presence of a 10-fold molar 
excess of heparin. This might be attributable to the bridging of thrombin 
and ADAMTSI3 by heparin but further investigation is required to 
confirm this contention. 
While examining the susceptibility of ADAMTS 13 to proteoly- 
sis by coagulation proteinases, we found that plasmin cleaved 
ADAMTS 13 at a faster rate than thrombin, and gave a similar, but 
not identical, fragmentation pattern. Physiologically, plasmin is 
generated following thrombin-dependent fibrin deposition and 
mediates fibrinolysis 4' Plasminogen activators bind to fibrin as it is 
deposited. Consequently, given the sensitivity of ADAMTSI3 to 
proteolysis at low plasmin concentrations (Figure 7), such cleavage 
might also be of physiologic importance with respect to the 
modulation of ADAMTS l3 activity at sites of hemostatic plug 
formation. Proteolysis of ADAMTSI3 by plasmin might also 
suggest a role for VWF in tissue repair. Postinjury vessel regenera- 
tion is associated with plasmin activity. If this process should also 
involve a role for VWF, plasmin-dependent ADAMTS 13 inactiva- 
tion during tissue repair might serve to maintain VWF function. It 
is interesting to note that whereas plasmin proteolytically activates 
several different prometalloproteinases, 42 it uniquely has an inacti- 
vating role against ADAMTS 13. 
Together, our data provide a plausible mechanism by which the 
thrombin-dependent inactivation of ADAMTS 13 might be specifi- 
cally localized to the site of hemostatic plug formation. Whereas 
thrombin (and plasmin) might rapidly inactivate ADAMTSI3 at 
the site of vascular injury (and so favor platelet aggregation), on the 
surface of the adjacent uninjured endothelium, any thrombin would 
preferentially bind to TM. Consequently, thrombin-dependent 
ADAMTSI3 proteolysis would be inhibited. ADAMTSI3 activity 
in this location would serve to limit platelet aggregation from 
spreading beyond the site of injury. 
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ADAMTS13 controls the multimeric size of circulating von Wil- 
lebrand factor (VWF) by cleaving the Tyr1605-Metl606 bond in the 
A2 domain. To examine substrate recognition, we expressed In bac- 
teria and purified three A2 (VWF76-(1593-1668), VWF115- 
(1554 -1668), VWFA2-(1473-1668)) and one A2-A3 (VW F115-A3- 
(1554-1874)) domain fragments. Using high pressure liquid 
chromatography analysis, the initial rates of 
VWF115 cleavage by 
ADAMTS13 at different substrate concentrations were deter- 
mined, and from this the kinetic constants were 
derived (K, 
 
1.61 
gLM; kk 0.14 s-1), 
from which the specificity constant kc, IIK,  was 
calculated, 8.70 x 104 M-1 s-'. 
Similar values of the specificity con- 
stant were obtained 
for VWF76 and VWF115-A3. To identify resi- 
dues important for recognition and proteolysis of VWF115, we 
introduced certain type 2A von Willebrand disease mutations by 
site-directed mutagenesis. 
Although most were cleaved normally, 
one (D1614G) was cleaved -8-fold slower. 
Mutagenesis of addi- 
tional charged residues predicted to 
be in close proximity to Asp' 614 
on the surface of the 
A2 domain (R1583A, D1587A, D1614A, 
E1615A, K1617A, E1638A, E1640A) revealed up to 13-fold reduc- 
tion in kcatlK, for D1587A, 
D1614A, E1615A, and K1617A 
mutants. When 
introduced into the intact VWFA2 domain, prote- 
olysis of the 
D1587A, D1614A, and E1615A mutants was also 
slowed, particularly 
in the presence of urea. Surface plasmon reso- 
nance 
demonstrated appreciable reduction in binding affinity 
between ADAMTS13 and VWF115 mutants 
(KD up to -1.3 µM), 
compared with 
VWF1 15 (KD 20 nM). These results demonstrate an 
Important role for Asp1614 and surrounding charged residues 
in the 
binding and cleavage of the VWFA2 domain 
by ADAMTS13. 
Von Willebrand factor (VWF)2 is a large multimeric plasma glyco- 
protein that mediates tethering and adhesion of circulating 
platelets at 
sites of vascular 
injury (1). Following endothelial damage, plasma VWF 
binds to the exposed sub-endothelial collagen (2). Once immobilized, 
the shear forces of the 
flowing blood induce a conformational transition 
that unravels the VWF molecule 
(3). This in turn exposes the binding 
sites for glycoprotein 
(Gp)lba, part of the Gplb-IX-V receptor on the 
surface of circulating platelets 
that confer platelet-tethering function 
(4). Once tethered, platelets become activated and subsequently present 
Gp11b/IIIa on their surface, which makes a tighter, more stable interac- 
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tion with both VWF and fibrinogen. Activated platelets provide the 
phosphatidylserine-rich surface critical for the assembly of the proco- 
agulant enzyme complexes that lead to the generation of thrombin (5). 
VWF is expressed by endothelial cells and megakaryocytes (6). It Is 
synthesized as 250-kDa monomers, which undergo intracellular proc- 
essing-glycosylation, multimerization, and propeptide removal-that 
leads to formation of mature VWF multimers (7). Although much of 
endothelial VWF is constitutively secreted into the blood as multimers 
of varying size, a proportion is stored either within Weibel- Palade bod- 
ies in endothelial cells or within a-granules in platelets (8). These stored 
pools, which can be released upon specific stimulation, contain predomi- 
nantly hyper-reactive "ultra-large" VWF that can exceed 2X 10° kDa. 
A wide range of VWF multimers (500-20,000 kDa) are found in 
normal plasma that differ only by the number of constituent VWF units. 
The largest VWF multimers unravel more readily in response to shear 
forces and contain more platelet binding sites. These species therefore 
confer the greatest hemostatic potential. The size of plasma VWF, and 
thus its platelet-tethering function, is regulated to prevent aberrant/ 
spontaneous platelet-rich thrombus formation. VWF multimeric size Is 
modulated by the plasma metalloproteinase ADAMTS13, which 
cleaves at a single site in the VWF A2 domain between Tyr160S and 
Met" (9). This proteolysis can only proceed once VWF has been 
unraveled, either by rheological forces or in vitro In the presence of 
denaturants, both of which induce the exposure of the A2 domain scis- 
sile bond (10). Physiologically, this occurs upon VWF secretion from 
endothelial cells, limiting the thrombogenic potential of newly secreted 
ultra-large VWF by converting it into smaller multimeric forms (11). 
The nature of ADAMTS13 recognition of the A2 domain is poorly 
understood. In part, this is because of complex folding and interdepen- 
dence of the Al-A2-A3 domains. This has been illustrated by proteoly- 
sis studies conducted with isolated domain fragments and certain VWF 
mutations that confer type 2A (group 11) von Willebrand disease (VWD) 
(12-14). The latter are proximate or within the A2 domain and manifest 
enhanced ADAMTS13-dependent VWF proteolysis. This Is thought to 
be because of structural changes that lead to constitutive/enhanced 
exposure of the A2 domain cleavage site (15). 
Because of the uncertainty surrounding A2 domain recognition 
mechanisms by ADAMTS13, we have prepared both wild-type and var- 
iant A2 domain fragments that span the Tyr"-Met" cleavage site. 
For the first time, the cleavage of these by ADAMTS13 has been evalu- 
ated kinetically under normal physiological ionic conditions. We show 
that critical residues in the vicinity of the cleavage site are required for 
optimum cleavage and form part of an ADAMTS13 docking site within 
the A2 domain. 
EXPERIMENTAL PROCEDURES 
Expression and Purification of Recombinant ADAMTS13 and VWF 
Fragments-Recombinant human ADAMTS13 with a C-terminal Myc/ 
His, tag was expressed and purified as previously described (16). For 
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FIGURE I Purification of recombinant VWF76, 
VWF115, VWFA2, and VWF11S-A3. A, diagram 
of the VWF Al AZA3 domains. Al and A3 each con- 
tain paired cyst eines, which are marked as are the 
amino acids at the boundary of each domain. 
Major ligands for each domain are highlighted. 
The ADAMTS13 cleavage site (V...... W) lies in 
the middle of the A2 domain. Labeled arrows rep- 
resent the recombinant VWF fragments (VWF7ti, 
VWF115, VWFA2, and VWFIl5-A3) expressed in 
E. eoli. All had an N-terminal polyhistidine/Xpress 
epitope tag. The VWF numbering of each sub- 
strate is given. In VWF115-A3, the 2 adjacent cys 
feine residues at 1669 and 1670(") were mutated 
to alanme. B, purification of VWF76 from cytoplas- 
mic fraction extracted from transformed Rosetta 
E. coll Chromatogram of VWF76 purification is 
shown. The eluted peak (1) was analyzed by SDS- 
PAGE and Coomassie staining. VWF76 was visual- 
ized as a single 12.5-kDa band, corresponding to 
its predicted mass. C, purification and refolding of 
VWF115 from inclusion body fraction extracted 
from transformed Rosetta E. coll. Inclusion bodies 
were solubilized with 8v urea and refolded on a 
nickel-chelating column using an 8-0 M urea lin- 
ear gradient. Chromatogram of VWFI 15 purifica- 
tion is shown. The eluted peak (1) was analyzed by 
SD5-PAGE and Coomassie staining VWF115 
migrated as a single 16 9-kDa band corresponding 
to its predicted mass. D, purification and refolding 
of VWFA2 
from bacterial inclusion bodies. Inclu- 
sion bodies were solubilized with 8M urea and 
refolded as 
for VWF 115. Chromatogram of VWFA2 
purification is shown. 
The eluted peak and 
stripped peaks 
(1) were dialysed and soluble mate- 
rial combined and analyzed 
by SDS-PAGE and 
Coomassie staining. As predicted, VWFA2 
migrated as a 26.9-kDa 
band. E, purification and 
refolding of 
VWFI 15-A3 from Rosetta-Gami V. cols 
inclusion 
bodies. Insoluble material was solubi 
trzed and purified as for VWF115 and VWFA2 The 
eluted peak 
(1) and peaks stripped with 6M guani 
dine/EDTA (2/3) were dialysed into 20 my Tris (pH 
7.8). The eluted peak (1), soluble stripped fraction 
(2) and insoluble precipitate after 
dialysis (3) were 
analyzed 
by reducing (R) and non-reducing (NR) 
5D5-PAGE and Coomassie staining. Under non re 
during conditions, soluble VWF 115-A3 in I anr, 
was visualized as a single 
38.6-kDa band cony 
sponding to 
its predicted mass. Correctly folded, 
monomeric 
VWF 1 15-A3 was obtained within frac 
tons 1 and 
2. The presence of the disulfide bond 
was demonstrated 
by the band shift seen under 
reducing conditions. 
The insoluble precipitate 
contained predominantly 
VWF I 15 A3polymers of 
higher molecular mass (3-NR). 
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surface plasmon resonance 
(SIT) and kinetic analysis experiments, an 
additional gel 
filtration step, using a Sephadex 26/10 column (Anter- 
sham Biosciences), was employed to obtain 
higher purity ADAMTS13. 
The coding regions fier different V\\'F A domain fragments (\'\\'F76, 
Scr'-")'-Arg"""; \'\\'Fl15, Glu'""''-Arg""; \'WFI15-A3, Glu''''- 
Glu'"-'; \'\X, FA2, Met"-'-Arg 
. '"'x) were PCR amplified from the 
human \, \X F cl)NA using Pfx high fidelity DNA polymerase (Invitro- 
gen) according 
to the manufacturer's instructions. Fragments were 
cloned 
into the bacterial expression vector pETI(x)/l)-TOP() (Invitru- 
gen), which 
fuses a His,, and Xpress epitope tag to the N terminus of 
cloned sequences. 
As the %AVF A3 domain contains two disulfide 
bonds, the adjacent paired cysteines at positions 
1669 and 1670, at the 
, tart 
f the A3 domain, were imitated to alanine using the QuikChan :r 
XL kit (Stratagenc). I his approach improved yields of VWFI 15 A3 and 
ensured that the conserved A domain disulfide bond between C ys'I'"^- 
Cys" was correctly paired. Certain type 2A VW1) mutations 
(8159 \X', R1597Q, D1614G, 11628T, G1629R. E1638K) and specific 
charged residue substitutions (R1583A, 1)1587A, I)1614A, E1fil5A, 
K161-A, E1638A, E1640A) were introduced into \'\\'Fl 15 and \'\C'FA2 
sequences using the QuikChange XI. kit (Stratagenc). All vectors were 
verified by sequencing. 
\'WI-76, \'\C'F1 15, and VWFA2 constructs were expressed in Rosetta 
Eschericlrin cnh cells (Novagen, Nottingham, UK). \'WFI IS A3 % as 
expressed in Rosetta-Garni E. cull (Novagen), which allows cytoplasmic 
disulfide band formation. I ransformed bacteria were grown in 2X yeast 
trvpt(inc riiltinr, at 37 C with shaking. Once in log phase growth. 
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recombinant protein expression was induced with 1 mm isopropyl-ß- 
o-thiogalactoside for 16 h. Bacteria were harvested, and soluble (cyto- 
plasmic) or insoluble (inclusion body) fractions were prepared using 
BugBuster reagent (Novagen). Recombinant His-tagged proteins were 
purified on an AKTA FPLC (Amersham Biosciences) using Nie -Hi- 
Trap-chelating columns (Amersham Biosciences). VWF76 was purified 
from the soluble fraction according to the manufacturer's instructions 
and eluted with 500 mm imidazole. VWF115-A3, VWF115, and 
VWFA2 inclusion bodies were solubilized In 8M urea/20 mm Tris-HCI 
(pH 7.8)/50 mm imidazole and bound to the Ni'+-chelating column. 
Protein refolding was achieved using an 8-0 M urea linear gradient (1 
MI/min for 40 min). Refolded, soluble material was eluted with 500 mm 
imidazole. Misfolded, precipitated protein was stripped from the col- 
umn with 6M guanidine/0.5 M EDTA. All recombinant proteins (eluted 
and stripped) were dialyzed into 20 mm Tris (pH 7.8) overnight at 4 °C. 
For VWFA2 and VWFl15-A3, the stripped material was refolded by 
this process. Thereafter, soluble and insoluble protein fractions were 
separated by centrifugation. The purity of each recombinant protein 
was assessed by SDS-PAGE and Coomassie staining and quantified 
using a BCA total protein assay kit (Perbio, Cramlington, UK). 
Cleavage of VWFFragments by ADAMTS13-For time course reac- 
tions, recombinant ADAMTS13 (final reaction concentration 5-16.5 
nm) was preincubated without substrate at 37 °C for 30 min in reaction 
buffer (final reaction concentrations 20 mm Tris, pH 7.8/150 mm 
NaCI/5 mm CaC12). In preliminary experiments, VWF76, VWF115, 
VWFA2, or VW F115-A3 were added as final concentrations of 4-8 Am 
to start each reaction. For analyses of the intact A2 domain, reactions 
were performed in the presence and absence of 1M urea. At 
different 
time points, 65-µl sub-samples were removed and stopped with EDTA. 
15 Al were analyzed by SDS-PAGE (16.5% Tris-Tricine gel; Invitrogen) 
and Coomassie staining. The remaining 50 Al were analyzed 
by HPLC. 
Samples were loaded on a BioBasic C4 column (Thermo Electron, Run- 
corn, UK), and the full-length and cleaved peptides were eluted/re- 
solved using a specific acetonitrile gradient 
(20-55% for VWF76, 
25-45% for VWF1 15,25-60% for VWFA2,20-65%for VWF115-A3). 
Mass spectrometry or N-terminal sequencing (Alta Bioscience, Edgbas- 
ton, UK) was performed to identify the polypeptide in each eluted peak 
and establish the precise site of proteolysis. 
For the determination of the 
specificity constant, low substrate concentrations 
<Km were used 
(250-500 nm substrate/5.5 nm ADAMTS13). Unicorn analysis software 
was used to calculate the areas under the peaks of the 
full-length and 
cleaved fragments. The measure of the catalytic efficiency, 
k 
., 
IK was 
determined using Enzfitter software by fitting the data to Equation 1 
-In(1 - [AP]l[APf]) kcal/Km ° 
et 
where LAP] is the area under the cleavage product peak I curve at time 
r, (APf] is the area under cleavage product peak 1 curve after complete 
cleavage, eis ADAMTS13 concentration, t 
is time. For individual deter- 
mination of the K, , 
V,,,, 
x, and 
k, 
A,, the 
initial rate of proteolysis of 
vWF115 (after 5-10 min) was measured at varying substrate concen- 
trations (100 nht-50 µm) as outlined above. 
Data were transformed into 
Michaelis-Menton and Lineweaver-Burk plots, and the catalytic con- 
stants were 
derived using Prism 4 software (GraphPad, San Diego, CA). 
Surface Plasmon Resonance-SPR, using a dual flowcell BlAcore X 
biosensor system (BlAcore, Eyeworth, UK), was employed for analysis 
of the interaction 
between ADAMTS13 and different VWF1 15 variants. 
Two different SPR approaches were used. In each case, the surface of a 
carboxymethylated 
dextran (CMS) sensor chip (BlAcore) was activated 
with 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and 0.1 M 
N-hydroxysuccinimide, according to the manufacturer's instructions, 
First, -600 response units of wild-type or variant VWF115 was 
covalently immobilized by amine coupling to one flow cell. To control 
for nonspecific binding, 600 response units of human endothelial pro- 
tein C receptor was immobilized onto the other flow cell. All free reac- 
tive surface groups on both flow cells were blocked using 1 tit ethanol- 
amine. Different concentrations (10-137 nm) of ADAMTS13In HBS-P 
buffer (BlAcore) were Injected over both flow cells at 30 µl/min, contact 
time 1-2 min. After each injection, any bound ADAMTS13 was 
stripped with 10 mtit NaOH prior to subsequent injections. Data anal- 
ysis was performed using the BlAevalutaion software 3.0 (BlAcore), 
which allowed determination of kk, kd, and Ko values by fitting the 
derived sensograms to 1: 1 Langmuir model. For the second approach, 
-8000 response units of ADAMTS13 or anti-endothelial protein C 
receptor antibody (control) were immobilized to respective flow cells of 
CM5 chips, as above. Various concentrations (80 nm-1 Am) of VWF115, 
or VWF115 variants, in HBS-P buffer (BlAcore) were injected over both 
Clow cells at 30 , u1/min. The chip surface was regenerated with 10 mm NaOH as before. Using this approach, data were analyzed using a het- 
erogeneous ligand (parallel reaction) model. 
Modeling of VWFA2 Domain-The VWF A2 domain was computer 
modeled using its sequence homology to the VWF A3 domain and the 
coordinates for the crystal structure of this domain (Protein Data Bank 
code latz_A), according to the method outlined by Sutherland et al. 
(17). Models were manipulated using Protein Explorer (www. molvis. 
sdsc. edu/protexpl/frntdoor. html), 
RESULTS 
Purification of Recombinant VWT Fragments-Different human 
VWF A2 domain substrate fragments (Fig. 1A) were expressed in, and 
purified from, bacteria. VWF76 was purified from the soluble, cytoplas- 
mic fraction by Nie+-chelating column affinity chromatography (Fig. 
IB). SDS-PAGE and Coomassie staining demonstrated a purified prod- 
uct of 12.5 kDa. VWF115. VWFA2, and VWF115-A3 were purified 
from inclusion body preparations. Refolding of these proteins was 
achieved using an 8-0 M urea linear gradient during purification. This 
technique produced high yields of soluble VWF115 and VWFA2 of the 
correct predicted size (16.9 and 26.9 kDa, respectively) that were essen- 
tially pure (Fig. 1, C and D). VWF115-A3 was initially purified and 
refolded similarly. However, after elution a relatively low yield of soluble 
material was purified (Fig. 1E, lane 1). The precipitated protein was 
stripped from the column and refolded by dialysis, yielding higher 
amounts of soluble material (lane 2) than the on-column refolded prep- 
aration. The eluted material and the refolded/solubilized stripped frac- 
tion obtained after dialysis contained a product of 38.6 kDa (lanes ! NR 
and 2NR). The presence of the disulfide bond between Cyslbs6 and 
Cys1872 was confirmed by the band shift upon reduction of this material 
(lanes 1R and 2R). The insoluble material after dialysis contained 
VV(/F115-A3 polymers arising through intermolecular disulfide bond 
formation (lane 3) and was discarded. 
Proteolysis of VWF76, VIVF115, and VWF115-A3-To first visualize 
the capability of ADAMTS13 to proteolyze each of the recombinant A2 
domain fragment substrates, recombinant ADAMTS13 was incubated 
at 37 °C with either VWF76, VWF115, or VWF115-A3 in the presence 
of physiological concentrations of Ca2+ and NaCl. Sub-samples were 
stopped between 0 and 6h and analyzed by SDS-PAGE and Coomassie 
staining to give a qualitative assessment of each reaction (Fig. 2, A-C). In 
each case, only the full-length substrate band was visible at 0 
h. There- 
after, the intensity of this band diminished and two smaller cleavage 
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FIGURE 2. Analysis of VWF76, VWF1 15, and VWF115-A3 proteolysis by ADAMTS13. 
VWF76 (A), VWF 1 15 (B), and VWF 115-A3 (O were incubated with ADAMTS 13 as outlined 
under "Experimental Procedures. " At various time points 
(0-6 h), sub-samples were 
stopped with EDTA and analyzed by SDS-PAGE/Coomassie staining and 
by HPLC, using 
a BioBasic C4 column. In each case (A-Q, both techniques resolved the 
full-length sub- 
strate from the two cleavage products generated 
by ADAMTS1 3 proteolysis. Using the 
area under peak 1 as a measure of the extent of substrate proteolysis, this technique 
enabled quantification of the extent of proteolysis at each time point. 
product bands appeared. In each case, these bands corresponded to the 
predicted molecular masses of fragments generated following cleavage 
at the '1yrý"" Mets"ýx' bond. N-terminal sequencing was performed 
Upon the smallest cleavage product and confirmed that proteolysis had 
occurred between the Tyr'`'"`-Met"'r"' bond. Visually, VWI-76, 
V\XWF115, and V\VFI 15-A3 appeared to he proteolyzed by ADAM'FSl3 
at similar rates. Parallel samples were also analyzed by HPLC. The res- 
olution of the full-length substrate from the two cleavage Iragments 
(peaks I and 2) arising from proteolysis (Fig. 2) of each different sub- 
strate allowed precise quantification of the extent of' cleavage at each 
time point, confirming that the rates of proteolysis of V'WF76, VWF11.5, 
and V/WFI l5-A3 were, as indicated by the Coomassie staining, very 
similar (not shown). 
'Fo confirm specific proteolysis by rADAM'1'S13 and to identify each 
peak, cleavage product 
fractions were collected and analyzed by mass 
spectromet ry. For all substrates, peak I corresponded to the tagged 
, 4-terminal cleavage product up to Tyr""'. Peak 2 corresponded to the 
C_terminal fragment, in each case starting at Met"'"' 
I tic 2.1 l' ll OM ntalrwr, aurl AI ): 1,117.5l. i I'rvh'uut crs' -Ihr so ititiile 
bond in V\VF is predir fed from it homology model (17) try he located in 
the center oft it folded A2 domain (Fig. 3A). Given that V\VI is the uuly 
known substrate for ADAM I'S13 and that it is pruteolyzcd at just it 
, inl; le site, we hypothesized that rýthrr A2 domain aniinýr acids that flank 
this site dictate the specificity of AI)AM'I'S1: 3 lilt the 10(15-1000 bond. 
As an initial step toward identifying A2 domain residues that intlurnrr 
V'\C'I protcolysis, we Individually m(roodul cd six type 2A V\VI) muta 
lions (. see www. shetficld. a( . uk/vwf/) 
into the V\VF115 construct (Fit;. 
3A). 13y mutating V\VPI I5, which unlike the intact A2 domain natrirally 
adapts a cunf matiun that is permissive to ADAM I SI3 prutculvsi. s, 
the influence of specific mutatiun. s upon suhstiat ' tipcr ificity (as 
Opposed ter effects upon overall A2 domain structure) could hr assessed 
under physiological i<mic conditions. H ITC analy.. is of the prutrolysis 
of \ \Vl'1 15 and V\VF1155 type 2A mutants (RI5Y7\V, 1%1 59IQ, 
I)161'10,110281, Glh29R, and h1638K) demonstrated that moist of 
these mutations (Rl597\V, R15970, I10281', and 010298) had little or 
nu effect upon V\VF115 pruteulysiS (1 11-1.313). However, the 11 038K 
mutant was protcoIyzed slightly slower than VW IF 15. and It II I)I0I4( 
mutant was cleaved -8 times slower (Fit;. 313). As (. ilu""8 and Asp'" 
are charged residues that arc predicted to be located in ehcse pruximily 
to each other on the surface of the V\X'I' A2 domain homology model, 
ve hýputhesiied that such residues might comprise part tit an 
AI )AM'l S13 interaction 
. site. 
Using this model, we subsequently Iden 
tificd additional acidic or basic amino acids predicted to lie on the sur- 
face ref the A2 domain in the vicinity rrl Aspr''r `and Gin '"'" (1'ig.: 3C and 
individually mutated each residue (Arg' 4' Asp' Asp's) `, Glu", r` 
l. ysr`, r C; lur°c Glu1o4U) in V\VFI 15 to alaninc (Fig. 3D). 
kinetic Analysis of 1'la'T. 7o, 1'14'1-11.5, l'WE115-A3, and UWE! 15 
C hanged A4utnnt Prutco(1'sis-As a qualitative assessment of the relative 
ability of ADAM PSI3 tu pnrteolyzc each of the charged residue 
mutants compared with the wild-type V\V'F76, VW1 115, and 
\'\VF115-A3 substrates, we analyzed cleavage reactions by Sl)Sf'AG1: 
and Cuomassic staining (Fig. 4A). From these gels, it seemed as if all of 
the mutants exhibited reduced rates of prutcolysi. s. However, the con- 
centrations of substrates needed ter facilitate visualization by gel staining 
were high. To perform kinetic analysis of proteolysis for different sub- 
strates, it was necessary tu monitor cleavage using substrate cuncentra- 
tions below the K, for the reaction. Consequently, we determined the 
individual kinetic constants (K,,,, k,,,, ) of V\VF115 by measuring the 
initial rates of proteolysis at different concentrations (100 ilm-Si) µsI). 
Fror the ADAMTS13-dependent proteolysis of VWF115 (n = 4), we 
derived a k,.,, of O. 14 -1 
0.06 s -I. The h,, for this reaction was deter- 
mined to be 1.61 c 0.47 µst, from which a value fror the specificity 
constant (catalytic efficiency, k,,,, /K,,, ) of 8.70 x 101 tit 's' could be 
derived. 
For separate determination of the catalytic efficiency of V'\VFl 15, 
repeated time course experiments were performed using low sub 
strate concentrations (25(1-5110 nm), Repeated time course experi- 
ments (rn = 8) gave a mean value of 7.83 x 10r vr 1s1 for k,.,, 1K,, 
('t'able 1). Confirmation of the pseudo-first order conditions was 
obtained by deriving the same k,,,, /K,,, value for V\VF 115 proteolysis 
at both 250 and 500 nn+. Determination of k, , 
! Kfor VWF76 and 
V\X'F115-A3 gave values of 6.39 X 10' xi 's1 and 6.71) X 101 nt 's1, 
respectively (Table 1). These kinetic data confirmed that the VWFA3 
domain does not significantly contribute to the rate of A2 domain pro- 
teolysis, despite containing an ADAMTS(3 binding site (19). 
The contribution of each selected charged amino acid to VWF pro- 
teolysis was assessed by determination of the catalytic efficiency of all 
the mutant VWF115 substrates at 500 rent (Fig. 4Cand'Fable 1). The rate 
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FIGURE 3. Mutagenesis of 
VWF 115. A, predicted model of the VWF Al domain. ttte Tyr' °"-'-Met' °"° sci ssile bond in the center of the A2 domain is highlighted in green. The positions 
pf certain type 
2A (group II) VWD mutations that were introduced into VWF115 are labeled and highlighted in red. 8, VWF115 and VWF11 S type 2A mutants (R1597W, R1597Q, 
D1614(. 11628T, 
G 16298, E 1638IQ were proteolyzed with 10 nM ADAMTS13 and time course reactions analyzed by HPLC and represented graphically as in panel B). Although VW F 115 
and the 
R 1597W, R 1597Q 11628T, and G 1629R mutants were proteolyzed at very similar rates, the VW F 11 S(E 1638K) mutant was leaved slightly slower. The VWF 115(D 16146) mutant 
. as proteolyzed 
at a markedly slower rate. C, predicted model of the VWF A2 domain. The Tyr' b05-Met1606 scissile bond in the center of the A2 domain is highlighted in green. The 
and 
surface 
VWF115 rýoA2 
domain in the vicinity of the 
are marked by 
most 
letter amino 
Dmutants at Asp'" gi and ä sihesred. D, di the VWF Al A2A3 domans. 
patch 
are highlighted in diagram regions Y arrows. The single sequence of of VWFlWF 11 t5 5 is given 
(VWF76 sequence is underlined with a 
dashed arrow). The ADAMT513 cleavage site is marked (4). Locations of acidic and basic amino acids mutated to alanine and predicted to form 
a char, patch 
on the surface of the VWF A2 domain are highlighted (1-7). 
of proteolysis of 
the R1583A mutant was not significantly different from 
that of VWF115, suggesting 
that this residue is not important for cleav- 
age. Mutation of 
GIu1638 and Glu' ° induced a mild (2-3-fold) reduc- 
tion in catalytic efficiency. 
The most affected (>12-fold reduction) sin- 
gle mutant was 
D 1587A, the k., /K_ of which was 0.64 ± 0.10 x 104 M-' 
s_, The 
k, /K,,, for K1617A, D1614A, and E1615A, which are predicted 
to lie on the same surface-exposed 
loop, were 1.90,1.36, and 1.13 X 104 
M- I S', respectively. 
These results implied that this loop might play an 
important role 
in the cleavage reaction. Consequently, we generated a 
triple mutant 
DEK1614/5/7AAA) containing all 3 residues substituted 
for alanine. 
Whereas individually these mutations caused a 4-7401d 
redu, tiun 
in kc/K,, in combination the catalytic efficiency was >13- 
fold less than wild-type 
VWFl15, implying that the amino acids in this 
charged 
loop may act in synergy. 
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Influence of D1587A, D1614A, and E1615A upon VWFA2 Proteoly- 
sis-To test whether the effects of the above mutations were maintained 
in a fully folded A2 domain, we introduced the most affected single 
charged mutants into the whole A2 domain. A variety of VWF A2 
domain mutations appear to alter the conformation of the domain, such 
that the scissile bond is more readily exposed and thus more accessible 
for ADAMTS13 cleavage under normal physiological ionic conditions. 
Therefore, this approach also served to ascertain whether the most 
affected charged residue mutants (D1587A, D1614A, E1615A) induced 
gross structural changes. Despite using increased concentrations of 
ADAMTS13 (16.5 nM) in the absence of a denaturant, the intact wild- 
type A2 domain was proteolyzed very slowly, as visualized by gel stain- 
ing (Fig. 5A), when compared with the A2 domain fragments VWF115. 
VWF76, and VWF115-A3. When samples containing 500 nm VWFA2 
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FIGURE 4. Proteolysis of VWF76, VWF115, VWF115-A3, and VWF1 15 mutants 
by ADAMTS13. A, SIDS PAGE and Coomass e staining o(d'feicnt substrate proteolysis ADAMTS13 
was incubated with 
different wild-type VWF A2 domain fragments or mutant VWF 11S as indicated, using high substrate concentrations 14 --8 pm). Samples analyzed were 0-, 1 and 
3-h time points. B, 
determination of the individual rate constants (K, -, and 
k_, ) for VW F 11 S proteolysis by HPLC analysis of the initial rate of VWF115 proteolysis at different substrate 
concentrations 
(100 nm-SO Hm). Michaelis-Menten and Lineweaver-Burk (inset) plots are shown. Values for K,,, and k,,,, for VWF 115 proteolysis were 1.61 . 
0,47 IM and 0.14 -006s ', 
respectively 
C, HPLC analysis of time course reactions of different substrates shown in panelAare represented graphically. Reactions employed 500 nm substrate (marked as in panel 
A) and 8 ma ADAMTS1 
3. The catalytic efficiency (k, /K,,, ) of proteolysis of each substrate was 
derived using Enzfitter software as shown in Table 1. 
were analyzed 
by HPLC (Fig. 50, it was clear that the cleavage reaction Confirmation nj ADAAAl TS13 Binding Site Residues in )')k'7.42 
did not proceed toward completion (--28% after 5 h), as previously Domain-AVe hypothesized that the most likely cause of the reduced 
reported 
(13). The 1)1587A, 1)1614A, and E1615A V\Y'FA2 mutants catalytic efficiency of the affected V\\'Fl IS charged mutants was 
were proteolyzed either at a similar or slower rate 
(Fig 5, A and C), impaired binding to AI)'I'51$. lo measure the inllurntc of each 
suggesting that these mutations 
do not slur the A2 domain structure mutation upon the interaction rtf V\V'F115 with A I)AN1 I SI3, we per 
Markedly. Under 
denaturing conditions (1 st urea), the wild-type formed SPR analysis. Monmitmal antibody-mediated orientation spe 
,, V\XIFA2 was proteolyzed faster, although it still slid not reach cunlple- cific coupling of either A'\X'F115i or AI)AM'1513 to the se[istsr chip was 
tion (--50'yß after 
5 h) (Fig. 5, B and D). Although all the mutants were not possible due to the relatively fast off-ratt'. s of these molecules with 
Cleaved at a 
higher rate under denaturing conditions, they were cleaved the available antibodies to nach ligand (not shown). Consequently, we 
appreciably slower 
than V\VFA2, corroborating the direct influence of cosalently bound either V\K'l'1 15 or ADAM I'S 13 toi the sensor chip by 
these mutations upon 
V\V'Ft 15 proteolysis. amino' coupling. With V'\V1=11: ß bound to the chip and A] )AN1*1 S13 
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;, i, hd v(. 1 the ßr! 1I. vcr iinnuklrrd ,iý, M, 1.1111 . 111, n Ild nl 
binding 1 CT0 nsr II (IicatI%'c oIa high aIIinIt y interaction (A,,, 20 nNi) I ur 
this Intrr. I(U II (l ü;. (1,: u%1t). Determination of both the association and 
dis SIKiati ,n rates I(11 the AI)AM1 I SH \'\\'I I15 interaction (ti - 3) 
demonstrated a slow tilt-rate (152 x 10 's 1), which would appear to 
be the niaior determinant for the high affinity binding. A second 
in which AI)A, \1 I sI3 was rnipl d to the sensor chip 'Ind 
. ý; in uni r ItI, ItI "TIN ,I\ 
\\ I trd, lý, Ivr a', iIIIIhI Iii h'IttinII 
TABLE 1 
Kinetic analysis of different VWF substrate proteolysis by 
ADAMTS13. 
i )A AIl'li was incubated N% 101 I(A) nyt substrate unrici pltv sI )Iul; u al wnu t Im, ý. 
n..; t i"C tiuh-samplcs from cac h time course rcacuun were taken obii 
the c, tent of proteolysis measured b)Y itl'I. C The catalytic rlticicnc)' .., i w 
proteolysis of each substrate as 
derived using En/fitter ., ft ware. The spc(tti, 
constants fur ea. h \'\\'F snbstratc'\'\VI 115 variant t> given (' S. F ). Vol \'\1'I I 
115-A3. and \'\Vi 7t ,n=8. 
For the least affected \'\C'F 115 variants (R I SSS: \ 
D1(414)A. F1638. A, and KI6I") and the triple mutant N klt, 1l'5, TAAA, n=1. in 
the most alte ictl in lc mutant (I)1b14A. F. 16I5F, and D15ti-). n 3 Numbering 
as in Fit; 4 
\'\VI' substrate k h 
V\K'FI 15 7.83 1.18 
\'\C'FI 15-A3 6.70 2.78 
\'WF; 6 6.39 1.18 
RI583A(1) 6.19 
Dl 641.5 (7) 2.74 
F 1638A (6) 2.74 
K1017A (5) 1.90 
1) 16 HA (3) 1.36 0.26 
['1615(4) 1.13 0.30 
1)1S8"A(2) 0.61-0.10 
D1(; 1 IA'F1615A/K161"A (8) 0.59 
111p .1 will lh, Iý II , l. n, l . Ii, %%I I Iir. r'Iii dcIII"I ', ti, rh, 
that tlt(- aIIirtity of AI )A NI I S13lot \'WI I 15 is sit; nifirIII( Iv higher It 11.111 
is suggcstt d by tIIcK,,, Irr V\\'I'I 15 protu'olysis. 
SITZ analysts of V\r'FI 15 mutants (01587A, I )IOHA, 111015A. and 
I)EKI(11/5) /, AAA)(IS rig bu )t ii 1)1 nd iii ahprýýacIIC'rtvr. tlt'dif markt-clly 
mciuc 'd affinity of Al )AM I'S 13 fia each of tltr mutant, when (ofIIi im 
with Wild ty'pt' \'\VI 115 (Fill,. ti). Because of tilt' low hin lung r c"ponsc 
inr, usured, an accurate K, could not be derive 1 (runt (lie \'\C'I 115 
mutant data. Despite the pour fitting the cstiuun ute fin the K fir the 
)f: h IhI 4 i/'; \AA mutant wati 1i pm. It was clear that for each var 
tilt the binding with Al)AM'IS13 was appmriably, ronupormitirecl and 
thus theliLu'It'r, trse of lh itrt'clucr"Ispurifirit%k onstmit,, 
DISCUSSION 
: AI): A. A1 I'll l Ir. ic .i ýini, 
(c ( nil eidun Ilia A \\l A. ' 
Undri static ()I], )%% shin c olldit iis, I Iotc ulv"Iti i. s slo%% hrc. uiu of tIIc 
globular conformation adopted by multimc rir V\VF Morcio'er, the 
complcs fi lding of the A2 and surrounding domains further conceals 
the scissile bond (10). The isolated intact A2 domain is also not readily 
pmtrolvzed by ADAM 7 S13 (19). In the absence of a denaturant, the 
intact domain residues N1ct' 1" Arg"") adopts a "non perms 
structure that restricts iicess of ADAM I'M i (13). This is poten 
ti, tlly explained by a \'\VF A2 domain model that suggests that the 
Tyr' " -\4(, t 
INk, bi nd lies hutted within t he cc ntcr oft he fi ldcd domain 
(17) and is thus not normally sot cent exposed i iiwevc r, inrumhlcte 
\'WI A2 domain fragments that span the ADAM IS 13 rlravagr , itr (c', C'. 
VWC'F713 Asp"""-Arg""' and \'\VF115 Glu'''e Arg"'") have harn 
shown, hrrr 'Intl elsewhere (12.20.: ' 1 ), to hr rr, uliii , 111(1 ', I )C( iIh ally 
A VWFA2 (1) VWFA2 D1587A (2) VWFA2 D1614A (3) VWFA2 E1615A (4) 
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FIGURE S. VWFA2 and 
VWFA2 charged mutant proteolysis. A, 6 rß+r VWFA2 l I) or VWFA2 carrying DI 587A 121, Dl ri 4A (il or LI O15A (ai w, o ricub, uccl with 16.5 nu ADAMTS 13 irr 
the absence of 
dc"n, rturant and analyzed by SDS-PAG[ and Coomassie staining. Samples were incubated for 0.1, and 3 has indicated 6,6l. m VWFA2 (5) or VWFA2 carrying Dl 587A 
(6) ,D 
1614A (7), or E 1615A (8) mutations was incubated with ADAMTS 13 as in panel A in the presence of) n+ urea. Samples were analyzed as in panel A. C, graph of HPLC analysis of time 
course reaction 
samples 1-4 (panel A) set up in parallel reactions containing 500 nr,, of each substrate. D, graph of HPLC analysis of time course reaction samples S-8 (panel 8) setup 
in parallel reactions containing 
500 flu of each substrate. 
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FIGURE 6 Binding of ADAMT513 to VWF115 and VWF115 mutants. VWF115 was 
immobilized by covalently coupling 600 response units of VWF 115 to one flow cell of a 
CMS sensor chip dnd human endothelial protein C receptor to the control flow cell. 
Sequential injections of ADAMTS1 3 (10-137 nM) in HBS-P buffer were injected over the 
surface of each chip. 
Data were fitted using a 1: 1 Langmuir model. Individual association 
(k. ) and dissociation (k,, ) rates for the ADAMTSI3-VWF I1S interaction are given, from 
which the K., (20.0 nm) was 
derived (k,, /k). Comparative SPR analysis was performed by 
covalently coupling 
VWF115, VWF115(D1587A1, VWF 115(D1614A), VWF 115(E161 SA) or 
VWF115(DEK1614/S/7AAA) as above. Results shown are overlaid data for VWF115 and 
VWF115(D1587A), VWF11S(D1614A), VWF115(E1615A), or VWF11S(DEK1614/5/7AAA) 
as marked, using 27.5 nM 
ADAMTS13 
cleaved at the site under normal physiological 
ionic 
conditions, suggesting that these 
fragments not only contain important 
recognition sequences for specific ADAMTSI3-dependent proteolysis 
but also that their structure presents the cleavage site in a permissive 
conformation, more akin to unraveled/denatured 
V\VF (12). In the 
present study, we 
have expressed and purified it number of related V\V'l' 
A2 and A2/A3 domain tragt ments to delineate those regions important 
for A2 domain proteolysis Previous studies have employed SDS- PAGE 
and/or Western 
blotting to monitor pn tee lysis, the latter to achieve 
high sensitivity in the early stages of the cleavage rear tion (13) 
Cleavage 
of V\\'F 
fragments by A DAM I'S l3 was quantified hereby H PL. C, allow- 
ing for the first time accurate and fully quantitative analysis of the 
kinct 
ies of these reactions. 
In our hands, most likely as a result of the smaller recombinant pro- 
tein tat' used in this study, VWFI 15 was marginally more susceptible to 
cleavage than the shorter substrate V'\VF76 (very similar to 
A'WI-73 that 
has been reported elsewhere (12,20)) when the cleavage reaction was 
fully quantified. Its K,,; was - 1.6 . ri, 
k, - 0.14 s 1, and its specificity 
constant (k,., 1! 
K,,, ) -Sx 16` st 's'. This estimate of specificity is 
quite similar to that recently reported for ADAMTSI3 cleavage of 
full- 
length V\VF multimers under conditions of low ionic strength (22). This 
is surprising, considering those experiments were performed under 
denaturing conditions and without the advantage of a released peptide 
with which to accurately quantitate the rate of proteolysis. VW-1 15-A3 
gave similar values fir the specificity constant, suggesting that the 
A3 
domain makes no appreciable contribution to the cleavage reaction 
despite its reported high affinity binding site (18). This finding corrob- 
orates previous semi-quantitative 
data obtained from the comparative 
analysis of recombinant 
V\V'FA2 and V\VFA2/A3 proteolysis under 
denaturing conditions (13) 
[2esidues surrounding the cleavage site are known to influence pro- 
tec)lysis of intact \AVF, as they are reported to 
be dysfunctional in cer- 
tain cases of type 
2A (group II) VWD (15). We therefore introduced 
Some of these mutations 
into the A2 domain fragment (\'\ß'F115) and 
evaluated proteolysis. 
Of course, the type 2A (group II) phenotype is 
,, c nrrallv associated with enhanccd, rather 
than reduced, proteolysis by 
AI)AM1 IS1, i. \r\i rtI wl cs , we selr IS! 1cpoIIt 
d nrutat rniIs "Ill ruun, 
eng the cleavage site, as not all had been tested cxtcnsrvr-ly in terms of 
At)Ah1'I S13 interaction Interestingly, of those mutations sclc ted, rrnc 
(1)1( l4(1) was prntcolvied sil; nifi( antl)" . slower when lilt] udu Cd 
into 
VW1 115. 'Fn fully c'har"rctrt'iu" how this mutation night meet a type 2A 
V\VI) phenotype. further studies exaniininl; its influent e upon lull 
length, multinueri V\VI will he required. I vpe2i\ group II V\VI)nruta 
Lions are generally believed to manifest their phenotype by unfolding of 
the Al-A2-A3 domain region, inrmasing Al )ANI FSI t access to, and 
therefore cleavage of, the scissile bond. 'l he possibility of reduced, 
rather than enhanced, rates of cleavage Of nIII taI Its. such as 1)16146, in 
the vicinity Of the cleavage site should he taken into ( onsideratirrn when 
evaluating the complex phcn type of cases of'potentia l type 2r\ group II 
\'\C'1). Because of this finding, wi mutated firth er' (harf; ed msidues 
thought to he in proximity with Aspii' on the basis of primary 
Sequence and the homology model Of the A2 domain. Of eight sue It 
mutants introduced into A'\VI-115i, six (1)1SB7A, I)1014A, F1615A. 
K 10I A, F l638A, and F 16 40A) had clearly rý due cd clr ava4, ý rates I he 
triple mutant, l)l. k101-1/5'7AAA, had 13 told reduc'tirm in the spr. c 
ificity constant fror proteolysis FO confirm that the delayed clcav, rgT Of 
the V\C'FI 15 substrate was not merely a feature of this parti( 111,11 Sub 
stratc, three of the mutations (D158 , 'A, I)I614A, and I. IW5A) were 
introduced into the fully folded intact A2 domain. Under denaturing 
conditions (I M urea), proteolysis of all three substrates was reduced in 
rate and extent when compared with the wild type VWFA2. Even under 
non-denaturing conditions, where under the conditions used proteoly 
sis of the A2 domain did not exceed 30% at 300 min. prutrulysis of 
1)1 87A and 1)161 4A was apprec iably' impaired. l'hesc results with berth 
V\VFI15 and A2 substrates suggested that specificity is appreciably 
Influenced by a charged patch on the surface of the A2 domain. 
Binding, ref AUAMTS13 to mtilt imeric V\VI: and A2 domain (rag 
ment substrates has been reported to be of high affinity (2: 3). Physiolog- 
ically, ADAM'I ', H seems to circulate in crm)plex with V\VF. 1lowever, 
the binding of Al)AMTS13 to \AVF need not neccssarily be ac: cumpa- 
nied by protculysis. Although Ca'' ions are required for efficient pro- 
teolysis (10), they are not necessary fier high affinity binding (21,23). A 
recent report of binding of AIAM I S13 to VWF73 in the absence of 
Ca", ions using a microtiter plate-based immunoassay fur ADAM l'S13 
suggested a K,, of -16 not (21). Because <rf uncertainties surrounding the 
use of antibody detection and equilibrium perturbation in the dctck tore 
step of binding in such assays, we used the alternative approach of SIB 
Coupling \'\VF115 directly to the sensor chip and injecting different 
concentrations of ADAM I S13 yielded a K, Of --20 nm. This high atfin- 
ity interaction appeared to be conferred by a slow dissociation rate (k,, ). 
Confirmation of tight binding was obtained by covalently immobilizing 
ADANITS13 and then injecting \'WF115 over the sensor chip. In this 
case, a K of 15 nm was obtained. However, there was also slime evi 
dcncc for heterogeneity of binding, and a lower affinity component was 
also apparent using this second approach. Importantly though, both 
SPR approaches demonstrated substantial loss (=>10-fold) in binding 
affinity of AI)ANITS13 to the mutant \'WI'115 fragments 1)154 A, 
I)1bl4A, and LI6ISA and the triple mutant I)EK16I, 5/7AAA irre- 
spective of whether SPR was performed with these fragments as analyte 
or ligand. This provides direct evidence that these residues form part Of 
a docking site fier ADAMTSI3 on the A'Wl-A2 domain. 
The present investigation has for the first time identified critical res- 
idues within the V\VF A'_) domain that are important fur both binding to 
ADAM'I'S1.3 and for proteolysis at the '1 yrrru'_tilrtr " bond. Given its 
specificity, proteolysis is unlikely to be determined solely by interaction 
with a limited number of residues surrounding the cleavage site. I'revi 
1 562 ;. JANUARY 20,2006 
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ous studies have shown that although VWF73 is cleaved by 
ADAMTS13, a 9-residue deletion at the C terminus of this fragment 
completely abolished cleavage (12). It remains uncertain precisely 
where these 9 amino acids lie in the fully folded intact A2 domain or in 
unraveled multimeric VWF In relation to the charged patch/residues 
identified in this study. Despite this, and the inability of a peptide that 
spans this region to inhibit proteolysis, it remains possible that residues 
within this 9-amino acid sequence contribute directly to high affinity 
binding to the protease (12). Structures remote from the cleavage site 
are also known to influence proteolysis. The Al domain of VWF was 
recently demonstrated to inhibit access of ADAMTS13 to the A2 
domain cleavage site (13). This inhibition was removed in the presence 
of Gplba, the principal Al domain ligand, suggesting that under phys- 
iological conditions platelet binding may enhance VWF proteolysis 
either by increasing scissile bond access or by revealing an ADAMTS13 
binding site. 
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